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CHAPTER 1 
 
INTRODUCTORY BACKGROUND  
& AIM OF THE THESIS 
 
1. POULTRY DISEASE CONTROL 
1.1. Introduction 
Since antiquity poultry products have played an important role in providing humans dietary 
proteins through either the consumption of eggs or meat. Poultry farming was therefore predisposed to 
become one of the most important sectors in animal farming. The demand for poultry meat continued 
to grow the past decades because of demographic growth, widespread consumer acceptance, the 
development of processed food products and the increase of disposable incomes [1].  
 
Figure 1: Summary of the total production of broiler meat in the most important countries in the world meat 
production sector. (Adapted from www.fas.usda.gov – April 2011); data for 2010 are preliminary. 
 
To keep up with the increased demand, poultry farming became a global industry characterized 
by large poultry farms housing high density flocks. When housing large flocks, it is important to realize 
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the substantial risk for outbreaks of infectious diseases, which can rapidly spread throughout the entire 
flock and beyond. The viability and successful expansion of poultry farms could therefore only be 
achieved through continuous advancements in poultry disease control and prevention. This has enabled 
the world broiler meat production to double over the past 10 years (Figure 1).   
 
1.2. Controlling infectious diseases  
 
The spread of infectious diseases from bird to bird depends largely on the environmental 
conditions on the farm, route of entry to the birds and virulence of the infectious agent and 
characteristics of the host such as defense and nutritional status. Preventing an outbreak of infectious 
disease amongst the chickens should be part of the day-by-day management on a poultry farm and 
includes the implementation of biosecurity measures, good hygiene practice, well-designed equipment 
and housing premises and effective vaccination [2]. 
Biosecurity involves the protection of livestock against transmissible infectious diseases from 
the outside environment. Although the flocks might be housed in a closed environment and are visibly 
cut off from any contact with wild birds, rodents or other wild animals possibly carrying infectious 
agents [3], other less obvious sources and routes of infection should be considered.  
Humans can introduce disease among others through the wearing of dust, feather- or 
excrement-contaminated clothes or the use of contaminated equipment while handling the animals. 
Prevention embodies disinfection of used materials and a change of clothes each time the premises are 
left and entered. 
The introduction of new livestock into a multiple age farm may also enable the spread of 
disease. Multiple age farms provide an ideal environment for the perpetual transmission of infectious 
diseases, where older infected flocks often contaminate young disease-free arrivals and so on. 
Therefore, isolation of new and older flocks should be made possible by providing quarantinable units 
for each flock. The so-called ‘all-in, all-out production’ principle anticipates to infection from older 
carrier birds by removing the entire flock from the farm before new animals are housed. This is 
combined with a thorough cleaning and disinfection of the farm houses [2, 3]. 
Finally, an important part of infectious disease control programs on a poultry farm is the 
vaccination of the animals against several infectious agents.  
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If despite all the taken measures an outbreak of infectious disease is suspected within a flock a 
diagnosis should be made as soon as possible by a veterinarian or by sending relevant biological samples 
to a diagnostic laboratory. The diagnosis will determine the further approach, which can vary from 
nursing care and drug treatment to eradication of the entire flock. In case the disease is hazardous to 
humans (e.g. salmonellosis), precautions should be taken to avoid human contact with the pathogen. 
Outbreaks of notifiable diseases such as Newcastle disease or avian influenza should be reported 
immediately to the competent authorities [2].  
 
1.3. Poultry vaccination 
1.3.1. Introduction 
Vaccination is an essential part of infectious disease control management. By exposing the birds 
to pathogen-specific antigenic bodies the stimulation of an immune response against the infectious 
agent of interest is elicited. After a primary vaccination of the pullets, a second booster vaccination is 
often performed on older chickens to optimize protection against a certain disease as illustrated in Table 
1. Various vaccine types and vaccination techniques are available in poultry farming, which ideally 
should be safe (absence of adverse reactions), effective (induction of sufficiently high immune 
response), readily available and cheap.  
 
Table 1: Standard vaccination schedule for poultry in Belgium (www.bcfi-vet.be)
1 
1 
A more detailed and updated vaccination schedule can be found at www.dgz.be. 
2 
Applies to reproduction animals, layers and broiler chickens. Due to their short life-span broilers are not vaccinated after 4 
weeks of age; ND = Newcastle disease; IB = infectious bronchitis. 
3
 Less than 72 hours old and unfed. 
4 
Vaccination against Newcastle disease is compulsory according to the Belgian Ministerial Order of January 25
th
 1993. 
 
 
Age Vaccination method Disease
2
 
1 day
3
 Intramuscular injection (I.M.) Marek's disease 
 Coarse spray vaccination ND
4
 
  IB 
2-4 weeks Drinking water or fine aerosol vaccination ND 
  Gumboro disease 
7-12 weeks Drinking water or fine aerosol vaccination ND 
  IB 
14-18 weeks Drinking water or fine aerosol vaccination Avian encefalomyelitis 
  ND 
 I.M. ND 
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Vaccination can also be used to elicit very high antibody levels in hens to maximize the 
maternally-derived antibodies in the hatched offspring in order to protect the chicks against infectious 
diseases during the early phase of life [2]. 
 
1.3.2. Types of vaccines  
The principle of vaccination (introduction of antigenic bodies to induce immunity against a 
specific pathogen, often viruses) allows several approaches, of which the most important ones are 
discussed below. 
 
1.3.2.1. Live (attenuated) vaccines 
Vaccination can be performed using live non-attenuated or attenuated vaccines. As non-
attenuated vaccines potentially may cause disease in the vaccinated host, live attenuated vaccine strains 
are preferred [4]. This implies the selection of avirulent strains unable to provoke disease yet 
maintaining the similar infectious and immunogenic capabilities. Most live attenuated vaccines are 
obtained by repetitive passage in specified pathogen free (SPF) embryonated eggs or tissue cultures 
from which the infectious avirulent types are selected as vaccine candidates. Another approach to 
develop live attenuated vaccines is plaque selection of clones from the parent virus strain, as performed 
for Newcastle disease La Sota vaccines [5]. This is based on the ability of animal viruses to form plaques 
in cells fixed as a monolayer in an agarose gel medium, in which case each plaque is the result of the 
infection of a cell by a single virus particle. It is considered that all viruses in one plaque are genetically 
identical and thus considered clonal [6]. 
However, these attenuation methods are difficult to control and safety concerns may arise. 
Both, reversion to virulence during virus replication in the host and insufficient attenuation may lead to 
clinical disease and/or adverse vaccinal reactions [5, 7-10].  
Live vaccines have the advantage to be applicable via the natural route of infection, generally 
enabling vaccination through mucosal tissue, which may induce mucosal besides systemic immunity [2, 
11]. They are also suitable for administration by mass application techniques (e.g. aerosol, drinking 
water) as the vaccine virus can replicate in the host and spread from one bird to another. This enables 
the administration of lower vaccine doses, making this kind of vaccines relatively cheap.  
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1.3.2.2. Inactivated vaccines 
Inactivated or killed virus vaccines are considered safer than the conventional live attenuated 
vaccines. After production of live virulent field strains, the virus is chemically inactivated by the addition 
of compounds, such as formaldehyde or β-propiolactone [4]. However, the success of the inactivation 
process depends mainly on the contact time between the chemical compound and the virus. The 
manufacturer must nevertheless guarantee 100% inactivation to prevent disease outbreaks [12]. 
Inactivated vaccines are generally less immunogenic as they do not promote the endogeneous 
production of antigenic proteins stimulating the cell-mediated immune response [13]. Therefore, 
successful vaccination with inactivated vaccines requires multiple inoculations and the presence of 
adjuvants (e.g. mineral oil, aluminium hydroxide) to enhance immunogenicity. These adjuvants have 
been reported to cause adverse local tissue reactions [14, 15]. Furthermore, as inactivated vaccines do 
not replicate in the host after administration, they are generally considered unsuitable for mass 
application and need to be administered by intramuscular injection. Despite what has been said 
previously, inactivated Newcastle disease vaccines have been successfully administered by aerosol, but 
were considered economically unviable due to the high vaccine doses required [12, 16]. Inactivated 
vaccines are usually applied as a secondary vaccination, following a primary vaccination with a live 
vaccine. 
 
1.3.2.3. Recombinant and DNA vaccines 
Due to better understanding of the biology of several pathogens and advances in molecular 
biology, new and safer vaccine types compared to the conventional vaccines are emerging. 
In the case of a recombinant vaccine, a gene coding for the antigen of a virus is inserted into a 
plasmid vector and combined with live attenuated virus vectors. The resulting recombinant vaccine 
invades the host’s cells, which will express the antigen genes and consequently stimulate the immune 
system of the host. This technique also allows defined modification of the antigen genes, such as 
blockage of virulence factors of live virus strains, enhancing the vaccine safety [9]. Recombinant vaccines 
protecting against Newcastle disease virus, infectious bursal disease virus and H5N2 avian influenza virus 
have been developed using the fowl pox virus as vector [17], although the Newcastle disease virus is 
also investigated as potential vaccine vector [18, 19]. As the plasmids are delivered by live virus vectors, 
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low doses are sufficient to elicit protective immunity and mass application to poultry seems feasible 
[19].  
A revolutionary approach to vaccination is reserved for the emerging DNA vaccines. DNA genes 
encoding antigens of a virus for which immunity is desired are delivered directly (without vector) to the 
host, so foreign antigens are expressed by the host’s cells. This would stimulate both the humoral and 
cell-mediated immunity of the host like live vaccines, but resemble to inactivated and recombinant 
vaccines regarding safety [20]. Additionally, their immunogenicity is not decreased by the presence of 
maternal antibodies, mutation to the virulent form as in live attenuated vaccines is non-existent [20] 
and one DNA vaccine can be developed for multiple pathogens, requiring only a single administration 
[13]. Although DNA vaccines against Newcastle disease and avian influenza have been applied 
successfully in poultry, technical challenges such as improvement of delivery and increasing the potency 
of the DNA vaccines are yet to be achieved [21, 22]. Currently, only individual administration of DNA 
vaccines to poultry has been investigated, requiring high doses of DNA to yield a positive immune 
response [20]. Some of the main safety concerns regarding the use of DNA vaccines are the possibility of 
unwanted DNA insertion into the DNA of the host and the stimulation of anti-DNA antibodies eliciting 
the development of auto-immune diseases [13, 20, 23].  
 
1.3.3. Vaccination methods 
In poultry farming there are individual and mass application methods available, each with their 
specific advantages and drawbacks. Which method is selected depends on the size and age of the flock, 
the vaccine type used and the costs. 
 
1.3.3.1. Individual vaccination methods 
Individual vaccination methods are labor intensive and costly as they require handling each 
single bird to deliver a vaccine dose. This needs to be done in such a way that growth retardation or 
drops in egg production due to stress are avoided [12]. Although individual vaccination should ensure 
the delivery of the required vaccine dose to each animal, it must be performed with great care to avoid 
‘missing’ or incomplete vaccination. 
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A. Subcutaneous and intramuscular injection 
Inactivated vaccines are often delivered by subcutaneous injection in the dorsal area of the neck 
or by intramuscular injection in the leg or breast of the bird. Sometimes a dye is added to the vaccine 
emulsion to form a colored spot under the skin after injection, allowing visual recognition of vaccinated 
animals [2]. During the vaccination procedure injection needles should be replaced (e.g. every 500 
chicks) and decontaminated frequently to minimize tissue damage and reduce contamination [24]. 
Moreover, the vaccinator should beware of accidental self-injection, which may result in local 
inflammatory reactions [25]. These risks can be reduced by using needle-free injection systems [26]. 
 
B. Wing web stab or scarification 
Vaccination against fowl pox is often performed through the wing web stab method using a live 
attenuated vaccine. The wing web usually contains few feathers and almost no bones or muscles, which 
makes it a suitable place to pierce the tissue without causing any damage. A specific applicator equipped 
with a needle is loaded with reconstituted vaccine suspension, pierced from below through the web of 
the wing so the needle sticks out at the top and subsequently withdrawn. Visual inspection of 
vaccination efficacy can be performed 7-10 days later by searching the wing webs for ‘takes’ or nodular 
scabs, which disappear about two weeks post-vaccination.  
 
C. Oculonasal vaccination 
One of the most effective ways to vaccinate poultry is probably by the oculonasal route [2, 27, 
28]. After manual immobilization of the chicken, the vaccine suspension is applied into the eyes and/or 
nares using a dropper. The dye mixed into the vaccine suspension colors the eyes and nares and allows 
distinction between vaccinated animals and those not yet treated [2]. In contrast to the injection or 
stabbing vaccination methods, this method also elicits mucosal immunity promoted by the Harderian 
gland in the eye [29]. 
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D. In ovo vaccination 
A new approach to poultry vaccination was introduced by the automated vaccination of eggs, a 
system called in ovo vaccination. This technique involves the piercing of the eggshell and injection of 
vaccine into the embryonated egg. Experiments have reported optimal protection against an early 
challenge with Marek’s disease when embryos were vaccinated at 17-18 days old [30]. Furthermore, 
these studies indicated that chicks vaccinated at embryo-stage were better protected against challenge 
than chicks vaccinated after hatching. Another advantage of this technique is that embryonated eggs are 
immobilized, as opposed to hatched chicks. This enabled the automization of this technique, resulting in 
inoculation speeds of up to 30 000 eggs per hour for commercial in ovo machines [2]. Nowadays, about 
80% of the vaccination against Marek’s disease in the USA is performed by mechanical in ovo 
vaccination [31]. Investigation is ongoing to apply this technique with other vaccines, such as Newcastle 
disease vaccine and avian influenza vaccines [31-33]. 
 
1.3.3.2. Mass vaccination methods 
A. Drinking water vaccination  
Vaccination by drinking water is an extensively applied technique for the administration of live 
attenuated vaccines [2, 24, 28]. Before reconstituting the freeze-dried vaccine into the drinking water, it 
is important to ensure the absence of chlorines, detergents or heavy metals in the water as they can 
promote inactivation of the live virus vaccines. To neutralize possible residues it is therefore advised to 
add skimmed milk powder (2.5 g/l) to the water some time in advance [24, 26, 34]. Nevertheless, the 
stability of live virus vaccines in water is limited to 2-3 hours, which is the time frame in which sufficient 
vaccine uptake should be achieved for each bird. Therefore, to stimulate drinking, birds should be 
deprived of water two hours before providing access to the vaccine-containing drinking water [2, 24]. By 
adding a blue dye to the vaccine water the success of the vaccination procedure can be assessed as the 
tongue and crops of the chickens will color more intensely blue according to the amount of the water 
with vaccine they consumed [2].  
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B. Spray and aerosol vaccination  
Spray and aerosol vaccination are often used for the delivery of live vaccines against respiratory 
diseases such as Newcastle disease and infectious bronchitis due to the ease and rapidity of the 
methods [2, 24, 28]. In spray vaccination, the reconstituted vaccine is administered as coarse droplets 
(100-800 µm), targeting the eyes and upper airways. Moreover, oral uptake of the vaccine will occur 
during preening of the wet feathers [28]. This method is considered a mass vaccination alternative for 
the individual vaccination via oculonasal route, although vaccine droplets are also orally ingested by the 
chicks [2]. The droplet size is of major importance as droplets smaller than 20 µm will penetrate into the 
lower airways [35] where they can elicit excessive respiratory reactions and even result in increased 
susceptibility to secondary infections [24, 36]. Spray vaccination is mainly reserved for the priming of 
hatched chicks, which can be performed automated at the hatchery (Figure 2), while aerosol vaccination 
is performed on 2- and 4-week-old chickens as part of secondary vaccination. Aerosols are characterized 
by small airborne particles (<5-10 µm) [24]. The small size of these droplets enables the vaccine to travel 
deeply into the respiratory tract of the chickens [35] where they elicit a strong immune response [37]. 
Spray and aerosol vaccination induce systemic and mucosal immune responses [37-39], due to the 
existence of the avian lung-associated immune system [11]. Moreover, spray and aerosol delivery are 
needle-free systems, requiring less technical skills from the administrator and reducing the needle-
related risks such as self-puncture and transmission of blood-borne diseases. However, as the freeze-
dried vaccine needs to be reconstituted in water prior to administration, the same precautions should 
be taken as for drinking water vaccination, described in Section 1.3.3.2.A.  
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Figure 2: Automated spray vaccination of one-day-old chicks at the hatchery (adapted from 
http://www.pasreform.com) 
 
 
1.3.4. Vaccine failures 
The success of vaccination depends on several factors, which are discussed below. A distinction 
should be made between ‘true’ vaccine failure, resulting in suboptimal protection due to insufficient 
vaccine dose delivery, and ‘apparent’ vaccine failure due to other factors irrespective of vaccine dose 
delivery. 
True vaccine failure may occur if the vaccine itself is handled improperly, leading to severely 
reduced vaccine concentrations even before commencing vaccination. After production, vaccines should 
always be handled following the manufacturer’s recommendations, which in most cases imply transport 
and storage under cold-chain conditions and protection from UV-light. Although inactivated vaccines are 
less heat-sensitive than live vaccines [4], thermostable live vaccines (e.g. against Newcastle disease) 
have been developed to overcome the lack of cold-chains in tropical climates, while maintaining the 
advantage of live vaccines [40]. Moreover, whenever vaccines are reconstituted in water (e.g. in case of 
drinking water or spray/aerosol vaccination), it is imperative that only water of good quality is used and 
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to bear in mind the limited stability of live vaccine viruses suspended in water as described previously 
(Section 1.3.3.2).  
One of the major causes of true vaccine failures is poor vaccine administration [28, 41]. This is 
especially relevant for individually administered vaccines (mostly inactivated vaccines), where it may 
result in ‘misses’. Animals that have not been infected will not develop an immune response and remain 
susceptible to the disease. Although during the mass application of live vaccines birds may be missed, 
live vaccine viruses are shed by vaccinated poultry and transmitted to susceptible flock mates, resulting 
in a delayed immune reaction and/or low serum antibody levels. The heterogeneous immunity of such a 
flock may prevent disease and mortality, but still allows unnoticed infection, shedding and transmission 
of virulent virus in vaccinated birds with low antibody titres [7, 42]. These flocks may form a risk for the 
transmission of virulent viruses by direct and indirect contact with susceptible birds [7]. Placing 
unvaccinated sentinels within the vaccinated flock may detect the presence of virulent virus, as well as 
possible serological differentiation of infected from vaccinated animals [43, 44]. 
Apparent vaccine failures may occur when live vaccine virus is neutralized due to the presence 
of maternal antibodies in newly-hatched chicks, which may impair the development of an adequate 
immune response following vaccination [2, 45, 46]. Further, especially relevant for multiage rearing 
farms, the age of vaccination and early field strain challenge may lead to disease outbreaks [47]. Also 
the presence of immunosuppressive infectious diseases may hinder effective vaccination [2, 41]. 
Vaccination may also fail when the flock was vaccinated with a vaccine serotype different from that of 
the field strain [2]. This may be prevented by tailoring vaccination programs according to the diseases 
found at each farm. However, for practical reasons vaccination programs are commonly designed for 
larger geographic areas following a more global spread of the diseases concerned [7, 41, 48]. 
 
2. NEWCASTLE DISEASE 
2.1. Introduction 
Newcastle disease has been included on the list A of notifiable diseases by the World 
Organisation for Animal Health (OIE) [49] and outbreaks have been first reported in 1926 in poultry from 
the island of Java, Indonesia by Kraneveld and in Newcastle-On-Tyne, England by Doyle [4]. The 
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emergence of the disease is of major global economic importance in terms of outbreak losses, disease 
control and prevention costs and possible international trade restrictions [50].  
 
2.2. Classification and structure 
Newcastle disease is caused by an infection with a virulent avian paramyxovirus type-1 (APMV-
1) of which the criteria for virulence are defined by the OIE as follows [51]:  
- “ the virus has an intracerebral pathogenicity index (ICPI) in day-old chicks (Gallus gallus) of 0.7 or greater or 
- multiple basic amino acids have been demonstrated in the virus (either directly or by deduction) at the C-
terminus of the F2-protein and phenylalanine at residue 117, which is the N-terminus of the F1-protein. The 
term ‘multiple basic amino acids’ refers to at least three arginine or lysine residues between residues 113 
and 116. Failure to demonstrate the characteristic pattern of amino acid residues as described above would 
require characterization of the isolated virus by an ICPI test. 
 
Note: In this definition, amino acid residues are numbered from the N-terminus of the amino acid sequence deduced 
from the nucleotide sequence of the F0 gene, 113-116 corresponds to residues -4 and -1 from the cleavage site.” 
 
The APMV-1 is a single-stranded, negative-sense RNA virus and is classified within the Avulavirus 
genus among the Paramyxovirinae subfamily belonging to the Paramyxoviridae family [52]. Its non-
segmented nucleic acid is covered by a helical capsid, which is in turn protected by a hydrophobic 
envelope containing two surface proteins: the haemagglutinin-neuraminidase (HN), responsible for 
attachment and release of host cells, and fusion (F) proteins, mediating the fusion of the viral envelope 
with the cell membranes [4, 53].  
In this work, the APMV-1 will be referred to as Newcastle disease virus (NDV). 
 
2.3. Clinical signs and pathotypes 
NDV is categorized into four pathotypes, depending on its virulence (i.e. its disease inducing 
potential and incubation period) and the type of clinical signs [54-56]. The velogenic NDV is 
characterized by an acute, lethal infection in chickens of all ages. Depending on the nature of the clinical 
 CHAPTER 1: INTRODUCTORY BACKGROUND & AIM OF THE THESIS 
 
17 
 
signs it is further classified into the viscerotropic velogenic NDV (hemorrhagic lesions in the intestines, 
diarrhea) and the neurotropic velogenic NDV (neurological signs such as depression, torticollis, 
paralysis). Respiratory signs such as gasping, sneezing and airsacculitis may precede the neurological 
signs. Less virulent are the mesogenic pathotypes, which may also cause neurological signs, although 
respiratory signs are more commonly seen in adult birds. In young susceptible birds these strains are 
generally fatal. Lentogenic viruses provoke mild or inapparent respiratory signs and are often used as 
live vaccines, such as the La Sota, Hitchner B1, Clone 30 and LZ58 strains. The avirulent viruses, also 
referred to as asymptomatic enteric NDV as they mainly replicate in the intestines, do not cause any 
clinical disease but are nevertheless immunogenic. Therefore, some viruses belonging to this category 
are used as vaccines, such as the Ulster 2C and Queensland V4 strains. NDV strains are also categorized 
by the intracerebral pathogenicity index (ICPI) obtained from the ICPI test [4, 57], which is the required 
in vivo virulence test by the OIE (Section 2.2) [51]. Lentogenic strains have ICPI values close to 0.0, while 
the most virulent strains show ICPI values of approximately 2.0 [54].  
 The difference in virulence between strains is in part due to the ease with which the F0-protein is 
cleaved before virus replication [54]. Virus particles become infectious after cleavage of the precursor 
F0-protein into the fusogenic F1- and F2-proteins, which is mediated by host cell proteases. In virulent 
strains the F0-protein cleavage is performed by a wide range of host proteases, whereas low virulent 
virus strains need more specific trypsin-like proteases [54]. However, it has been demonstrated that also 
the HN protein, amongst others responsible for triggering the fusion activity of the F-protein, plays a 
role in determining the virulence of the virus strain [58]. Although studies investigating the influence of 
the HN-protein on the virus virulence were not able to consistently demonstrate an impact of the HN-
protein on the ICPI-value of the virus strain, increases in intravenous pathogenicity index were observed 
when the gene for the HN-protein or parts of it was replaced in lentogenic strains by those of a more 
virulent strain. In fact, it has been suggested that the genes for the F- and HN-protein together 
determine cell fusion, virus tropism and virulence [59]. Furthermore, the V-protein produced during the 
virus replication may enable the evasion or nullification of the interferon production or signaling 
pathway in the host cell, allowing the spread of virus and the infection of neighboring cells. This protein 
is therefore considered an important determinant of the virulence of a virus strain, although more 
studies are needed to confirm this [59].  
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2.4. Transmission and spread 
As NDV replicates in the respiratory tract, it can be transmitted to other animals through 
exhaled aerosols [60]. Aerosols of dust, mainly originating from feathers, feed and faeces, may also play 
a role in the transmission of NDV [61]. The airborne transmission of NDV over short distances has been 
demonstrated in the past by Hugh-Jones [62]. NDV of the enteric pathotype is mainly shed by infected 
birds through the faeces, which can infect other birds upon ingestion [54]. It has also been 
demonstrated that NDV can be transmitted through eggs to the progeny [63], although this usually leads 
to death of the embryo and plays a limited role in its transmission [54].   
NDV may spread over long distances through live birds amongst others migrating birds and 
racing pigeons. The latter have been considered an important reservoir and the cause of NDV outbreaks 
in the European Union during the past 10 years [64]. Also the displacement of other animals (e.g. 
rodents, foxes, dogs, which have been feeding on infected fowl carcasses) [65], poultry products and 
contaminated feed and water may contribute to the spread of NDV [7, 54]. Additionally, the 
transmission of NDV may also be favored by the movement of people or equipment between poultry 
farms [50]. 
 
2.5. Immune response to Newcastle disease virus 
Infection with low virulent NDV stimulates both the humoral and cell-mediated immune 
response of the avian host and depending on the route of inoculation a local immune response. The cell-
mediated response can be detected as early as 2 – 3 days after infection [54]. Although low amounts of 
leukocytes are present in the respiratory tract in non-infective conditions, a rapid and high influx of 
leukocytes is obtained after intratracheal inflammatory stimuli enabling a first line cell-mediated 
defense [11]. Through the release of cytokines cytotoxic CD8+ T-cells and CD4+ helper T-cells are 
activated. These latter cells stimulate the proliferation and differentiation of antibody producing B-cells, 
responsible for the humoral immune response, and memory B-cells, which enable a fast specific 
antibody production after future infection. 
The humoral immune response becomes detectable within 6 – 10 days after infection, reaching 
a peak antibody concentration approximately 3 weeks after infection [54]. Antibodies bind to infected 
cells and reduce the production of virus, as well as to progeny virus reducing its spread within the host. 
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Local antibodies in secretions of the upper respiratory tract and intestinal tract, especially those against 
the viral haemagglutination and fusion proteins, are considered to protect against clinical signs and 
death, but do not prevent viral shedding [66]. In the respiratory mucosa mostly secretory 
immunoglobulines A (Ig A) are found, but also Ig G and Ig M are present in contrast to the serum 
antibodies consisting mainly of Ig G and Ig M. After ocular inoculation the Harderian gland, behind the 
chicken’s eye, is responsible for the production of mainly Ig A, providing a local and systemic immune 
response. Although mucosal immunisation induces both local and systemic antibody production, the 
production of local secretory Ig A in the mucosa is not induced after parental immunisation [67].  
 
3. DRY POWDER VACCINES FOR MASS APPLICATION IN POULTRY 
3.1. The need for a new approach in spray and aerosol vaccination  
Spray and aerosol vaccination methods are widely used mass application techniques for 
respiratory pathogens in intensive poultry farming. However, their efficiency can become greatly 
reduced by a number of factors: (1) the currently used nebulizers generate sprays and aerosol with a 
wide droplet size distribution [68], reducing the inhalable fraction of vaccine particles. Moreover, in case 
of primary vaccination of young birds, fine respirable vaccine particles (produced during spraying) may 
cause adverse vaccinal reactions [36, 69]; (2) after nebulization, the airborne vaccine droplets 
evaporate, leading to vaccine inactivation and uncontrolled vaccine particle size spectra [70-72]; and (3) 
the tap water used for vaccine reconstitution cannot stabilize the vaccine sufficiently [34, 71] and is 
often contaminated with virucidal agents such as chlorines. 
In order to circumvent mentioned drawbacks dry powder vaccines may represent a better 
alternative for current liquid spray and aerosol vaccines. Dry powders for aerosol therapy have been 
widely investigated before in human medicine for local (e.g. corticosteroids to treat asthma [73, 74]) and 
systemic drug delivery (e.g. inhaled insulin to treat diabetes [75-77]) as well as vaccination (e.g. measles 
[78-80], influenza virus [81, 82]). Moreover, dry formulation of vaccines may improve the storage 
stability and decrease the need for cold-chain transport requirements [80].  
The ideal powder vaccine for mass vaccination of poultry should meet the following 
requirements: (1) shows no or only limited virus loss during production and storage; (2) is 
monodisperse; (3) has a size that will enable exclusive targeting of the high respiratory tract for primary 
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vaccinations or the lower respiratory airways for secondary (booster) vaccinations; (4) is easy to disperse 
into its primary particle size; (5) is non-hygroscopic to prevent hygroscopic growth of the vaccine 
powder particles in the airways during respiration [83]; and (6) is non-toxic for man, animals and the 
environment. 
 
3.2.  Production of dry powder vaccines  
3.2.1.  Conventional production of respirable dry vaccine particles 
The most conventional method to produce dry vaccines from a liquid vaccine is by freeze-drying. 
This technique involves the separation of the water phase from the solid material by freezing (-50 to -
80ºC) and the subsequent removal of formed ice crystals by sublimation at a higher temperature and 
under low pressure (i.e. primary drying phase). In a secondary drying phase, remaining not frozen water 
can be removed by a further increase of the temperature under low pressure [84]. Afterwards, a porous 
freeze-dried cake is obtained, which requires additional micronisation into respirable particle sizes (e.g. 
<5 µm for human pulmonary vaccine delivery [85]), usually performed by air-jet milling. However, air-jet 
milling may alter the physical properties of the powder by introducing amorphous regions into 
crystalline material and allows poor control over particle size, shape and morphology [86, 87]. Also, 
milling can result in cohesive electrostatically charged micronized particles, complicating redispersion of 
particles into their primary size [87]. 
Furthermore, freeze-drying and subsequent milling are batch processes, coping with a number 
of issues associated with batch processing such as limited reproducibility of product quality, scaling-up 
difficulties and high costs, mainly due to poor product yield [88, 89].  
 
3.2.2. Spray drying of dry powder vaccines 
Due to constraints of freeze-drying and air-jet milling, recently the production of dry powder 
vaccines was attempted using spray drying, a continuous and cost-effective production process [90]. 
Powder vaccines produced using this technique were successfully used to immunize broilers against 
NDV and showed to be equally effective as current spray and aerosol vaccines at inducing humoral 
response against this virus [91]. 
. 
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3.2.2.1. Principle  
Spray drying is a single-step process, converting a solids-containing liquid into a dry product by 
removal of the liquid phase, usually water. Figure 3 shows a schematic overview of a co-current and 
mixed flow open spray drying process.  
 
 
 
Figure 3: Schematic overview of (A) a co-current and (B) a mixed flow open spray drying system 
 
In short, a liquid feed is pumped and atomized into a drying chamber under a stream of hot air. 
The liquid phase in the airborne droplets evaporates, yielding dry powder particles at the bottom of the 
drying chamber. Coarse particles can sediment from the air stream due to gravitation and can be 
recovered from the bottom of the drying chamber. Fine particles are engulfed by the air stream 
travelling towards the cyclone for particle recovery (Figure 3A & B). In an open spray drying system, the 
air is discharged into the open air after filtering. The term ‘co-current’ refers to the nebulization of the 
liquid feed in the same direction as the stream of hot air throughout the spray drying system (Figure 3A), 
while in the mixed flow mode or ‘fountain’ mode the feed is introduced in the bottom of the drying 
chamber and the hot air in the top (Figure 3B). 
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3.2.2.2. Spray drying vaccines for aerosol delivery 
Essential product characteristics of powder vaccines such as particle size, morphology, density 
and moisture content can be defined by adjusting the process parameters of spray drying.  
Particle size is a critical parameter in aerosol drug delivery as it defines the particle deposition 
area within the respiratory tract. A key parameter for particle size control in spray drying is atomization. 
The droplet characteristics will define the particle characteristics, i.e. droplet size proportionally affects 
the resulting particle size [92]. Various atomization systems are available for spray drying with different 
driving forces to tear up the fluid into droplets (e.g. pneumatic, pressure, rotary and ultrasonic forces). 
An excellent description of each atomizer is given by Masters [92]. Apart from atomizer design variation, 
also the atomization settings such as spray rate and atomization air flow may affect the droplet 
characteristics and thus the particle properties [92].  
 Relevant to drying heat-sensitive products such as vaccines is the process temperature. In spray 
drying, hot air of a set temperature, referred to as the inlet temperature, is introduced at a single point. 
The evaporation of droplets cools down the system until complete drying, resulting in a lower outlet 
temperature compared to the inlet temperature. In co-current drying, feed and hot air move in the 
same direction so the dry product is mainly exposed to the outlet temperature. It is stated that heat 
stress to the product after atomization, caused by the high inlet temperature, is limited due to the 
cooling effect of the evaporating liquid phase. However, in a mixed flow mode (Figure 3B), the liquid 
feed is atomized in the opposite direction of the hot air, so the evaporative cooling effect on the drying 
product is lower, making this a less suitable method for drying heat-sensitive products. 
 Nevertheless, spray drying biopharmaceuticals (e.g. vaccines, proteins, bacteria) requires the 
addition of stabilizing excipients to conserve their integrity during the dehydration process and during 
storage afterwards. In case of vaccines, which are low in mass, stabilizers also provide bulk mass, 
facilitating handling and dosing. Moreover, as in the case of dry powder vaccines the yielded powder 
mainly consists of stabilizers, their inherent characteristics in dry state, such as hygroscopicity, will 
largely determine the powder vaccine properties. Sugar compounds (e.g. trehalose [93, 94], sucrose [95, 
96], inulin [82, 97], mannitol [93, 95], myo-inositol [78]) are often used for the protection of 
biopharmaceuticals subjected to spray drying. The sugar molecules, which are rich in hydroxyl functional 
groups, will conserve the three-dimensional conformation of the biopharmaceutical by replacing the 
water molecules by hydrogen-bond interaction. The solid stabilizer matrix, often of amorphous nature, 
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serves during storage as a physical barrier between the biopharmaceutical particles and reduces the 
particle mobility, preventing particle aggregation and degradation [98]. Other compounds may be added 
such as polymers (e.g. dextran [93, 99], polyvinylpyrrolidon [100, 101]) and proteins (e.g. bovine serum 
albumin [102, 103]) to preserve the amorphous character of the solid matrix or to interact directly with 
the biopharmaceutical compound.  
 Although the nature of the solid compounds in the feed formulation largely determines the 
powder properties, also the amount of solids in the liquid feed generally leads to larger particles and 
higher process yields [92]. 
 
3.3. Previous developments of Newcastle disease dry powder vaccines 
It is very important to know the particle size required to target specific areas of the respiratory 
tract of each poultry category when developing dry powder vaccines. Broilers are usually vaccinated 
immediately after hatch (primary vaccination) and at 2 and/or 4 weeks of age (secondary vaccination). 
As the respiratory tract differs in size according to age, also the particle size deposition pattern will be 
altered. Moreover, while vaccine deposition in the lower airways is required during secondary 
vaccination, it is undesired during primary vaccination (Section 1.3.3.2.B). Therefore, a detailed 
deposition study using differently size microspheres in broilers was performed by Corbanie et al. [35], 
who defined the optimal particle size required to target the upper or lower airways at different ages. 
Coarse particles exceeding 20 µm were considered suitable for the primary vaccination of newly-
hatched chicks in order to avoid vaccine deposition in the lower respiratory tract. The cut-off size for 
particle deposition in the lower airways for secondary vaccination was set at 5 and 10 µm for broilers of 
2 and 4 weeks of age, respectively. 
NDV powder vaccines were produced previously by Fournier and Gaudry by milling the freeze-
dried vaccine cakes into fine powders [104, 105]. Although good serological responses were obtained 
after administration [105], this technique did not allow the manufacturing of powder vaccines with 
narrow-sized particle spectra. In contrast, Corbanie et al. were able to improve the monodispersity of 
NDV powder vaccines by means of spray drying, although particle size distributions were not optimal for 
secondary vaccination (<5 µm or <10 µm) [91, 106]. Upon dry air-dispersion the fine powder vaccines 
were not well deagglomerated and only powders with a primary particle size below 10 µm were 
produced.  
 CHAPTER 1: INTRODUCTORY BACKGROUND & AIM OF THE THESIS 
 
24 
 
Although the produced spray dried powder vaccines, consisting of trehalose with 
polyvinylpyrrolidon and/or bovine serum albumin, stabilized the NDV vaccine during spray drying, they 
were highly hygroscopic and significant vaccine losses were observed during storage. An exception was 
the low hygroscopic mannitol powder vaccine, which was stable during storage, but suffered from 
severe vaccine loss during spray drying [106].  
Nevertheless, all formulations elicited similar serological responses after vaccination of 4-week-
old SPF broilers compared to the commercial liquid spray and aerosol vaccines [72]. 
 
4. AIM OF THE THESIS 
 
In general, this project aims to provide a valuable alternative to the liquid spray and aerosol 
mass vaccination techniques currently used in large poultry farms. As many shortcomings of the liquid 
vaccination techniques, described in Section 3.1, are due to the presence of water, dry powder vaccines 
are considered to provide a good alternative. The ideal powder vaccine for mass vaccination of poultry 
should meet the following requirements: (1) no or only limited virus loss during production and storage; 
(2) monodisperse; (3) a size that will enable exclusive targeting of the high respiratory tract for primary 
vaccinations to avoid adverse vaccinal reactions or the lower respiratory airways for secondary (booster) 
vaccinations to improve vaccination efficiency; (4) easy to disperse into its primary particle size; (5) non-
hygroscopic to prevent hygroscopic growth of the vaccine powder particles in the airways during 
respiration; and (6) non-toxic for man, animals and the environment.  
Previous research has determined the ideal particle size for each vaccination age (>20 µm for 
primary vaccination of one-day-old chicks, <5 µm and <10 µm for secondary vaccination of 2 and 4-
week-old chickens, respectively). The particle size cut-off at 20 µm for primary vaccination of one-day 
old chickens was set to avoid vaccine deposition in the lower respiratory tract, which would induce more 
adverse vaccinal reactions. Previous research by Corbanie et al. demonstrated that a dry powder vaccine 
could be produced by spray drying and induce similar immune responses after vaccination as the liquid 
vaccines.  
In this work the dry powder vaccines were re-formulated and compared in vivo with 
corresponding liquid vaccines regarding vaccination efficiency and the induction of adverse vaccinal 
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reactions. In addition, confirmation of the hypothesis that the increased occurrence of adverse vaccinal 
reactions after primary vaccination is due to vaccine deposition in the lower airways, was pursued.  
 In a first part, the composition of the vaccine formulation was reviewed and optimized in order 
to develop a powder vaccine with good vaccine stability during spray drying and storage. Furthermore, 
the powders were evaluated according to their suitability for aerosolization, such as low hygroscopicity 
(to prevent hygroscopic growth during inhalation) and good dry dispersion performance. 
 Next, the spray drying process was investigated and adjusted to produce the selected 
formulation into adequate particle sizes as defined by the deposition study performed by Corbanie et al. 
[35] (i.e. >20 µm for the primary vaccination of day-old chicks, <5 µm and <10 µm for the secondary 
vaccination of 2- and 4-week-old broilers, respectively). NDV powder vaccines produced by Corbanie 
[68, 91] for secondary vaccination were not well deagglomerated upon dry air-dispersion and were only 
produced with a primary particle size below 10 µm suitable for the secondary vaccination of 4-week-old 
chickens. 
The developed NDV powder vaccines (coarse and fine powders vaccine) were then evaluated in 
vivo in 4-day-old SPF broiler chicks and compared with the commercially available liquid spray and 
aerosol vaccines regarding adverse vaccinal reactions and vaccination efficiency. 
Finally, an in vivo study was performed to investigate whether the manufacturing of a 
monodisperse coarse dry powder vaccine, devoid of small particles (<20 µm), could significantly reduce 
the adverse vaccinal reaction compared to the conventional coarse liquid vaccine, while maintaining a 
similar immune response. Therefore, an eye-nose drop Newcastle disease vaccination, warranting 
vaccine deposition in the upper airways, was compared with a conventional liquid spray vaccine 
regarding adverse vaccinal reactions and humoral response.  
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CHAPTER 2 
SUITABILITY OF DIFFERENTLY FORMULATED DRY 
POWDER NEWCASTLE DISEASE VACCINES FOR MASS 
VACCINATION OF POULTRY 
1. INTRODUCTION  
To provide a better alternative for current liquid spray and aerosol vaccines, the ideal powder 
vaccine should meet the following requirements: (1) shows no or only limited virus loss during 
production and storage; (2) is monodisperse to improve vaccination efficiency; (3) has a size that will 
enable exclusive targeting of the high respiratory tract for primary vaccinations or the lower respiratory 
airways for secondary vaccinations; (4) is easy to disperse into its primary particles; (5) is non-
hygroscopic to prevent hygroscopic growth of the vaccine virus particles in the airways during 
respiration (Morrow, 1986); and (6) is non-toxic for man, animals and environment. 
Corbanie and others were able to produce Newcastle disease virus (NDV) powder vaccines with 
narrow particle size distributions by means of spray drying [1]. Although these spray dried powder 
vaccines consisting of trehalose with polyvinylpyrrolidone (PVP) and/or bovine serum albumin (BSA) 
stabilized the NDV vaccine during spray drying, they were highly hygroscopic, complicating complete 
deagglomeration upon dry dispersion, and significant vaccine losses were observed during storage. An 
exception was the low hygroscopic mannitol powder vaccine which was stable during storage, but 
suffered from severe vaccine titre loss during spray drying [1].  
Therefore, further improvement of spray dried powder vaccines regarding vaccine stability, 
hygroscopicity and dispersibility, was attempted in a series of studies. At this stage, it was not the aim to 
produce powder vaccines with defined particle sizes and a narrow span.  
To combine the stabilizing properties of the carriers used by Corbanie et al. [1] during spray 
drying and storage, in this study mannitol was spray dried with trehalose and PVP and/or BSA. In order 
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to minimize hygroscopicity, the formulation mainly consisted of mannitol. Inositol, a low hygroscopic 
sugar, was introduced as a new stabilizer as substitute for trehalose in the powder formulation. After 
preliminary experiments focusing on vaccine stability, dry-dispersibility and hygroscopicity, the 
optimization of a selected NDV vaccine formulation was investigated in the main experiments. 
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2. MATERIALS AND METHODS 
2.1. Preliminary experiments 
2.1.1.  Powder formulations and spray drying 
Combinations of mannitol (C*Mannidex, Cargill, Krefeld, Germany), trehalose (Treha 16400, 
Cargill, Krefeld, Germany), inositol (myo-inositol, Sigma-Aldrich, Steinheim, Germany), PVP (Plasdone® K-
25, ISP, Switzerland) and BSA (Sigma-Aldrich, Steinheim, Germany) were prepared as 5% (wt/wt) 
aqueous solutions, using the ratios as shown in Table 1. The feed solutions supplied at a rate of 7.5 
ml/min were spray dried in a Büchi B-290 spray dryer (Büchi Labortechnik AG, Flawil, Switzerland) with 
an inlet temperature set at 150ºC and an outlet temperature at 70-75ºC. Immediately before spray 
drying NDV vaccine virus (LZ58 strain, kindly provided by Intervet, Boxmeer, the Netherlands) was added 
to the feed solution aiming at a virus titre of 1010 50% egg infectious dose (EID50) per 100 ml feed 
solution. A sample of 1 ml feed suspension was taken immediately after preparation and stored on ice 
until virus titration was performed, which was done within 3 h. During the spray drying process, the 
feedstock was kept on ice to minimise the virus loss. The spray dried powder samples were stored in 
sealed glass vials at 6ºC (conditioned room) or 25ºC (incubator; Memmert INP 600, Memmert GmbH, 
Schwabach, Germany) packed in airtight aluminium bags.  
 
Table 1: Preliminary experiments: composition of feed solutions
1
 for preparation of NDV powder vaccines
2
 
 
Content (wt/wt %) 
 
Mannitol Trehalose Inositol PVP BSA 
Mannitol trehalose series 90 10 - - - 
 
80 10 - 10 - 
 
80 10 - - 10 
 
60 20 - 10 10 
      Mannitol inositol series 90 - 10 - - 
 
80 - 10 10 - 
 
80 - 10 - 10 
 
60 - 20 10 10 
1
 5% (wt/wt) aqueous solutions. 
2
 approximately 10
10
 EID50 LZ58 NDV was added per 100 ml feed for the production of powder vaccines. 
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Powder vaccines without polymer or protein were prepared once while those containing 
polymers were spray dried in duplicate. Placebo powders used to assess the powder characteristics 
were spray dried in triplicate. 
 
2.1.2. Assessment of virus concentrations 
Samples of the feed solution (1:10 dilution in Dulbecco’s phosphate buffered saline (DPBS, 
Gibco, Invitrogen, Paisley, UK)) and powders (100 mg dissolved in 1 ml DPBS) were titrated in specified 
pathogen free (SPF) chicken eggs in order to determine the loss of vaccine virus infectivity during spray 
drying. The vaccine virus titre of the powders was also determined after 1, 6 and 12 months storage at 
6ºC or 25ºC to investigate the stabilizing properties of the powders. Tenfold dilution series of the 
samples were prepared in sterile DPBS containing 1% penicillin-streptomycin solution (Penicillin G 
(10,000 IU/ml)-streptomycin sulphate (10,000 µg/ml) solution, Invitrogen, Paisley, UK). Of each dilution, 
100 µl was injected into the allantoic cavity of 10-day-old embryonated SPF eggs (4 eggs per dilution).  
After incubating the eggs during 72 h at 37 ºC the allantoic fluid of the eggs was tested for 
haemagglutinin activity [2]. Virus titres were calculated as EID50 according to Reed and Muench [3]. The 
detection limit was calculated through assumption of the minimal requirements for applying the 
formula of Reed and Muench (i.e. 3/4 infected eggs using the undiluted suspension and no infected eggs 
injected with diluted suspensions) leading to a detection limit of 102.3 EID50 per g powder. 
 
2.1.3. Characterization of powders 
2.1.3.1 Moisture-related powder properties 
To determine the residual moisture content, Karl Fischer titrations (Mettler DL35, Mettler 
Toledo, Zaventem, Belgium) were performed on the powder samples immediately after production. 
Powder (100-200 mg) was added to an airtight beaker containing absolute dry methanol (Biosolve, 
Valkenswaard, the Netherlands). Titration of the samples was performed using Karl Fischer reagent 
(Hydranal® Composite 2, Sigma-Aldrich, Munich, Germany). The mixture was stirred for 5 min before 
actual titration. All titrations were carried out in triplicate. 
The hygroscopic nature of the powders was investigated by dynamic vapor sorption (DVS 
Advantage, Surface Measurement Systems, Middlesex, UK). Using this technique, water sorption 
isotherm curves were recorded for each powder sample. Powder (10-20 mg) was weighed in the sample 
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cup. Prior to exposure to various relative humidities (RH), the samples were dried under a stream of dry 
nitrogen at 25ºC until equilibrium (i.e. a weight change of less than 0.002% per minute during at least 15 
min). Subsequently, the RH was increased from 0 to 90% by steps of 10% at 25ºC allowing equilibration 
at each interval. 
 
2.1.3.2 Physical state of powders 
The occurrence of amorphism and crystallinity in the spray dried powders was investigated 
using differential scanning calorimetry (DSC) (DSC Q2000, TA Instruments, Zellik, Belgium). Samples of 
spray dried powders (5-10 mg) were transferred into a hermetically sealed aluminium cup, and after 1 
min equilibration at 10ºC the temperature was increased at a rate of 20ºC/min to 250ºC. 
 
2.1.3.3  Dry dispersion properties of the spray dried powders 
Particle size distributions of the powders were measured within 24 h after production by laser 
diffraction using a Malvern Mastersizer-S long bench (Malvern Instruments, Malvern, UK). Primary 
particle sizes were compared to the particle sizes measured during dry dispersion of the powder to 
evaluate the dry dispersion properties of the powder. The obtained particle size parameters from the 
measurements were volume diameters D(v, 0.1), D(v, 0.5), D(v, 0.9). The results were expressed as the 
ratio of the particle size parameters measured by dry and wet dispersion (dry/wet ratio). Powders with a 
significant increase (P <0.05) in D(v, 0.1), D(v, 0.5) and D(v, 0.9) parameters upon dry dispersion (dry/wet 
ratio >1) were categorized as poorly dry dispersible. When only D(v, 0.1) significantly increased upon dry 
dispersion, the dry dispersibility of the powder was classified as ‘incomplete’. 
Measurement of the primary particle size distributions was taken by the wet dispersion method 
using the 300 RF lens (Malvern Instruments, Malvern, UK). Powder samples were dispersed in Miglyol  
812N (capric triglyceride; Sasol, Hamburg, Germany) with 0.2% Tween  80 (polysorbate 80; Fagron, 
Waregem, Belgium) and subsequently sonicated to remove visible agglomerates. 
Dry dispersion of the powders was performed using an experimental nebulizer consisting of a 
small compressor (OMRON CX3, Hoofddorp, the Netherlands) generating an air flow of 10 l/min coupled 
to a glass Büchner flask (Schott Duran 100 ml, Mainz, Germany) and expelling the powder particles via a 
21 cm long plastic tube (Tygon  Laboratory Tubing R3603, Saint-Gobain Performance Plastics, Akron 
(OH), USA). Powder samples were dispersed directly into the laser beam of the laser diffractor. During 
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the measurements, the orifice (2x10 mm) of the disperser was held 4 cm from the laser beam and 4 cm 
from the lens (300 mm lens, Malvern Instruments, Malvern, UK). All measurements were taken in 
triplicate. 
 
2.2. Main experiments 
2.2.1. Powder formulations and spray drying 
Based on the stabilizing properties of the powders observed in the preliminary experiments, 
mannitol, inositol and BSA were selected as powder compounds in the main experiments. A modified 
simplex centroid mixture design [4] was carried out to investigate the influence of each stabilizer on 
vaccine stability (i.e. remaining vaccine titre), the residual moisture content and the hygroscopicity after 
spray drying. To assure sufficient powder yield after spray drying, each formulation contained a 
minimum of 60% mannitol as concluded from other experiments (unpublished results). The ratios 
between mannitol, inositol and BSA were varied as shown in Table 2. Three centre points were included 
in the design to allow random error estimation. The design was generated and analysed using MODDE 
software (MODDE 9.0, Umetrics, Sweden) [4].  
 
 
Table 2: Main experiments: composition of the feed solutions
1
 for preparation of NDV powder vaccines
2
 
Formulation Content (wt/wt %) 
 
Mannitol  Inositol BSA 
1 100 - - 
2 60 40 - 
3 60 - 40 
4 80 20 - 
5 80 - 20 
6 60 20 20 
7 86.7 6.7 6.7 
8 66.7 26.7 6.7 
9 66.7 6.7 26.7 
10, 11, 12
2
 73.3 13.3 13.3 
1
 10% (wt/wt) aqueous solutions. 
2 
Approximately 10
10
 EID50 LZ58 NDV was added per 100 ml feed for the production of powder vaccines.  
3
 Replicate experiments. 
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Formulations were prepared as 10% (wt/wt) aqueous solutions with approximately 1010 EID50 of 
NDV vaccine virus (LZ58) per 100 ml and subsequently spray dried using a Büchi B-290 laboratory scale 
spray dryer at the same settings as for the powders of the preliminary experiments. Placebo powders 
were spray dried in triplicate to determine the powder characteristics. 
 
2.2.2. Assessment of virus concentrations and powder characteristics 
Virus titres of the feed solutions and spray dried powders were determined by virus titrations in 
chicken SPF eggs immediately after production and after 1 and 6 months storage at 6ºC or 25ºC. 
Titrations were performed as described in ‘Assessment of virus concentrations’ (Section 2.1.2). The 
detection limit was 102.3 EID10 per g powder. 
Placebo powders were characterized immediately after production for moisture content, 
hygroscopicity at 60% RH and dry dispersion properties as described previously (Section 2.1.3). The 
morphology of the spray dried samples was examined by scanning electron microscopy (SEM) (SEM 
Quanta 200F, FEI, Hillsboro (OR), USA). To improve the electron conductivity of the samples, a gold 
coating of approximately 40 nm was sputtered onto the samples. 
 
2.3. Statistical analysis 
The moisture content data and particle size parameters of the preliminary experiments obtained 
by wet and dry dispersion were statistically evaluated by a one-way ANOVA (SPSS 16.0; SPSS, Chicago 
(IL), USA) and checked for homogeneity of variances using the Levene test. Log-transformation of data 
was performed when needed to obtain good homogeneity of variances.  
The dry and wet dispersion data of the powders from the main experiments were analysed in 
the same way. The raw data of the remaining vaccine titre (%) after spray drying and storage were 
evaluated by means of a replicate plot (MODDE 9.0, Umetrics, Sweden). A replicate plot evaluates the 
random variability of the data versus the variability obtained by changing factors. The data of residual 
moisture content and hygroscopicity of the samples were also analysed using this software and plots of 
the scaled and centred model coefficients were generated. 
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3 RESULTS 
3.1 Preliminary experiments 
3.1.1. NDV vaccine concentrations after spray drying and storage 
The virus titre of the feeds ranged from 109.0-10.5 EID50 per 100 ml for both the preliminary and 
the main experiments. The loss of virus titre after spray drying of the NDV vaccine containing feeds and 
after storage of the powders at 6ºC or 25ºC is shown in Table 3. The mannitol/trehalose combination led 
to the highest titre loss after spray drying (2.9 log10 EID50), while a loss of 1 log10 EID50 was observed 
using the combination of mannitol with inositol. The virus titres in the powder formulations containing 
also PVP and/or BSA were reduced by 1.3-2.6 log10 EID50 after spray drying. 
 
Table 3: Preliminary experiments: loss of virus titre after spray drying and storage of the spray dried NDV powders 
(n = 2) 
Formulation
1
 Loss of virus titre (10
x
 EID50) 
 
after spray 
drying 
1 month 6 months 12 months 
 
6ºC 25ºC 6ºC 25ºC 6ºC 25ºC 
Mannitol/trehalose 2.9 1.9 2.5 -
2
 - - - 
Mannitol/trehalose/PVP 1.3/2.3 0.5/0.8 3.2/- 2.5/1.8 >5.7
3
/- >5.7/3.5 >5.7/- 
Mannitol/trehalose/BSA 1.8/2.3 0.5/0.3 0.8/1.2 1.5/1.0 3.5/2.2 1.7/1.3 4.8/3.5 
Mannitol/trehalose/PVP/BSA 2.5/1.5 0.0/0.0 1.0/0.7 0.3/0.0 3.3/2.8 0.8/0.7 >4.2/3.3 
        Mannitol/inositol 1.0 0.3 3.8 1.1 3.8 2.3 >5.0 
Mannitol/inositol/PVP 2.0/2.0 1.0/0.0 2.2/2.1 1.5/- >5.2/- 2.0/-  >5.2/-  
Mannitol/inositol/BSA 2.1/1.8 1.0/0.5 1.0/0.2 1.0/0.0 2.0/2.9 1.2/1.2 3.3/>4.9 
Mannitol/inositol/PVP/BSA 2.0/1.8 0.0/0.0 0.5/0.5 0.5/1.7 2.3/3.3 1.5/0.8 >4.7/4.2 
1
 Ratios of powder compounds are given in Table 1. 
2
 Not done. 
3
 > Symbol indicates virus titre was below detection limit (10
2.3
 EID50/g). 
 
After 12 months storage, the powder vaccine titres declined more severely when stored at 25ºC 
than at 6ºC, resulting in final vaccine titres below the detection limit (102.3 log10 EID50/g) for most powder 
formulations. The vaccine stability in the powders did not depend on the use of trehalose or inositol as 
similar results were obtained for both powder series. However, the presence of BSA in the powder 
formulation enhanced the vaccine stability when powders were stored during 12 months at 6ºC, losing 
between 0.7 and 1.7 log10 EID50, regardless whether BSA was used together with PVP or not.  
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3.1.2. Moisture-related powder properties 
Although the moisture contents of all powders were low (max. 1.5%), adding PVP and/or BSA 
significantly (P <0.05) increased the moisture content of powders (Table 4). This effect was more 
pronounced for the trehalose powders, as shown also by the water sorption experiments (Figure 1). The 
water uptake by trehalose powders was generally higher than that of inositol powders: a maximal water 
uptake of 8.7% was observed at 90% RH in case of the mannitol/trehalose/PVP/BSA formulation, while 
the mannitol/inositol/PVP/BSA powder contained 3.2% water at 90% RH. 
 
 
Table 4: Preliminary experiments: mean moisture content (n = 3), mean melting and glass transition temperature 
(n = 3) of spray dried powders 
Powder formulation
1
 Mean moisture content ± SD DSC
2
 
 
 Tm ± SD Tg ± SD 
 
(%) (ºC) (ºC) 
Mannitol/trehalose  0.5 ± 0.1
a
 164 ± 3 73 ± 10 
Mannitol/trehalose/PVP 0.8 ± 0.0
b
 160 ± 2 88
3
 
Mannitol/trehalose/BSA 1.1 ± 0.1
c
 160 ± 3 59 ± 3 
Mannitol/trehalose/PVP/BSA 1.5 ± 0.1
d
 161 ± 0 58 ± 7 
   
89 ± 1 
    Mannitol/inositol 0.3 ± 0.1e 160 ± 1 - 
Mannitol/inositol/PVP 0.5 ± 0.0
a
 157 ± 3 86 ± 2 
Mannitol/inositol/BSA 0.5 ± 0.0
a
 156 ± 2 62 ± 3 
Mannitol/inositol/PVP/BSA 0.5 ± 0.1
a
 157 ± 3 90
3 
1
 Ratios of powder compounds are given in Table 1. 
2
 DSC = Differential scanning calorimetry experiments: Tm = melting temperature; Tg = glass transition temperature. 
3 
Measured once. 
a-e 
Values with different superscript were significantly different (P <0.05). 
 
 
  
 
 
 
Figure 1: Preliminary experiments: Water sorption isotherms (25ºC) obtained from dynamic vapor sorption 
experiments; A. mannitol/trehalose series; B. mannitol/inositol series. 
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3.1.3. Physical state of powders 
According to the DSC-results, presented in Table 4, all powders were crystalline with a melting 
peak around 160ºC due to the presence of mannitol. However, except for the mannitol/inositol 
formulation, glass transition temperatures were observed in the powders, indicating that these powder 
matrices are not purely crystalline, but are to a certain degree also amorphous. PVP-containing powders 
showed the highest glass transition temperatures (Tg= 88-90ºC), followed by the mannitol/trehalose 
powder (Tg = 73ºC).  
 
3.1.4. Dry dispersion properties of the spray dried powders 
The D(v, 0.1), D(v, 0.5) and D(v, 0.9) of the powders when measured in wet dispersion mode 
ranged from 1.7 to 13.3 µm, 7.5 to 62.7 µm and 17.5 to 221.5 µm, respectively. Table 5 shows the 
dry/wet ratio of the particle size parameters when measured by wet dispersion (primary particle size) 
and by dry dispersion method immediately after production. All powders had a significantly higher D(v, 
0.1) after dry dispersion, while D(v, 0.5) and D(v, 0.9) were similar upon wet and dry dispersion. This 
indicated that only the smallest particles could not be deagglomerated via the dry dispersion method 
and the dispersibility of the powders was categorized as incomplete via the dry dispersion method. 
 
Table 5: Preliminary experiments: Ratio of dry/wet particle size (n = 3) and dry powder dispersibility of spray dried 
powders 
Powder formulation
1
 Ratio of dry/wet particle size Dry powder dispersibility 
     
 
D(v, 0.1) D(v, 0.5) D(v, 0.9) 
 Mannitol/trehalose  3.8A 0.9 0.7 incomplete 
Mannitol/trehalose/PVP 1.7
A
 1.0 1.5 incomplete 
Mannitol/trehalose/BSA 1.4
A
 1.1 1.1 incomplete 
Mannitol/trehalose/PVP/BSA 2.7
A
 0.9 1.1 incomplete 
     Mannitol/inositol 3.6A 1.0 0.9 incomplete 
Mannitol/inositol/PVP 3.0
A
 0.9 0.7
A
 incomplete 
Mannitol/inositol/BSA 3.1
A
 1.1 1.2 incomplete 
Mannitol/inositol/PVP/BSA 3.6
A
 1.1 0.9 incomplete 
1
 Ratios of powder compounds are given in Table 1. 
A
 Particle sizes measured by dry and wet dispersion method were significantly different (P <0.05). 
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3.2. Main experiments 
No valid model could be calculated for vaccine loss after spray drying and storage; however, 
some trends could be observed from the individual experiments (Table 6).  
 
Table 6: Main experiments: Loss of virus titre after spray drying and storage (n = 1) of the powder formulations 
1
 10% (wt/wt) Aqueous solutions. 
2
 
 
> Symbol indicates virus titre was below detection limit (10
2.3
 EID50/g). 
3
 Not done. 
 
The highest titre loss, being 4.5 log10 EID50, occurred when only mannitol was used during spray 
drying. Integrating inositol and/or BSA in the mannitol matrix limited the titre loss to 1.4-3.7 log10 EID50, 
depending on the ratio of the stabilizer compounds. In general, inositol concentrations ≥20% in the 
mannitol-matrix resulted in higher titre loss after spray drying (2.9-3.7 log10 EID50) in comparison with 
BSA-containing powders (±2 log10 EID50), with the exception of mannitol/inositol/BSA (60:20:20) which 
lost only 1.4 log10 EID50. 
When stored for 1 month at 6ºC, notable titre losses were observed for only 2 formulations: 
formulation 2 (mannitol/inositol (60:40)) with 1.1 log10 EID50 and formulation 10 (mannitol/inositol/BSA 
(73.3:13.3:13.3)) with 0.8 log10 EID50. The decline in vaccine titre was more pronounced when the 
powder vaccines were stored at 25ºC during the same period. Exceptions were formulations 11 and 12 
(a replicate of 11) in which no loss of vaccine was observed. In contrast, formulation 10, having identical 
composition as formulation 11 and 12, did show vaccine titre loss after 1 month storage. 
Formulation Content
1
 (wt/wt %) Loss of virus titre (10
xEID50) 
  after spray 
drying 
1 month 6 months 
 
Mannitol 
 
Inositol BSA 6ºC 25ºC 6 ºC 25ºC 
1 100 - - 4.5 0.2 1.0 0.5 >1.7
2
 
2 60 40 - 2.9 1.1 2.1 1.6 2.8 
3 60 - 40 2.8 0.3 0.7 0.5 3.5 
4 80 20 - 3.7 0.0 1.1 0.3 1.3 
5 80 - 20 2.2 0.0 1.3 1.0 3.3 
6 60 20 20 1.4 0.2 2.3 1.3 >5.0 
7 86.7 6.7 6.7 2.1 0.2 1.0 1.2 3.7 
8 66.7 26.7 6.7 2.9 0.3 1.3 -
3
 -  
9 66.7 6.7 26.7 2.1 0.0 1.0 1.3 4.2 
10 73.3 13.3 13.3 1.7 0.8 1.6 0.8 3.1 
11 73.3 13.3 13.3 1.6 0.0 0.0 - -  
12 73.3 13.3 13.3 2.0 0.0 0.0 - -  
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Titre losses after storage during 6 months at 6ºC were relatively low (max. 1.6 log10 EID50 for 
mannitol/inositol (60:40)), while stored at 25ºC the titre of mannitol (100%) and mannitol/inositol/BSA 
(60:20:20) dropped below the detection limit (102.3 EID50/g).  
Higher BSA concentrations in the powder increased moisture content and hygroscopicity of the 
formulations as indicated by the coefficient plots in Figure 2. The highest moisture content (3.5%) and 
water uptake at 60% RH (5.6%) were found for the powder formulation with the highest BSA content 
(mannitol/BSA (60:40); Table 7).  
 
Figure 2: Main experiments: coefficient plots of residual moisture content (A) and hygroscopicity (B) responses 
(man = mannitol; ino= inositol; BSA = Bovine Serum Albumin). Note the significant positive effect of BSA on the 
residual moisture content and hygroscopicity. 
Table 7: Main experiments: mean moisture content (n = 3), water sorption at 60% RH (n = 1), ratio of dry/wet 
particle size (n = 3) and dry powder dispersibility 
Formulation Content (wt/wt %) Mean 
moisture 
content 
± SD 
Water 
sorption 
at 60% 
RH 
Ratio of dry/wet particle size Dry powder 
dispersibility 
  Mannitol Inositol BSA (%) (%) D(v, 0.1) D(v, 0.5) D(v, 0.9)   
1 100 - - 0.2 ± 0.0 0.2 0.8 1.1 1.9 good 
2 60 40 - 0.1 ± 0.0 0.1 1.1 0.7
A
 0.8
A
 good 
3 60 - 40 3.5 ± 0.1 5.6 3.2
A
 0.9 1.1 incomplete 
4 80 20 - 0.1 ± 0.0 0.1 1.1 0.7 1.3 good 
5 80 - 20 2.0 ± 0.2 2.9 2.1
A
 1.1 1.0 incomplete 
6 60 20 20 0.5 ± 0.2 3.1 2.9
A
 1.9
A
 3.7
A
 poor 
7 86.7 6.7 6.7 1.0 ± 0.3 0.4 0.8 0.5
A
 0.5
A 
good 
8 66.7 26.7 6.7 1.1 ± 0.0 1.0 0.4
A
 0.2
A
 0.3
A
 good 
9 66.7 6.7 26.7 2.1 ± 0.1 4.2 2.4
A
 1.2 1.1 incomplete 
10 73.3 13.3 13.3 1.4 ± 0.2 2.1 1.1 0.8
A
 0.8
A
 good 
11 73.3 13.3 13.3 1.1 ± 0.2 2 1.1 0.9
A
 0.9
A
 good 
12 73.3 13.3 13.3 1.3 ± 0.0 1.9 1.2
A
 1.0 1.0 incomplete 
A
 Particle sizes measured by wet and dry dispersion methods are significantly different (P <0.05). 
A            B 
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When measured in wet dispersion, the D(v, 0.1), D(v, 0.5) and D(v, 0.9) of the powders ranged 
from 2.1 to 15.4 µm, 7.7 to 193.0 µm and 15.8 to 449.0 µm, respectively. The dry dispersibility of the 
powders is outlined in Table 7. Powders with ≥20% BSA showed incomplete to poor deagglomeration of 
the particles upon dry dispersion.  
The powder particle morphology (Figure 3) was mainly influenced when 40% of inositol or BSA 
was present in the powders: spray drying 100% mannitol resulted in spherical particles (Figure 3A), while 
the spray dried powder mannitol/inositol (60:40) consisted of large agglomerates (Figure 3B) and 
mannitol/BSA (60:40) of strongly corrugated particles (Figure 3C). In other powders such as the 
mannitol/inositol/BSA formulation (73.3:13.3:13.3) in Figure 3 J, K and L (clusters of) spherical particles 
were observed. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Main experiments: scanning electron microscopy images of formulations 1-12 (A-L, respectively) of which 
compositions are given in Table 2.
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4. DISCUSSION 
Immediately after spray drying, the NDV powder vaccines were evaluated on several aspects: (1) 
NDV vaccine stability in the powder during production and storage; (2) dry dispersibility of the powder 
into its primary particles and (3) moisture content and hygroscopicity. 
To limit the NDV vaccine titre loss in the mannitol-matrix during spray drying, the incorporation 
of trehalose, inositol or polymers such as PVP and/or BSA was required: a reduction in titre loss from 4.5 
log10 EID50 in the mannitol powder (Table 6) to 1.3-2.9 log10 EID50 (Table 3) in the preliminary 
experiments was achieved. The amorphous fractions in the crystalline mannitol-matrix induced by 
trehalose, BSA or PVP could have added to the vaccine stability during spray drying by preserving its 
structural integrity through immobilization in a glassy matrix (vitrification) [5]. However, in the 
mannitol/inositol powder of the preliminary experiments, no glass transition temperature was 
measured, while only 1 log10 EID50 was lost after spray drying. It is possible that the amorphous phase 
induced by inositol remained undetected by DSC [6] or that vaccine virus stabilization mainly occurred 
due to hydrogen bond interaction between virus and inositol during drying (water replacement theory) 
[7]. The latter theory seems unlikely as the enveloped NDV vaccine is hydrophobic [8].  
A low storage temperature was beneficial for the vaccine integrity in the powders, as derived 
from the experiments, probably because the amorphous powder structure remains intact when stored 
at temperatures well below the glass transition temperature [9] and vaccine degradation reactions 
occur slower [10]. Although high glass transition temperatures would keep the vaccine more stable 
during storage, replacing PVP by BSA enhanced vaccine virus stability (Table 3). Probably other 
stabilizing mechanisms such as hydrophobic interaction of BSA [11-13] with the enveloped NDV vaccine 
were responsible for the vaccine storage stability, while PVP can only engage in hydrophilic interactions 
[14]. 
In the main experiments, mannitol was combined at varied ratios with inositol and BSA using a 
design of experiments, as inositol occurred less hygroscopic than trehalose in the preliminary 
experiments and BSA resulted in better vaccine stabilization during storage. Nevertheless, no valid 
model could be calculated for vaccine loss after spray drying and storage because the random variability 
of vaccine titre loss between the replicate samples (formulations 10, 11 and 12) was higher than the 
response variability obtained by changing the ratio of the compounds (formulations 1-9). This was 
partially due to the assay-inherent variability of 0.5-1.0 log10 units of the virus titration [15].  
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Based on the individual experiments, the mannitol/inositol/BSA (73.3:13.3:13.3) formulation 
was selected as the most suitable combination for stabilizing the NDV vaccine during production (virus 
titre loss of 1.6-2.0 log10 units) and storage (virus titre loss of 0.0-0.8 log10 units after 6 months at 6ºC). 
Considering its low hygroscopicity and good dry dispersibility (Table 7), the combination is qualified as a 
powder for inhalation. Mannitol is a well-tolerated sugar upon inhalation [16, 17] and is widely used in 
the pharmaceutical field [18] as well as in food industry [19]. Inositol is commonly present in food [20] 
and has no adverse effects after human oral consumption [21]; however, its effects upon inhalation by 
man or animal have not yet been reported. As BSA is a protein from animal origin, present in beef and 
cow milk, its consumption can in some cases provoke allergic reactions in humans [22]. Nevertheless, 
this powder combination is generally considered safe, although inhalation experiments in both man and 
animal should be performed to confirm this. 
This study did not focus on the production of powder vaccines with suitable particle size 
parameters (>20 µm for primary vaccination of young chicks, <5 µm and <10 µm for secondary 
vaccination of 2- and 4-week-old chickens [23]) as this can be achieved by adapting the spray dry 
equipment and process. However, for the production of powders consisting of particle sizes exceeding 
20 µm intended for primary vaccination of chickens, a higher BSA content could be needed as this will 
favour the formation of larger droplets upon feed atomization by increasing the feed viscosity and so 
larger particles will be formed [24].  
Although these powder NDV vaccines lose more vaccine titre during spray drying (average of 2 
log10 EID50) compared to their commercially freeze-dried counterparts (up to 0.5 log10 EID50 [25]), the 
titre loss of the spray dried powder vaccines after 1 year storage at 6ºC (1-1.5 log10 EID50) approximates 
that of the commercially freeze-dried NDV vaccines (1 year titre loss of max. 1 log10 EID50 [26]). It should 
be considered that in this study, all powders were spray dried at the same process parameters and the 
titre loss during spray drying could be decreased further by optimizing the spray dry process. 
Furthermore, the used spray dryer was a laboratory scale model in which case the powder recipient and 
powder remained into contact with the exhaust air temperature throughout the entire process. The 
powder is therefore exposed to higher temperatures than would be achieved in larger models in which 
powder discharge occurs during spray drying [24]. The feasibility of preparing NDV powder vaccines on a 
larger spray dryer model (Mobile Minor D-2000, GEA Niro, Soeborg, Denmark) was previously 
demonstrated [27]. 
                                                       CHAPTER 2 – SUITABILITY OF DIFFERENTLY FORMULATED DRY POWDER NEWCASTLE DISEASE VACCINES FOR MASS VACCINATION OF POULTRY 
 
 
50 
 
The potential advantages of dry powder NDV mass vaccination, i.e. improved airborne vaccine 
stability, reduction of negative vaccinal reactions and improvement of immune response in the birds 
might overcome the higher titre loss during spray drying. This will be examined in future experiments in 
which the effects of powder NDV vaccines will be compared with those of the currently applied liquid 
spray and aerosol vaccination methods in young broiler chicks. 
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5. CONCLUSION 
In conclusion, combining mannitol, inositol and BSA (in a ratio of 73.3:13.3:13.3) resulted in a 
storage-stable spray dried powder NDV vaccine with a low moisture content, low hygroscopicity and 
good dry powder dispersibility. Next, this stabilizer formulation will be used to develop powder vaccines 
with suitable particle size distributions for primary (>20 µm for day-old chicks) and secondary 
vaccination of broilers (<5 µm and <10 µm for 2- and 4-week-old broilers, respectively). 
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CHAPTER 3 
SPRAY DRYING POWDERS 
WITH SUITABLE PARTICLE 
SIZE DISTRIBUTIONS 
1. INTRODUCTION  
According to the deposition study performed by Corbanie [1], powder vaccines for primary 
vaccination of one-day-old broilers should consist of particles exceeding 20 µm, while for secondary 
vaccination of 2-week and 4-week-old chickens, vaccine particles smaller than 5 µm and 10 µm, 
respectively, are appropriate. During powder vaccine stability tests (Chapter 2) the particle size 
distribution of the produced powder formulations did not meet the above mentioned requirements. 
 In order to obtain the desired particle size distribution in spray dried powders, it is important to 
understand how particles are formed during the spray drying process. In short, after atomization of the 
feed liquid the moisture migrates from the inner droplet to the droplet/air surface by diffusional or 
capillary mechanisms and evaporates, causing shrinkage of the droplet until surface wetness can no 
longer be maintained, forming the particle [2]. Additional residence time of the formed particle in the 
spray drying equipment will lead to further removal of moisture until powder discharge. Thus, this 
indicates that the size of a spray dried particle is mainly defined by the size of the droplet and its solids 
content, meaning that the atomization system will play an important role throughout the spray drying 
process. In this chapter, a strategy to obtain powders with the required particle size distributions was 
designed. 
First, a laboratory scale spray dryer was used to define the most important process parameters 
which determine the particle size spectrum of a powder after spray drying. Then, the most significant 
process parameters were tested on a pilot plant dryer equipped with several atomization systems in 
order to determine the particle size range that can be produced with each configuration. Finally, based 
on the gathered knowledge, powders with specific particle sizes (<5 µm, <10 µm and >20 µm) were 
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produced and evaluated. For screening experiments mannitol was used as only excipient, while final 
experiments were conducted using the most suitable stabilizer combination as identified during 
previous experiments (mannitol 73.3 %, inositol 13.3 %, BSA 13.3 %; Chapter 2). 
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2. MATERIALS AND METHODS 
2.1 Screening of spray dryer systems  
2.1.1. Büchi™ B-290 laboratory scale spray dryer 
An experimental design (Table 1) was carried out using a laboratory scale spray dryer (Buchi™ B-
290, Flawil, Switzerland) with a maximum water drying capacity of 1 kg/h and equipped with an 
externally mixing two-fluid nozzle (air orifice = 1.5 mm ; feed orifice = 0.7 mm ).  
 
Table 1: Spray dry parameters for the experimental design performed using the Büchi™ B-290 lab-scale spray dryer 
Run Inlet air temperature Air flow
1 
Feed rate Solids
2
 
Nº (ºC) (ln/min) (ml/min) (wt/wt %) 
1 130 7.3 3.5 2.5 
2 170 7.3 3.5 2.5 
3 130 11.1 3.5 2.5 
4 170 11.1 3.5 2.5 
5 130 7.3 7.0 2.5 
6 170 7.3 7.0 2.5 
7 130 11.1 7.0 2.5 
8 170 11.1 7.0 2.5 
9 130 7.3 3.5 15 
10 170 7.3 3.5 15 
11 130 11.1 3.5 15 
12 170 11.1 3.5 15 
13 130 7.3 7.0 15 
14 170 7.3 7.0 15 
15 130 11.1 7.0 15 
16 170 11.1 7.0 15 
17, 18, 19
3 
150 9.0 5.0 8.75 
1 
Atomization air flow; ln/min = normalized l/min at 20ºC and 1 bar absolute. 
2 
Mannitol was used as excipient. 
3 
Replicate experiments. 
 
The impact of following spray dry parameters on the powder particle size was investigated: inlet 
temperature (130-170 ºC), atomization air flow (7.3 – 11.1 ln/min) and feed rate (3.5 – 7.0 ml/min). The 
solids content of mannitol in the solutions was varied between 2.5 – 15 % (wt/wt), the upper level was 
determined by the aqueous solubility of mannitol (17.5 % at 25 ºC; [3]). Three centre point replicate 
experiments were included to allow random error estimation. The regression model was improved by 
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removing non-significant coefficients from the model [4]. The experimental design was generated and 
analyzed using MODDE software (MODDE 9.0, Umetrics, Umeå, Sweden). 
 
2.1.2. Mobile Minor™ pilot plant dryer 
A pilot plant spray dryer with a maximum water evaporation capacity of 7.0 kg/h was used 
(Mobile Minor™ 2000-D, GEA Niro, Soeborg, Denmark). The Mobile Minor™ was operated in two-point 
powder discharge mode (Figure 1) for all experiments. This enabled coarse particle collection below the 
drying chamber (coarse fraction) and fine particle collection below the cyclone (fine fraction) to 
investigate to what extent a coarse powder fraction can be obtained during the spray drying process, 
with a view to the production of powder particles exceeding 20 µm. Three atomization systems (Figure 
2) were evaluated: a pneumatically driven rotary atomizer (TS-Minor SL-24-50, GEA Niro, Soeborg, 
Denmark), an externally mixing two-fluid nozzle (  = 1 mm) in co-current mode and a two-fluid nozzle 
(  = 1.5 mm) in mixed-flow mode (further referred to as the fountain nozzle). 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: A. Mobile Minor™ spray dryer (adapted from www.niroinc.com); B. Two-point powder discharge 
configuration. 
 
Figure 2: A. Rotary atomizer; B. Two-fluid nozzle (co-current); C. Fountain nozzle (adapted from www.niro.com). 
A           B 
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In all experiments, outlined in Table 2, mannitol was used as excipient. The air flow supplied to 
the two-fluid nozzles (two fluid nozzle: 41.7 – 113.9 ln/min; fountain nozzle: 83.3 – 159.7 ln/min), as well 
as the air pressure supplied to the rotary atomizer for control of the rotation speed of the atomizer 
wheel (23,000 – 32,000 rpm) were varied according to the recommendations of the manufacturer. The 
solids content of the feedstock solution ranged between 5 and 15% (wt/wt) for all atomization systems. 
Inlet- and outlet temperature (Tinlet = 160 ºC; Toutlet = ± 70 ºC) were kept constant during all experiments 
by adjusting the feed rate (± 20-25 ml/min). The fan was rotating at 3,240 rpm, 95 % of its capacity, 
throughout the entire process. All experiments were performed in randomized order. 
Table 2:  Experimental design: testing the influence of various atomizers and the most significant process 
parameters on the powder particle size range after spray drying, using a Mobile Minor™ pilot plant. 
Atomization system Mode Run Varied parameters  
   
Solids
1
 Air flow
2 
Rotation 
speed 
  
Nº
 
(wt/wt %) (ln/min) (rpm) 
rotary atomizer  co-current 1 5 - 23,000 
  
2 15 - 23,000 
  
3 5 - 32,000 
  
4 15 - 32,000 
  
5, 6, 7
3 
10 - 27,500 
two-fluid (  = 1 mm) co-current 1 5 41.7 - 
  
2 15 41.7 - 
  
3 5 113.9 - 
  
4 15 113.9 - 
  
5, 6, 7
3 
10 83.3 - 
fountain (  = 1.5 mm) mixed-flow 1 5 83.3 - 
  
2 15 83.3 - 
  
3 5 159.7 - 
  
4 15 159.7 - 
  
5, 6, 7
3 
10 113.9 - 
1 
100% mannitol. 
2
 Air supplied to nozzle for feed atomization; ln/min = normalized l/min at 20ºC and 1 bar absolute. 
3 
Replicate experiments. 
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2.2. Manufacturing powders with a specific particle size distribution 
Based on the results of the screening experiments with 
the Büchi™ B-290 laboratory and Mobile Minor™ pilot spray 
dryers, process parameters and spray dry equipment were 
chosen as shown in Table 3,  depending on the required particle 
size distribution of the powders i.e. smaller than 5 µm and 10 
µm and larger than 20 µm. A new spray dryer module 4M8-TriX 
(Figure 3), kindly contributed by Procept (Procept, Zelzate, 
Belgium), was introduced, which was compatible with two-fluid 
nozzles of various orifice diameters (  = 0.15 – 1.20 mm) as 
well as with ultrasonic nozzles (available frequencies: 25-60-120 
kHz). To produce powder particles smaller than 5 µm, the two-
fluid nozzle with the smallest orifice (  = 0.15 mm), leading to 
the smallest droplets, was used in combination with an 
increasing atomization air flow to investigate its effect on the 
particle size distribution. 
 
 
Powder particles smaller than 10 µm were spray dried using the Mobile Minor™ using the two-
fluid nozzle (  = 1.0 mm) at high atomization air flow, low feed rate and low feed solids content. The 
Mobile Minor™ was operated in one-point discharge mode, allowing particle recovery only below the 
cyclone. For the production of the coarse powder the Procept spray dryer was combined with an 
ultrasonic nozzle operating at low frequency (25 kHz) as this generated the largest droplets [5]. Although 
all powders were spray dried as a combination of mannitol, inositol and BSA (73.3:13.3:13.3), the coarse 
powder (>20 µm) was also spray dried as a mannitol/BSA combination (60:40) as a high BSA 
concentration in combination with a high feed solids content increased the feed viscosity, favoring the 
formation of coarse spray droplets during atomization and thus the formation of large particles [2, 6]. In 
all experiments an outlet temperature of 65ºC was maintained, adjusting the inlet temperature 
according to the used spray drying equipment and feed rate (Table 3). 
Figure 3: The 4M8-TriX Procept spray dryer    
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To further reduce the small particle fraction (<20 µm) in the coarse powder, the powder with 
the lowest yield of fine particles was sieved through a micro-sieve of 20 µm (W 0.02MM, Hosokawa 
Alpine, Cheshire, UK) using an air jet sieve (A200LS-N, Hosokawa Micron, Cheshire, UK).  
 
Table 3:  Spray dry process parameters and equipment for manufacturing powders with a required particle size (<5 
µm, <10 µm and >20 µm). 
1
 MIB = mannitol inositol BSA (73.3:13.3:13.3); MB = mannitol BSA (60:40). 
2 
Atomization air flow; ln/min = normalized l/min at 20ºC and 1 bar absolute. 
3
 % wt/wt; aqueous feed solution. 
4
 TF = two-fluid nozzle (co-current mode). 
 
2.3  Powder characterization 
2.3.1.  Particle size distribution 
Particle size distributions were measured by laser diffraction (Mastersizer-S long bench, Malvern 
Instruments, Malvern, UK). Powders produced during the screening experiments were measured by the 
wet dispersion technique using the 300 RF lens (Malvern Instruments, Malvern, UK) to measure the 
primary particle size. This implied the dispersion of powder samples in Miglyol  812N (capric 
triglyceride; Sasol, Hamburg, Germany) with 0.2% Tween  80 (polysorbate 80; Fagron, Waregem, 
Belgium) after which the samples were vortexed and sonicated to remove agglomerates.  
The spray dried powders with a specific particle size (Section 2.2) were analysed by the laser 
diffractor operated in open mode. Powders were air-dispersed using an experimental device consisting 
of a compressor (OMRON CX3, Hoofddorp, the Netherlands) attached to a glass Büchner flask (Schott 
Duran 100 ml, Mainz, Germany) containing the powder. Using a normalized air flow of 10 ln/min the 
powder particles were expelled through a 21 cm long plastic tube (Tygon  Laboratory Tubing R3603, 
Required 
particle size 
Formulation
1
 Spray dryer Nozzle Air flow
2
  Feed rate  Solids 
 in feed
3
  
Tinlet -
Toutlet 
n 
        (ln/min) (ml/min) (%) (ºC)   
<5 µm 5-MIB-1 Procept dryer TF
4
 (  = 0.15 mm) 2.2 2 1 100-65 1 
 
5-MIB-2 Procept dryer TF (  = 0.15 mm) 8.0 2 1 100-65 1 
 
5-MIB-3 Procept dryer TF (  = 0.15 mm) 38.5 2 1 100-65 1 
       
 
 <10 µm 10-MIB Mobile Minor™ TF (  = 1.0 mm) 113.9 12 1 120-65 3 
       
 
 >20 µm 20-MIB Procept dryer ultrasonic (25 kHz) - 2 15 100-65 1 
  20-MB Procept dryer ultrasonic (25 kHz) - 2 15 100-65 1 
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Saint-Gobain Performance Plastics, Akron (OH), USA) and dispersed directly into the laser beam. The 
orifice of the plastic tube (2 x 10 mm) was held 4 cm from the lens (300 mm, Malvern Instruments, 
Malvern, UK) and 4 cm from the laser beam. As fine powder particles generally show a cohesive 
behaviour [7], 5-MIB powders were also measured after dispersion at higher air flow rates (33, 56 and 
72 ln/min) to investigate its influence on particle de-aggregation. The air flow was measured by an air 
flowmeter (LoFlow LF3135, Parker Hannifin, Warwick, UK) installed downstream from a manometer 
(Cubeair 12 bar, Allerud, Denmark) indicating the air pressure from a compressed air tap.  
All measurements were performed in triplicate. Results were expressed as volume diameters 
D(v, 0.1), D(v, 0.5), D(v, 0.9). The span of the volume diameter distributions was calculated as: 
 (D(v, 0.9)-D(v, 0.1))/D(v, 0.5)      
 
2.3.2 Morphology 
Powders were examined by scanning electron microscopy (SEM) (JEOL JSM-5600-LV, Tokyo, 
Japan). Prior to visualization, the electron conductivity of the powder samples was improved by 
sputtering a gold coating of approximately 40 nm onto the particles. 
 
2.3.3 Hygroscopicity 
For dynamic vapor sorption (DVS Advantage, Surface Measurement Systems, Middlesex, UK), 
powder samples (10-20 mg) were weighed into the sample cup and dried under a stream of dry nitrogen 
at 25 ºC until equilibrium (i.e. a weight change of less than 0.002% per minute during at least 15 min). 
Subsequently, the samples were exposed to various relative humidities (RH) at 25ºC, increasing from 0 
to 90 % in steps of 10 %, allowing equilibration at each interval. 
 
2.3.4 Moisture content 
Immediately after production, the powder samples were analysed by Karl Fischer titration (V30 
Volumetric Titrator, Mettler Toledo, Zaventem, Belgium) to determine the residual moisture content. 
Powder (100-200 mg) was added to an air tight recipient containing methanol (Hydranal - Methanol 
dry, Sigma-Aldrich, Munich, Germany). Titration was performed adding Karl Fischer reagens (Hydranal - 
Composite 5, Sigma-Aldrich, Munich, Germany) following a 5 min stirring period. Powders were analysed 
in triplicate. 
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2.3.5 Particle density 
Helium pycnometry (AccuPyc 1330, Micromeritics, Norcross (GA), USA) was performed to 
determine the true density of the spray dried powders. Powder samples were accurately weighed prior 
to analysis, performed at 20ºC in 10 consecutive runs, including 10 purges per run. The purge fill 
pressure was set at 1.3 bar and the equilibration rate at 0.0003 bar/min. 
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3 RESULTS 
3.1   Screening of spray dryer systems 
3.1.1 Büchi™ B-290 laboratory scale spray dryer 
Median particle sizes (D(v, 0.5) values) of the spray dried mannitol powders are shown in Figure 
4. The replicate powders (runs 17, 18 and 19) exhibited similar D(v, 0.5) values, demonstrating good 
reproducibility of the results.  
The exclusion of the ‘feed rate’ factor and two-factor interactions resulted in a model with 
higher R2 and Q2-value, indicating their non-significant influence on the powder particle size.  After 
calculation of the best fitting regression model an R2-value of 0.80 was obtained along with a Q2-value of 
0.71.  
 
Figure 4 : Median particle size of spray dried mannitol powders of the experimental design performed on a Büchi™ 
B-290 spray dryer, varying inlet temperature, atomization air flow, feed rate and solids content of the feedstock. 
Exact process parameters are outlined in Table 1. 
 
 
According to the derived coefficient plot (Figure 5), the atomization air flow and solids content 
of the feedstock were significant factors for the median powder particle size. Increasing the atomization 
air flow decreased the powder particle size, while increasing the solids content of the feedstock yielded 
bigger powder particles. Varying the inlet temperature did not influence the median particle size of the 
spray dried powders.  
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Figure 5: Scaled and centered coefficient plot (CI = 0.95) for the median particle size of spray dried mannitol 
powders by a Büchi™ B-290 laboratory scale spray dryer varying inlet temperature (inlet tº), atomization air flow 
(air flow), feed rate and solids content of the feed (solids). The feed rate factor as well as two-factor interactions 
were removed from the regression model to obtain better fitting. 
 
 
 
3.1.2. Mobile Minor™ pilot plant dryer 
The results of the runs performed with the Mobile Minor™ using different nozzles while varying 
the atomization air flow and solids content of the feed were outlined in Table 4. The replicate runs (runs 
5, 6 and 7) performed by the rotary atomizer yielded powders with similar particle size distributions, 
while some particle size variation between the replicate powders was observed when spray drying with 
the two fluid and fountain nozzle.  
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Table 4: Average particle size distributions (n = 3) of the coarse and fine fraction of mannitol powders obtained 
after spray drying on the Mobile Minor™ dryer using the rotary atomizer, the two fluid nozzle or the fountain 
nozzle while varying the solids content of the feedstock and the atomization air flow or rotation speed for rotary 
atomization. Exact process variables of the runs are outlined in Table 2. 
 
   
Average particle size parameters (µm) ± SD 
Atomizer system Run Fraction D (v, 0.1) D(v, 0.5) D(v, 0.9) Span 
       rotary 1 coarse
1 
3.9 ± 0.2 14.0 ± 1.4 24.0 ± 0.8 1.4 ± 0.1 
wheel 
 
fine
2 
2.9 ± 0.1 8.4 ± 0.1 17.2 ± 0.7 1.7 ± 0.1 
 
2 coarse 7.7 ± 3.3 19.7 ± 1.6 30.4 ± 2.1 1.2 ± 0.2 
  
fine 3.4 ± 0.2 9.9 ± 0.3 20.7 ± 1.5 1.7 ± 0.2 
 
3 coarse 4.1 ± 0.4 11.7 ± 0.3 20.6 ± 0.4 1.4 ± 0.1 
  
fine 3.0 ± 0.1 9.6 ± 0.3 21.6 ± 2.1 1.9 ± 0.2 
 
4 coarse 6.2 ± 0.9 17.1 ± 1.7 27.4 ± 3.6 1.2 ± 0.1 
  
fine 3.5 ± 0.3 9.5 ± 1.5 18.8 ± 2.8 1.6 ± 0.1 
 
5 coarse 4.2 ± 0.9 17.0 ± 0.4 27.6 ± 1.2 1.4 ± 0.0 
  
fine 3.3 ± 0.3 8.9 ± 1.9 18.4 ± 4.3 1.7 ± 0.2 
 
6 coarse 3.6 ± 0.1 16.2 ± 0.2 25.6 ± 0.5 1.4 ± 0.0 
  
fine 3.2 ± 0.0 8.0 ± 0.2 16.3 ± 0.9 1.6 ± 0.0 
 
7 coarse 3.5 ± 0.8 15.6 ± 0.2 24.7 ± 0.1 1.4 ± 0.1 
  
fine 3.2 ± 0.1 7.9 ± 0.6 16.0 ± 3.1 1.6 ± 0.3 
       two fluid 1 coarse 8.2 ± 1.5 23.8 ± 0.5 38.5 ± 1.2 1.3 ± 0.0 
  
fine 3.1 ± 0.3 9.5 ± 0.1 21.3 ± 0.8 1.9 ± 0.1 
 
2 coarse 10.3 ± 0.9 25.9 ± 1.4 45.0 ± 4.5 1.3 ± 0.1 
  
fine 3.0 ± 0.5 11.8 ± 4.6 26.1 ± 9.5 2.0 ± 0.1 
 
3 coarse -
3
 - - - 
  
fine 2.6 ± 0.1 6.0 ± 0.9 11.4 ± 2.4 1.5 ± 0.2 
 
4 coarse 3.0 ± 0.2 10.6 ± 1.4 20.1 ± 3.1 1.6 ± 0.1 
  
fine 2.5 ± 0.1  7.9 ± 1.0 15.7 ± 1.9 1.7 ± 0.0 
 
5 coarse 4.8 ± 0.4 20.3 ± 1.4 41.7 ± 3.9 1.8 ± 0.0 
  
fine 3.0 ± 0.3 9.4 ± 1.7 20.9 ± 3.9 1.9 ± 0.0 
 
6 coarse 4.7 ± 0.0 17.6 ± 0.1 37.4 ± 0.2 1.9 ± 0.0 
  
fine 2.7 ± 0.1 7.5 ± 0.7 15.6 ± 2.0 1.7 ± 0.1 
 
7 coarse 4.1 ± 0.4 13.3 ± 0.9 25.5 ± 3.8 1.6 ± 0.1 
  
fine 2.9 ± 0.2 8.7 ± 1.9 19.2 ± 5.8 1.9 ± 0.2 
       fountain 1 coarse 8.2 ± 0.6 24.1 ± 0.7 45.4 ± 3.9 1.5 ± 0.1 
  
fine 2.9 ± 0.2 7.8 ± 0.7 17.3 ± 1.1 1.8 ± 0.1 
 
2 coarse 10.6 ± 0.9 29.3 ± 1.1 52.1 ± 3.1 1.4 ± 0.0 
  
fine 3.0 ± 0.1 9.8 ± 0.6 25.2 ± 0.4 2.3 ± 0.1 
 
3 coarse - - - - 
  
fine 2.3 ± 0.1 5.7 ± 1.0 11.0 ± 2.8 1.5 ± 0.2 
 
4 coarse 4.7 ± 0.2 17.8 ± 0.4 36.5 ± 0.8 1.8 ± 0.0 
  
fine 2.3 ± 0.1 7.0 ± 0.7 14.1 ± 1.8 1.7 ± 0.1 
 
5 coarse 8.9 ± 0.3 27.4 ± 0.2 53.8 ± 1.4 1.6 ± 0.1 
  
fine 3.1 ± 0.1 8.4 ± 0.7 20.1 ± 1.8 2.0 ± 0.1 
 
6 coarse 5.7 ± 0.2 20.2 ± 0.4 41.2 ± 3.1 1.8 ± 0.1 
  
fine 2.9 ± 0.1 8.1 ± 1.2 18.0 ± 3.2 1.9 ± 0.1 
 
7 coarse 3.4 ± 0.1 11.1 ± 0.4 23.9 ± 0.8 1.9 ± 0.0 
  
fine 2.7 ± 0.5 6.9 ± 0.8 13.4 ± 1.9 1.5 ± 0.1 
1
 Particle recovery below the drying chamber. 
2
 Particle recovery below the cyclone. 
3
 No powder yield. 
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Spans were generally below 2.0 and did not vary distinctively depending on the applied 
atomizer. 
Within the same run, the coarse powder fraction generally showed larger D(v, 0.5) and D(v, 0.9) 
values than the fine powder fraction. However, the D(v, 0.1) parameter only differed for some runs 
(runs 2 for all atomizers; runs 1 for two-fluid and fountain nozzle and run 5 for the fountain nozzle), 
indicating that the coarse powder fractions also contained a considerable amount of fines. 
 
 
Figure 6: Average particle size distributions (PSD) of spray dried mannitol powders with the largest (maximal) and 
smallest (minimal) particles obtained for each atomizer system by varying solids content of the feedstock and the 
atomization air flow or rotation speed for rotary atomization. TF = two fluid nozzle. 
 
Figure 6 gives a graphic overview of the largest and smallest average particle size distributions of 
mannitol powders produced on the Mobile Minor™ by each atomizer system at variable spray dry 
parameters.  
Taking into account the particle size variation between the replicate experiments, a limited 
particle size shift was obtained by varying the solids content and rotation speed of the rotary atomizer 
(7.9 – 9.9 µm for D(v, 0.5) of the fine fraction; 14.0 – 19.7 µm for D(v, 0.5) of the coarse fraction), 
compared to the two fluid nozzle (6.0 – 11.8 µm for D(v, 0.5) of the fine fraction; 10.6 – 25.9 µm for D(v, 
0.5) of the coarse fraction) and the fountain nozzle (5.7 – 9.8 µm for D(v, 0.5) of the fine fraction; 11.1 – 
29.3 µm for D(v, 0.5) of the coarse fraction).   
The powder with the smallest particles (D(v, 0.9) = 11.0 – 11.4 µm) was obtained by both the 
two fluid nozzle (run 3; Table 4) and the fountain nozzle (run 3; Table 4) when spray drying a feedstock 
with low solids content (5% wt/wt) at a high atomization air flow (two fluid: 113.9 ln/min; fountain: 
159.7 ln/min).  
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The powder with the largest particles (coarse fraction of run 2, Table 4; D(v,0.1) = 10.6 µm) was 
obtained when a feedstock with high solids content (15% wt/wt) was spray dried using the fountain 
nozzle at low air flow (83.3 ln/min). The fountain nozzle was the atomization system which could 
generate the widest particle size range, although it also showed the largest variation between replicate 
experiments.  
 
3.2  Manufacturing powders with a specific particle size distribution 
3.2.1. Evaluation of particle size distributions 
Table 5: Average particle size distribution (± SD) (n = 3) of powders measured by laser diffraction after dry 
dispersion of the powder in an air stream at an air flow of 10 l/min 
Formulation
1 
D(v, 0.1) D(v, 0.5) D(v, 0.9) Span Average fraction
2
 below 
 
(µm) (µm) (µm) 
 
5 µm 10 µm 20 µm 
5-MIB-1 5.8 ± 0.7  12.9 ± 1.7 354.2 ± 262.3 26.9 ± 18.4 6.6 % -
3
 - 
5-MIB-2 2.1 ± 0.7 17.8 ± 7.4 393.6 ± 217.3 22.0 ± 8.1 26.7 % - - 
5-MIB-3 1.1 ± 1.2 48.3 ± 63.2 395.8 ± 95.5 8.2 ± 70.0 37.0 % - - 
        10-MIB (Batch 1) 1.5 ± 0.7 4.6 ± 1.3 10.0 ± 2.6 1.8 ± 0.3 55.0 % 90.1 % - 
10-MIB (Batch 2) 2.2 ± 0.3 4.9 ± 0.7 10.0 ± 1.6 1.6 ± 0.1 51.0 % 90.1 % - 
10-MIB (Batch 3) 2.9 ± 0.1 6.1 ± 0.4 12.8 ± 1.9  1.6 ± 0.2 36.4 % 79.9 % - 
      
  
 20-MIB 17.0 ± 0.6 27.6 ± 1.2 44.9 ± 4.2  1.0 ± 0.2 - 5.5 % 17.3 % 
20-MB 23.7 ± 0.7 41.6 ± 0.7 87.6 ± 4.8 1.5 ± 0.1 - 0.8 % 4.8 % 
20-MB sieved 25.6 ± 1.9 39.5 ± 2.4 60.7 ± 2.0 0.9 ± 0.1 - 0.0 % 2.6 % 
1 
MIB = mannitol, inositol, BSA (73.3:13.3:13.3); MB = mannitol, BSA (60:40); process parameters are specified in Table 3. 
2
 % v/v. 
3
 Not relevant. 
 
 
Upon dry dispersion of the 5-MIB powders, spray dried by the Procept spray dryer, high D(v, 0.9) 
values with large standard deviations were measured for each powder (Table 5). Figure 7A shows the 
bimodal particle size distribution upon dispersion indicating incomplete powder deaggregation (Figure 
7A). Although the fraction of dry dispersed particles smaller than 5 µm increased proportionally to the 
atomization air flow during spray drying, a maximum of 37.0% (v/v) of the powder could be dispersed as 
particles smaller than 5 µm (Table 5; Figure 7A).  
CHAPTER 3 – SPRAY DRYING POWDERS WITH SUITABLE PARTICLE SIZE DISTRIBUTIONS 
 
71 
 
0 
2 
4 
6 
8 
10 
12 
0.1 1 10 100 1000 
V
o
lu
m
e
 %
 
Particle size (µm) 
B Batch 1 
Batch 2 
Batch 3 
10 micron 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
0 1 10 100 1000 
V
o
lu
m
e
 %
 
Particle size (µm) 
A 
5-MIB-1 
5-MIB-2 
5-MIB-3 
5 micron 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
0.01 0.1 1 10 100 1000 
V
o
lu
m
e
 %
 
Particle size (µm) 
C 20-MIB 
20-MB 
20 micron 
The Mobile Minor™ with the two fluid nozzle was used for spray drying the 10-MIB powders 
from a feedstock containing 1% (wt/wt) of solids, at a high atomization air flow (113.9 ln/min) and a feed 
rate of 12 ml/min. Between 80 - 90% of the spray dried particles were smaller than 10 µm and 36 - 55% 
smaller than 5 µm upon dry dispersion. Overall, the 3 batches showed similar particle size distributions 
(Figure 7B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Average particle size distribution (n= 3) determined by laser diffraction upon dry dispersion (10 ln/min) of 
A. 5-MIB powders spray dried by the Procept dryer; B. 10-MIB powders spray dried by the Mobile Minor™ ;C. 20-
MIB/MB powders spray dried by the Procept dryer. MIB = mannitol, inositol, BSA (73.3:13.3:13.3); MB = mannitol, 
BSA (60:40). Exact process parameters are given in Table 3. 
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Spray drying the mannitol/inositol/BSA combination (ratio: 73.3:13.3:13.3) as a 15% (wt/wt) 
aqueous solution with the ultrasonic nozzle in the Procept spray dryer, resulted in a finer powder 
compared to mannitol/BSA (ratio: 60:40) under the same process conditions. The latter powder 
contained 4.8% particles smaller than 20 µm, while the 20-MIB powder contained up to 17.3%. Sieving 
the 20-MB powder reduced the amount of particles below 20 µm to 2.6%, without particles smaller than 
10 µm (Table 5).   
To investigate the impact of the air flow rate on the particle deaggregation during dry 
dispersion, the cohesive 5-MIB powders were dispersed in an air stream at various air flow rates.  
 
 
 
 
 
 
 
 
 
Figure 8: Average particle size distribution (n = 3) of 5-MIB powders determined by laser diffraction upon dry 
dispersion at various normalized air flow rates: A. 5-MIB-1; B. 5-MIB-2; C. 5-MIB-3. 
 
The results (Figure 8) indicate that increasing the air flow does not affect the particle size 
distribution upon dry dispersion, except for the 5-MIB-3 powder in which case an air flow higher than 10 
l/min could de-aggregate the biggest agglomerates. In contrast, at 10 l/min a higher fraction of particles 
smaller than 5 µm could be dispersed compared to dispersion at higher air flows (37% vs. maximal 20%, 
respectively). 
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3.2.2. Morphology 
Scanning electron microscope images of all powders are given in Figure 9. Particles of the 5-MIB 
powders tended to agglomerate, inversely proportional to the atomization air flow during spray drying. 
The primary particle size also seemed to decrease when the atomization air flow during the production 
process was increased. 
The three batches of the 10-MIB powder showed a similar particle morphology, i.e. corrugated 
particles agglomerated into loose clusters.  
The coarse powders 20-MIB and 20-MB exhibited different particle morphologies as the MIB 
powder consisted of smooth surfaced particles while the surface of MB particles was highly corrugated. 
 
 
 
 
 
 
Figure 9: Scanning electron microscope images of A. 5-MIB-1; B. 5-MIB-2; C. 5-MIB-3; D. 10-MIB-1; E. 10-MIB-2; F. 
10-MIB-3; G. 20-MIB; H. 20-MB. 
 
 
 
 
 
CHAPTER 3 – SPRAY DRYING POWDERS WITH SUITABLE PARTICLE SIZE DISTRIBUTIONS 
 
74 
 
4.4 
3.9 
4.1 
0 
1 
2 
3 
4 
5 
0 10 20 30 40 50 60 70 80 90 
C
h
an
ge
 in
 m
as
s 
(%
) 
Target RH (%) 
B 
10-MIB-1 
10-MIB-2 
10-MIB-3 
4.2 
4.1 
4.0 
0 
1 
2 
3 
4 
5 
0 10 20 30 40 50 60 70 80 90 
C
h
an
ge
 in
 m
as
s 
(%
) 
Target RH (%) 
A 
5-MIB-1 
5-MIB-2 
5-MIB-3 
12.0 
5.7 
0 
5 
10 
15 
0 10 20 30 40 50 60 70 80 90 
C
h
an
ge
 in
 m
as
s 
(%
) 
Target RH (%) 
C 
20-MB 
20-MIB 
3.2.3. Hygroscopicity, moisture content and particle density 
The hygroscopic behavior of the spray dried powders is shown in Figure 10. Exposing the 5-MIB 
and 10-MIB powders to a 90% RH at 25 ºC resulted in a similar maximal water uptake between 3.9 – 
4.4% wt/wt (Figure 10 A-B), while the 20-MIB powder retained a maximum of 5.7% water (Figure 10 C), 
despite the same compound combination.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Water sorption curves of A. MIB powders with particles smaller than 5 µm; B. MIB powders with 
particles smaller than 10 µm and C. MB powder and MIB powder with particles bigger than 20 µm. 
 
 
The water sorption of the 20-MB powder was higher at each RH interval compared to MIB 
powders, with a maximal water uptake of 12.0% wt/wt at 90% RH. This behavior was also reflected in 
the higher moisture content of the 20-MB powder immediately after production compared to the MIB-
formulations (Table 6). 
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Table 6: Average moisture content (n = 3) after production and average particle density (n = 10) of <5 µm, <10 µm 
and >20 µm powders 
Formulation
1
 Moisture content ± SD Particle density ± SD 
 
(%) (g/cm
3
) 
5-MIB-1 2.71 ± 0.24 1.68 ± 0.02 
5-MIB-2 2.48 ± 0.05 1.69 ± 0.02 
5-MIB-3 2.32 ± 0.20 1.65 ± 0.02 
   10-MIB-1 1.63 ± 0.09 1.69 ± 0.02  
10-MIB-2 1.99 ± 0.21 1.69 ± 0.02 
10-MIB-3 1.64 ± 0.23 1.58 ± 0.00  
   20-MIB 2.07 ± 0.15 1.47 ± 0.01 
20-MB 3.45 ± 0.09 1.53 ± 0.01 
1
 MIB = mannitol, inositol, BSA (73.3:13.3:13.3); MB = mannitol, BSA (60:40); process parameters are specified in 
Table 3. 
 
The true density of the 5-MIB and 10-MIB powders varied between 1.6 and 1.7 g/cm3, while the 
20-MIB and 20-MB powders exhibited a true density of 1.5 g/cm3. 
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4. DISCUSSION 
In this chapter it was the aim to prepare three powders by spray drying with different particle 
size distributions: 1) a powder with particles smaller than 5 µm for the secondary vaccination of 4-week-
old chickens; 2) a powder with particles smaller than 10 µm for the secondary vaccination of 2-week-old 
chickens and 3) a powder with particles larger than 20 µm for primary vaccination of one-day-old 
chickens.  
Although powder particles for pulmonary delivery are often characterized by aerodynamic 
diameter, which takes the irregular shape and particle density into account and is used for predicting 
the deposition pattern in the lung, this study made use of the geometrical particle size diameter 
measured by laser diffraction as a screening guide tool for suitable powder particle sizes. Powder 
vaccines with suitable particle sizes, according to the laser diffraction experiments, will then be 
evaluated in vivo regarding their vaccination efficiency and their ability to induce adverse vaccinal 
reactions.  
During the screening experiments with the Büchi™ B-290 laboratory spray dryer, the 
atomization air flow and the solids content of the feedstock were the most defining process parameters 
for the particle size distribution of the powder product. These findings are in line with the general 
guidelines for controlling the particle size distribution of a powder during spray drying [2]. Although the 
droplet size and thus particle size is described in literature to vary with feed rate at constant atomization 
air flow [2], no significant effect of the feed rate was observed on the median particle size during the 
design of experiments with the Büchi™ spray dryer. The fitted regression model showed a R2 value 
above 0.75 and a Q2 value greater than 0.5, which means that a useful and predictive model was 
obtained [4] with good reproducibility as derived from the similar particle size of the replicate powders.  
Next, the influence of the solids content of the feed solution and atomization air flow or rotation 
speed was evaluated in the Mobile Minor™ pilot plant using three different atomization systems (rotary 
wheel, two-fluid and fountain nozzle). According to the findings from the experiments with the Büchi™ 
spray dryer, the powders spray dried at the lowest atomization air flow (or rotation speed for rotary 
wheel atomizer) from the highest feed solids content should result in the coarsest powder and vice 
versa for the finest powder.  This was valid for the powders spray dried with the two-fluid and fountain 
nozzle. However, the rotary atomizer was less flexible for varying the particle size of powders by 
adjustment of process parameters, yielding small variations between particle sizes of different runs 
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(Table 4). These findings were not unexpected and belonged to the common knowledge about rotary 
atomizers [2]. 
Based on the experiments with the Mobile Minor™ the finest mannitol powder (D(v, 0.9) = 11.0 - 
11.4 µm) could be produced with the two-fluid and fountain nozzle atomizing the feed with lowest 
solids content (5% wt/wt) at the highest recommended atomization air flow. As the particles were 
generally smaller than 10 µm, these process settings and atomization systems were qualified for 
manufacturing a powder vaccine for secondary vaccination of two-week-old chickens. However, the 
mixed flow configuration (fountain nozzle) is less favorable for spray drying thermo-unstable products, 
such as live vaccines, due to heat exposure of the driest product. Therefore, spray drying in co-current 
mode is preferred, as in this case the driest product is exposed to the lowest temperature [2]. 
None of the Mobile Minor™ spray dryer settings could be used for the production of powder 
particles exceeding 20 µm for primary vaccination of one-day-old chicks as the coarsest powder still 
consisted of a large fraction of fine particles (D(v, 0.1) = 10.6 µm (fountain nozzle, run 2, coarse fraction; 
Table 4).  Also for the production of particles smaller than 5 µm, suitable for secondary vaccination of 4-
week-old chickens, another spray drying process had to be used. 
Powders with a particle size <5 µm were spray dried with a two-fluid nozzle with smaller orifice 
diameter (Procept spray dryer, nozzle  0.15 mm) to atomize the feed into smaller droplets, in 
combination with a feed with lower solids content (1% wt/wt). However, although particles smaller than 
5 µm were visually clearly obtained (Figure 9 A-C), a cohesive behavior between the particles was 
observed when dispersed at an air flow of 10 l/min (Table 5). This particle aggregation is characteristic 
for micron-sized particles, due to higher Van Der Waals attraction forces with decreasing particle size [7, 
8]. It has been shown that the particle size, the air flow and the dispersion device design contributed to 
the final powder dispersion pattern [7]. That powder deagglomeration is affected by the particle size 
was also observed in these experiments: at the same dispersion settings, up to 55% (v/v) particles 
smaller than 5 µm were measured upon dispersion of the 10-MIB powders, compared to a maximum of 
37% (v/v) for the 5-MIB powders (Table 5), while the SEM images clearly showed that the 5-MIB 
powders consisted of smaller particles than those of the 10-MIB powders (Figure 9). According to 
literature, increasing the dispersion air flow generally leads to better powder deagglomeration [7, 9]. 
The air flow creates a turbulent flow inside the powder disperser device, which enables particle 
deagglomeration [10, 11]. In these experiments, only the biggest agglomerates of the 5-MIB-3 powder 
could be de-agglomerated at higher air flows (Figure 8). However, in general the air flow did not yield 
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better redispersion of dry particles. On the contrary, in some cases the fine particle fraction below 5 µm 
even decreased when the dispersing air flow was increased (Figure 8). The swirling of the particles in the 
flask, driven by the strong air flow, could have electrostatically charged the particles, resulting in highly-
cohesive interparticulate behavior [12]. Therefore, powder dispersion should be optimized by varying 
the device design by e.g. introducing a grid or other geometrical variations to improve particle/particle 
or particle/wall collision within the powder disperser [13]. 
Using the Mobile Minor™ spray dryer with the two fluid nozzle (  1.0 mm), MIB powders could 
be prepared consisting of 80 - 90% v/v dispersible particles smaller than 10 µm, showing limited 
variation between the three batches. With 36 - 55% v/v of dispersible particles smaller than 5 µm, the 
10-MIB powders were more appropriate for secondary vaccination of 4-weeks-old chickens than the 5-
MIB powders produced by the Procept spray dryer when aerosolized with the current dispersion system 
at 10 l/min. 
For primary vaccination of one-day-old chickens, particles larger than 20 µm were required [1]. 
Spray drying the MIB formulation led to a considerably higher fraction of particles below 20 µm 
compared to the MB formulation after spray drying with the ultrasonic nozzle (17.3% vs. 4.8%, 
respectively; Table 5). Furthermore, the particles smaller than 20 µm in the 20-MB powder were 
generally between 10 and 20 µm (0.8% smaller than 10 µm), while the 20-MIB powder contained 5.5% 
of particles smaller than 10 µm. Therefore, the 20-MB powder was considered more suitable for further 
particle size optimization by sieving the powder through a micro-sieve of 20 µm. This reduced the 
amount of particles below 20 µm from 4.8% v/v to 2.6% v/v.  
Although the 5-, 10- and 20-MIB powders consisted of the same ratios of mannitol, inositol and 
BSA, the water sorption curve of the 20-MIB powder showed a higher water uptake above 70% RH 
compared to the smaller-sized MIB powders (Figure 10). The water sorption curve of the MIB-powders 
can be classified as a type II sigmoid shaped curve, which can be divided into three parts each 
representing a different water/solid interaction (Figure 11): A. water molecules are strongly bound to 
the solids surface as a monolayer and are not available for chemical reactions; B. water molecules are 
bound as less tight multilayers and are limitedly available for biochemical reactions; C. an excess of 
water is present in macro-capillaries of the solid matrix and can act as a solvent [14].  
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Figure 11:  Type II water sorption isotherm divided in 3 zones: A. Strongly bound water monolayer; B. Less tightly 
bound water in multilayers; C. Excess of water into macro-capillaries of solid matrix. 
The discrepancy between the water sorption curves of the MIB powders occurs at higher 
relative humidities (>70%) indicating higher water adsorption in zone C of the curve for the 20-MIB 
powder as more water is retained in macro-capillaries of the solid matrix. This was confirmed by the 
pycnometric analyses, measuring a lower true density for the 20-MIB powder compared to the 5- and 
10-MIB powders (Table 6). 
Despite the more suitable particle size distribution of the 20-MB powder, compared to the 20-
MIB, it is more hygroscopic, which may cause hygroscopic growth in the broiler airways upon inhalation. 
However, unlike for secondary vaccination, primary vaccination targets particle deposition exclusively in 
the upper respiratory tract as vaccine particles in the lower airways may induce adverse vaccinal 
reactions, hence, the requirement for particles bigger than 20 µm. The possible shift of particle 
deposition towards the higher airways resulting from hygroscopic growth [15] is therefore considered 
not to be an issue. Furthermore, the higher hygroscopicity of the powder did not cause any dry-
dispersion difficulties. 
In the following chapter, a coarse (particles bigger than 20 µm) and fine (particles smaller than 
10 µm) Newcastle disease virus (NDV) powder vaccine are compared to the conventional coarse and fine 
NDV liquid vaccines regarding vaccinal reactions and serum antibody response induced in young 
chickens. 
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5. CONCLUSION 
Powders with particle sizes smaller than 5 µm, 10 µm and larger than 20 µm for the secondary 
vaccination of 2-weeks and 4-weeks-old chickens and the primary vaccination of one-day-old chicks, 
respectively, were produced by spray drying. Atomization system, atomizing air flow and solids content 
of the feed solution were found to be defining production parameters for the particle size of the spray 
dried powder. Powders with particles smaller than 10 µm were successfully spray dried with a two-fluid 
nozzle ( = 1 mm) of the Mobile Minor™ pilot plant, while particles smaller than 5 µm and larger than 20 
µm were spray dried using a laboratory scale Procept spray dryer combined with a two-fluid ( = 0.15 
mm) and ultrasonic nozzle, respectively. 
Powders aiming for particles smaller than 5 and 10 µm were spray dried as a combination of 
mannitol/inositol/BSA (73.3:13.3:13.3) while the powder aiming for particles bigger than 20 µm showed 
a more suitable particle size distribution when spray dried as a mannitol/BSA (60:40) formulation. 
Subsequent sieving of the 20-MB powder reduced the fraction of particles below 20 µm.  
In contrast to the 10-MIB and 20-MB powders, the 5-MIB powders could not be fully de-
agglomerated by the current powder dispersion system, not even at varying dispersing air flows. 
Therefore, the design of the air-dispersion device needs revision for the dry dispersion of particles 
smaller than 5 µm.  
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CHAPTER 4 
COMPARISON OF NEWCASTLE DISEASE POWDER 
VACCINES WITH LIQUID VACCINES IN BROILERS 
CONSIDERING THE SERUM ANTIBODY RESPONSE AND 
ADVERSE VACCINAL REACTIONS 
 
1. INTRODUCTION 
Fine and coarse spray dried powder NDV vaccines, as developed in Chapter 3, were evaluated in 
4-day-old specified pathogen-free (SPF) broilers and compared with the commercial coarse liquid spray 
and fine aerosol vaccination.  
To investigate the vaccination efficiency, the serum antibody response was compared between 
powder and liquid vaccines. It is known that fine liquid aerosols induce higher and faster immune 
responses than coarse liquid sprays, due to vaccine deposition into the lower respiratory tract [1, 2]. 
However, especially in young birds, adverse vaccinal reactions can be induced by these fine vaccine 
particles, which are still present in the coarse liquid spray used for primary vaccination, albeit in smaller 
amounts than in the liquid aerosol vaccine. Nevertheless, the efficiency of commercial fine liquid 
aerosols, aiming at vaccine particle sizes smaller than 5 µm, is decreased by the generation of large 
droplets (>100 µm) reducing the vaccine fraction available for inhalation. Also, the uncontrolled 
evaporation of airborne droplets affects the integrity of live vaccines, reducing the vaccine dose, and 
alters the deposition pattern [3]. Thus, powder vaccines with narrow particle size distributions, 
unaffected by evaporation, could improve the vaccination efficiency. 
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Adverse vaccinal reactions are characterized by respiratory distress, growth retardation and 
increased susceptibility to secondary infections (especially colibacillosis caused by virulent Escherichia 
coli strains) [4]. Colibacillosis is an important cause of mortality, growth retardation and condemnation 
of broilers (due to polyserositis) at processing, leading to intensive use of antibiotics in the sector [5]. In 
this study, adverse vaccinal reactions are compared after vaccination with a coarse or fine vaccine 
administered as powder or liquid. As secondary pathogen, a virulent avian Escherichia coli strain (strain 
506, serotype O78K80) was selected, isolated from the inflamed pericardium of a broiler chick suffering 
from natural colibacillosis. 
In this study, it was investigated if adverse vaccinal reactions can be reduced after vaccination 
with a coarse powder vaccine (>20 µm) and if vaccination efficiency can be increased using a fine 
powder vaccine with narrow particle size distribution (<10 µm) compared to their liquid counterparts. A 
third powder vaccine, consisting of 90% coarse (>20 µm) and 10 % fine ( 20 µm) particles (further 
referred to as ‘mixed powder vaccine’), was included in the study design to investigate the influence of 
fine particle contamination in a coarse powder vaccine on the adverse vaccinal reactions.  
The used powder vaccines were the coarse mannitol/BSA powder (ratio of 60:40) with particles 
larger than 20 µm (Chapter 3) and a fine mannitol/BSA powder (80:20) with particles smaller than 10 
µm, produced as the MIB-10 powders in Chapter 3. The fine powder consisted of mannitol and BSA for 
reasons of consistency with the coarse powder, although the BSA content was lowered in order to 
obtain sufficiently small particles. 
Broilers were used in this study as they are more sensitive to airsacculitis and polyserositis 
induced by E. coli than layers during rearing [6]. Although no longer commercially available, the LZ58 
NDV strain was used for vaccination as it provokes stronger vaccinal reactions than the Ulster 2C and 
Clone 30 NDV strains [4]. As maternal antibodies interfere with the serum antibody response [7, 8], SPF 
animals were used. E. coli inoculation was performed intratracheally as the natural route of infection is 
probably airborne [9]. 
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2. MATERIALS AND METHODS 
2.1. Experimental design 
Newly-hatched SPF broiler hens (day of hatch = day 0), obtained from the Animal Health Service 
(Deventer, the Netherlands), were divided into 8 experimental groups of 40 animals each.  
 The experiment was conducted according to Table 1. Parameters for assessing the adverse 
vaccinal reactions were growth, susceptibility to colibacillosis and mortality. Before each treatment, 
broilers were individually weighed to register the growth in each group. Throughout the entire 
experiment, birds were observed daily for respiratory distress and depression as clinical signs of adverse 
vaccinal reactions.  
Table 1: Experimental design for the evaluation of coarse and fine powder and liquid NDV vaccines regarding 
adverse vaccinal reactions and serum antibody response in SPF broiler hens 
 
Treatment
1
 
Group
2 
Vaccination
3 
E. coli inoculation
4 
1 None no 
2 coarse/fine placebo powder (1:1) PBS 
3 coarse/fine placebo powder (1:1) yes 
4 coarse powder vaccine yes 
5 coarse liquid vaccine yes 
6 mixed powder vaccine
5
 yes 
7 fine powder vaccine yes 
8 fine liquid vaccine yes 
1
 Day 0 = day of hatch; day 4: vaccination; day 11: E. coli inoculation; day 18: post-mortem examination, serum 
sampling (end of the experiment). 
2
 n = 40. 
3
 LZ58 NDV vaccine strain; exposure time = 30 min. 
4
 E. coli intratracheal dose = 10
4.3
 cfu per bird. 
5
 90% coarse powder vaccine + 10% fine powder vaccine (wt/wt). 
 
2.2. Housing and handling of broilers 
Birds were housed in negative pressure HEPA isolators (Beyer & Eggelaar, Utrecht, the 
Netherlands) with a volume of 1.38 m3 (194 cm width, 95 cm height and 75 cm depth) from day of hatch 
(day 0) until the end of the experiment (day 18). From day 0 broilers were exposed to 22h of light per 
day, which was reduced to 16h per day from day 8 on. The isolator temperature was set at 35ºC on day 
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0 and was gradually decreased to 25ºC on day 18. Commercial broiler feed and tap water were provided 
ad libitum. On day 18 surviving animals were stunned using a mixture of CO2 and O2 after which they 
were debleeded by incision of the vena jugularis. 
 
2.3. Vaccination against Newcastle disease 
2.3.1. Preparation of powder and liquid vaccines 
The coarse powder vaccine (>20 µm) was produced by spray drying using a 4M8-TriX Procept 
spray dryer, kindly supplied by Procept (Zelzate, Belgium), equipped with a 25 kHz ultrasonic nozzle. One 
ampoule containing a maximum of 1010 50% Egg Infectious dose (EID50) of LZ58 NDV vaccine, kindly 
provided by Intervet-Schering Plough Animal Health (Boxmeer, the Netherlands), was suspended into 
100 ml of a 15% (wt/wt) aqueous solution containing 60% mannitol (C*Mannidex, Cargill, Krefeld, 
Germany) and 40% BSA (Sigma-Aldrich, Steinheim, Germany). The vaccine liquid was then spray dried at 
an inlet temperature of 100ºC and a feed rate of 2 ml/min, resulting in an outlet temperature of 
approximately 65ºC. After production, the coarse powder vaccine was sieved through a micro-sieve of 
20 µm (W 0.02 MM, Hosokawa Alpine, Cheshire, UK) using an air jet sieve (A200LS-N, Hosokawa Micron, 
Cheshire, UK) in order to minimize the particle fraction below 20 µm. 
The fine powder vaccine was produced by the Mobile Minor D-2000 pilot plant spray dryer (GEA 
Niro, Soeborg, Denmark). LZ58 NDV vaccine (approximately 1010 EID50) was dispersed into 1500 ml 1% 
(wt/wt) aqueous solution containing 80% mannitol (C*Mannidex, Cargill, Krefeld, Germany) and 20% 
BSA (Sigma-aldrich, Steinheim,Germany) and subsequently spray dried. The feed was atomized by a two 
fluid nozzle ( = 1 mm) operated at an air flow of 113.9 l/min and dried at an inlet temperature of 120ºC 
and a feed rate of 12 ml/min, resulting in an outlet temperature of approximately 65ºC. 
During the production process, the powder recipients of the spray dryers were emptied every 10 
minutes in order to minimize vaccine loss by heat stress. Placebo powders were produced via the same 
process. 
To obtain the mixed powder vaccine, 4.5 g of sieved coarse powder vaccine was physically 
mixed with 0.5 g of fine powder vaccine. For placebo powders, coarse and fine particles were mixed in a 
1:1 weight ratio. 
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The liquid vaccines for fine liquid aerosol and coarse liquid spray vaccination were prepared on 
the day of vaccination. From an LZ58 NDV vaccine vial containing approximately 1010 EID50/ml a dilution 
in sterile demineralized water was made aiming at a virus titre of 107.3 EID50/ml.  
Virus vaccine titres of the powders were determined by virus titrations (Section 2.3.2.1) 7 days 
before vaccination and the powders were stored until vaccination in sealed glass vials at 6ºC 
(conditioned room) packed in airtight aluminium bags. Samples of the liquid vaccines were frozen at -
78ºC by immersion of the sample containing test tubes (sterile polypropylene conical test tube, 15 ml, 
MEUS, Piove di Sacco, Italy) into a mixture of dry ice and 70% ethanol (Chemlab, Zedelgem, Belgium) 
and subsequently stored at -80ºC until virus titration. 
 
2.3.2. Vaccine characterization 
2.3.2.1. Virus titrations 
Prior to virus titration, 100 mg of each of the powder vaccines was dissolved into 1 ml 
Dulbecco’s phosphate buffered saline (DBPS, Invitrogen, Paisley, UK) with 1% penicillin-streptomycin 
solution (penicillin G (10,000 IU/ml) – streptomycin sulphate (10,000 µg/ml)). Samples of liquid vaccines 
were thawed at room temperature. 
Ten-fold dilutions (10-3 – 10-9) of each solution were made in DPBS with penicillin-streptomycin 
and inoculated (0.1 ml) into the allantoic cavity of 10-day-old embryonated SPF chicken eggs, using 4 
eggs per dilution. After 72h incubation time at 37ºC, the allantoic fluid was tested for haemagglutination 
activity [10]. Virus titres were expressed as EID50, calculated according to the formula of Reed and 
Muench [11]. The detection limit was calculated by setting minimal conditions needed for applying the 
formula of Reed and Muench (i.e. 3 positive eggs out of 4 inoculated eggs for the undiluted sample 100), 
resulting in a detection limit of 102.3 EID50/g or ml for powder and liquid vaccine, respectively. 
 
2.3.2.2. Particle/droplet size distribution 
Particle/droplet size distributions of the vaccines were determined by a laser diffractor operated 
in open mode (Mastersizer-S, long bench; Malvern Instruments, Malvern, UK) and equipped with a 300 
mm lens.  
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Powder samples were dispersed directly into the laser beam using an experimental air-assisted 
device consisting of an air compressor (OMRON CX3, Hoofddorp, the Netherlands) forcing air (10 l/min) 
into a glass Büchner flask (Schott Duran 100 ml, Mainz, Germany) and transporting the powder particles 
to the outlet of the flask through a plastic tube (Tygon  Laboratory Tubing R3606, Saint-Gobain 
Performance Plastics, Akron (OH), USA) of 21 cm with an orifice opening of 2x10 mm.  
The droplet size spectra of the fine liquid aerosol and coarse liquid spray were determined using 
demineralized water as dispersion liquid. The fine liquid aerosol was generated by the Walther Pilot I 
spray-head with a 0.5 mm nozzle diameter (Walther Spritz-und Lackiersysteme, Wuppertal, Germany) 
attached to a compressor (Mecha Concorde type 7SAX, 1001, SACIM, Verona, Italy) operated at 2 bar. 
The coarse liquid vaccine was dispersed by manually actuating a hand-held spray bottle (Powerplus 
Garden POW 63868, Varo, Lier, Belgium) at a frequency of 1 actuation per second. During the 
measurements with the hand-held spray bottle an air flow parallel to the lens protected it from 
moisture deposition. 
During analysis, all orifices were held 4 cm from the laser beam and 4 cm from the optic lens. All 
measurements were performed in triplicate and results were expressed as volume diameters D (v, 0.1), 
D (v, 0.5), D (v, 0.9) and span. Span was calculated as [D (v, 0.9) – D (v, 0.1)]/ D (v, 0.5). 
Based on the measured droplet size parameters D (v, 0.x), the size of solid particles obtained 
after complete evaporation of the liquid vaccine droplets was estimated using the following equation, 
taking the solids content (1.25 mg/ml) and density (assumed at 1 g/ml) of the liquid vaccine droplet into 
account: 
D (v,0.x) ∙ (1.25 mg/ml / 1000)^⅓ 
The solids content of the liquid vaccine was determined in threefold by drying a sample of known 
volume on a watch glass until constant weight (i.e. until ± 0.05 µg accuracy; analytical balance AG245, 
Mettler Toledo, Zaventem, Belgium) in an incubator (Memmert INP 600, Memmert, Schwabach, 
Germany) set at 40ºC. 
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2.3.2.3. Particle density 
The true density of the fine and coarse placebo powders was determined to allow calculation of 
the volume percentage of fines in the mixed powder vaccine. Accurately weighed samples were 
analyzed in ten-fold by helium pycnometry (AccuPyc 1330, Micromeritics, Norcross (GA), USA) at 20ºC in 
10 consecutive runs, including 10 purges per run. The purge fill pressure was 1.3 bar and an equilibration 
rate of 0.0003 bar/min was used. 
 
2.3.3. Vaccine dispersion in isolators 
Vaccination of the broilers was performed in the negative pressure HEPA isolators in which they 
were housed. During the vaccination process, the isolator ventilation was switched off until 30 min after 
the end of the vaccine dispersion period. The environmental conditions (temperature and relative 
humidity (RH)) inside the isolator were recorded every 2 seconds during the experimental period by a 
temperature and humidity logger (Testostor 171-2, Testo, Ternat, Belgium). Five grams of powder 
vaccine or 5 ml of liquid vaccine was dispersed in the corresponding isolator with the aim of dispersing a 
total vaccine dose 108 EID50. Powders and liquids were dispersed as described in Section 2.3.2.2. 
 
2.3.4. Air sampling 
Air sampling was performed using a Sartorius MD8 airscan sampling device (Sartorius, 
Nieuwegein, the Netherlands). A sterile gelatin filter (17528-80-ACD, Sartorius Stedim Biotech, 
Goettingen, Germany) with a pore size of 3.0 µm was installed vertically at a height of 15 cm above the 
isolator grid floor. Each time, air was filtered during 2 min at 2000 l/h, sampling a total air volume of 67 
l. Samples were taken immediately after vaccine dispersion and 10 and 20 min thereafter. Gelatin filters 
were processed immediately after the sampling period as described in Section 2.3.5. 
 
2.3.5. Assessment of airborne virus concentrations and estimation of inhaled vaccine dose 
Gelatin filters from the air sampling were each dissolved in 10 ml preheated (37ºC) sterile DPBS 
(Invitrogen, Paisley, UK) frozen as described in Section 2.3.1 and subsequently stored at -80ºC until 
analysis by virus titrations (Section 2.3.2.1). Thawed samples were inoculated as 100 to 10-6 dilutions into 
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five 10-day-old embryonated SPF eggs per dilution, using an inoculation volume of 0.3 ml per egg. Virus 
titres were expressed per m3 air, taking into account the dissolution volume of the gelatin filters (10 ml) 
and the amount of sampled air (67 l). The detection limit was 102.9 EID50 per m
3 air. 
To assess the vaccine loss during sample processing (freezing, thawing) 100 mg of powder 
vaccine was manually distributed over a sterile gelatin filter, dissolved in DPBS and frozen as previously 
described (Section 2.3.1). A sample of the powder vaccine, the unfrozen vaccine liquid and a thawed 
sample of the frozen vaccine were analyzed by virus titration within 2 hours after manipulation. 
The amount of vaccine inhaled per broiler in a period of 30 min (including the dispersion period) 
was estimated based on the ventilation rate of the birds of 738 ml/min.kg [12]. The following 
assumptions were made for the calculation of the virus-uptake: (1) all aerosol particles detected by air 
sampling are inhalable; (2) the increase and decline of the vaccine aerosol concentration in the isolator 
is linear; and (3) 30 min after dispersion the aerosol virus titres are considered to be ‘0’; all aerosol virus 
titres below the detection limit are considered to be ‘0’; (4) vaccine retention by the birds is 100% [13, 
14]. 
 
2.4. Escherichia coli inoculum 
The Escherichia coli (strain 506, serotype O78K80) used is a flumequine resistant and 
doxycycline intermediary sensitive strain that was isolated from the inflamed pericardium of a broiler 
chick suffering from natural colibacillosis. Frozen beads (-70ºC) containing this strain were submerged 
into 0.1% glucose broth (1000 ml purified water, 5 g Lab Lemco (Oxoid LP0029), 10 g bacteriological 
peptone (Oxoid LP0-037), 5 g NaCl (VWR 1.06404.1000) (Merck) and 1 g glucose (VWR 1.08342.1000) 
(Merck)), which was incubated during 17 hours at 37°C. This broth was diluted 1:5000 in phosphate 
buffered saline (PBS), in order to obtain a bacterial concentration of approximately 104.5-5.5 cfu/ml and 
kept on ice during the inoculation procedure. Every bird received a volume of 0.3 ml intratracheally, 
aiming at a dose of 104.0-5.0 cfu per broiler. 
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2.5. Post-mortem examination 
During post-mortem examination, the left and right thoracic air sacs, the pericardium and the 
liver were macroscopically examined for colibacillosis lesions, which was done blindly. The scoring (0 – 3 
for each organ with a maximum score of 12 per bird) was performed according to Van Eck and Goren 
[4]. For each group the mean lesion score, percentage of affected animals and percentage of birds with 
generalized colibacillosis were calculated. An animal was considered ‘affected’ when lesions were 
observed, while general colibacillosis was diagnosed when lesions occurred on the pericardium and/or 
liver.  
The gender of each broiler was re-evaluated during post-mortem examination to correct the 
mean body weights for sex faults on day 0. 
 
2.6. Serology 
NDV antibodies in serum samples of 24 surplus animals were determined on day 0 by means of 
the haemagglutination inhibition (HI) test [15]. On day 18, serum samples from surviving birds of the 
experimental groups were tested by HI to evaluate the serum antibody response to the NDV 
vaccination. All samples were analyzed in one run. 
 
2.7. Assessment of bacterial concentration of the inoculum, bacteriology of 
birds and Pulsed-Field Gel Electrophoresis (PFGE) 
Determination of the bacterial concentration of the inoculum was performed by means of 
bacterial counting according to international standards  [16, 17] using a sample taken at the start and 
the end of the inoculation procedure.  
Bone marrow from animals which died during the experiment was sampled during post-mortem 
examination and bacteriologically examined to determine the specificity of mortality. Mortality was 
considered specific in case dead birds showed generalized colibacillosis and/or E. coli was isolated from 
their bone marrow. E. coli was also isolated from colibacillosis lesions in pericardium, air sac or liver of 
surviving birds. A maximum of 5 birds per group were selected for bacteriological analysis. All reisolates 
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and the inoculum strain were stored at -80°C for PFGE analysis. The surface of organs was sterilized with 
a hot scalpel blade after which they were incised in order to take a sample for bacteriology with a wire. 
After inoculating sheep-blood agar plates (K004P090; Biotrading) they were incubated overnight at 37°C 
and thereafter visually inspected for purity. Biochemical identification of colonies was performed using 
the indole and β-glucuronidase test, which are both positive for E. coli.  
In order to study the clonal relationship between reisolated E. coli bacteria and the parent E. coli 
strain PFGE was used. 
The PFGE-technique of contour-clamped homogeneous electric fields (CHEF) was used for 
genomic typing of the isolates (one isolate per positive sample) [18]. Genomic DNAs were digested in 
agarose plugs with Xba I (10 U)(Roche Diagnostics, Mannheim, Germany). The resulting fragments were 
resolved by CHEF-PFGE with a CHEF-DR  III apparatus (Bio-Rad Laboratories, Richmond (CA), USA) at a 
constant voltage of 6 V/cm for 20 h at 14ºC, an included angle of 120º and an initial and final switch 
time of 2.2 and 54.2 seconds, respectively. The generated fingerprints were processed using 
BioNumerics software (Applied Maths NV, Sint-Martens-Latem, Belgium). The similarity was calculated 
using the band-based DICE coefficient with 1% optimization and 1% tolerance. Clustering was performed 
by the unweighted pair method with arithmetic averages (UPGMA). Isolates were considered 
‘indistinguishable’ if 100% of the fragments were identical.  
 
2.8. Statistics 
The survival rate between groups was compared using the Mantel-Cox log-rank test. 
Body weight analysis was performed on the weight differences and weight at day 4 with a one-
way ANOVA followed by the post-hoc Scheffé’s test after verifying the normality of residuals with a Q-Q 
plot and homogenicity of variances with the Levene’s test. Survival analysis and body weight analysis 
were performed in SPSS version 20 (IBM, New York, USA). 
Serum antibody titres and E. coli scores were compared between the 8 groups using the Kruskal-
Wallis test. Pairwise comparisons were carried out using Wilcoxon rank sum test, adjusting the p-values 
for the number of performed tests with the Bonferroni correction. 
Number of affected and generalized infected birds was compared in the vaccinated groups by 
fitting a logistic regression with infection as response and vaccination treatment as explanatory variable. 
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Only vaccinated groups were compared to the control group 3, treated with the placebo powder and 
inoculated with E. coli.  
All analyses were performed in R (version 2.14.1, the R Foundation for Statistical Computing) 
unless specified differently. For all analyses a significance level of P <0.05 was applied. 
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3. RESULTS 
3.1. Vaccination against Newcastle disease 
Figure 1: Relative humidity in isolators during exposure of broilers to dispersed vaccines: immediately after vaccine 
dispersion (t = 0 min) until 30 minutes after. 
 During vaccination the relative humidity in all isolators varied between 50-80% (Figure 1) at an 
average temperature of 30.4 ± 1.2 ºC.  
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3.1.1. Vaccine characterization 
Table 2 shows the average particle/droplet size spectra, spans and powder density of the 
dispersed vaccines. 
Table 2: Newcastle disease powder and liquid vaccines: particle and droplet size distributions and powder particle 
density 
 Vaccine type   Average particle/droplet size distributions
1 
Powder  
  D(v,0.1) D(v,0.5) D(v,0.9) span density
2
 
    (µm)   (g/cm
3
) 
Fine powder    2.7 ± 0.6 6.5 ± 0.3 13.8 ± 2.2 1.7 ± 0.4 1.6 ± 0.005 
      
 
Coarse powder 
 
24.0 ± 0.6 37.0 ± 0.5 54.7 ± 0.5 0.8 ± 0.0 1.5 ± 0.010 
      
 
Mixed powder
3 
 
15.1 ± 7.2 33.6 ± 1.1 59.8 ± 6.5 1.3 ± 0.3 1.5 
      
 
Fine liquid aerosol (Walther 
pilot I) droplets 2.6 ± 0.0 10.0 ± 0.25 237.0 ± 190.1 23.5 ± 18.5 - 
 
solid 
particles
4 
0.3 1.1 25.6 23.5 - 
      
 
Coarse liquid spray (Hand-
held bottle) droplets 35.6 ± 6.7 106.4 ± 20.7 297.6 ± 77.2 2.5 ± 0.6 - 
 
solid 
particles
4 
3.9 11.5 32.1 2.5 - 
   
    
 
1
 Values represent mean ± SD of n = 3 (particle and droplet size) and n = 10 (density). 
2
 Analysis performed on placebo powders. 
3 
90% coarse powder and 10% fine powder (wt/wt); powder density has been calculated. 
4 
Estimated values of solid particles originating from airborne droplets after complete evaporation, based on droplet size, solid 
content of the feed (1.25 mg/ml) and dry matter density (assumed 1 g/cm
3
). 
 
 
The coarse powder vaccine contained 4.4% (v/v) particles smaller than 20 µm, with 0.01% (v/v) 
smaller than 10 µm. The coarse liquid spray generated by the hand-held bottle contained 2.5% (v/v) 
droplets smaller than 20 µm, however, as calculated, upon complete evaporation of the airborne 
droplets this would increase to more than 50% (v/v) as the D (v, 0.5) would drop from 106.4 µm to 11.5 
µm. Also the fine liquid aerosol, produced by the Walther Pilot I spray-head, would consist of more fine 
particles upon complete droplet evaporation (D (v, 0.5) reduced from 10.0 to 1.1 µm). 
In general, the dispersed coarse or fine liquid showed wider spans than their powder 
counterparts. The most remarkable difference was observed between the fine liquid aerosol (span = 
23.5) and the fine powder vaccine (span = 1.7). 
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Taking into account the particle density and weighed mass of the powders, the mixed powder 
vaccine consisted of 90.6% (v/v) sieved coarse powder vaccine and 9.4% (v/v) fine powder vaccine. As 
the coarse powder vaccine and the fine powder vaccine contained 4.4% (v/v) and 91.7% (v/v) particles 
smaller than 20 µm, respectively, it was calculated that the mixed powder vaccine contained 12.6% (v/v) 
particles smaller than 20 µm. However, when measured, the mixed powder vaccine contained 15.2% 
(v/v) particles smaller than 20 µm.  
 
3.1.2. Airborne virus concentrations and estimation of inhaled vaccine dose 
Table 3: Exposure of SPF broiler hens to NDV vaccines
1
: vaccine dose per m
3
 air, airborne vaccine titre after 
dispersion of powder and liquid vaccines and estimated inhaled vaccine dose per broiler 
Group Treatment Dispersion 
time 
NDV virus titres (10
x
 EID50/m
3
) Estimated 
vaccine dose 
inhaled per 
broiler
2
 
   
Dose Airborne virus titre 
 
  
(min:s)  
t = 0 
min
3 
t = 10 
min 
t = 20 
min 
10
x
 EID50 
1  None - - - - - - 
2 coarse/fine placebo powder (1:1)  6:21 - <2.9
4 
<2.9 <2.9 - 
3 coarse/fine placebo powder (1:1)  5:34 - <2.9 <2.9 <2.9 - 
4 coarse powder vaccine 3:05 8.3 4.2 <2.9 2.9 0.9 
5 coarse liquid vaccine 0:05 8.4 3.0 <2.9 <2.9  -0.5 
6 mixed powder vaccine
5
  2:54 8.3 5.9 4.5 3.2 2.6 
7 fine powder vaccine 6:35 8.1 7.1 6.1 4.4 3.9 
8 fine liquid vaccine 0:15 8.5 5.5 3.9 <2.9 2.1 
1
 Exposure to NDV vaccine strain LZ58 during 30 min at 4 days of age. 
2
 Based on a ventilation minute volume of 65 ml per broiler (738 ml/min.kg; Fedde, 1998). 
3
 t = 0 min is the moment the dispersion was ended. 
4
 Detection limit = 10
2.9
 EID50/m
3
. 
5
 90% coarse powder vaccine + 10% fine powder vaccine (wt/wt). 
 
 
 Although an initial vaccine dose of 108.1-8.5 EID50/m
3 (Table 3) was administered, broilers were 
exposed to lower vaccine concentrations due to an initial vaccine loss (i.e. the difference between the 
start vaccine dose and the vaccine concentration measured at t = 0). The decrease in vaccine 
concentration depended on the particle size and the physical state of the dispersed vaccine: coarse 
vaccines showed more initial vaccine loss than their fine counterparts, while liquid vaccines also lost 
more than powder vaccines. The vaccine concentrations of the liquid vaccines were below the detection 
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limit at t = 10 min and t = 20 min for the coarse and fine liquid vaccine, respectively. Also the air samples 
taken at t = 10 min and t = 20 min after dispersing the coarse powder vaccine were below or equal to 
the detection limit. 
 Based on the measured airborne vaccine concentration, it was estimated that broilers exposed 
to the fine or mixed powder vaccine would have inhaled the highest vaccine dose, 103.9 and 102.6 EID50 
per bird, respectively, followed by the fine liquid aerosol (102.1 EID50/bird).  
 All air samples taken during dispersion of placebo powders in group 2 and 3 were below the 
detection limit of the virus titrations. No vaccine titre losses were detected during freezing and thawing 
of the vaccine samples.  
 
3.2. Inoculation dose of E. coli 
The E. coli inoculum contained 104.8 cfu/ml both at the start and the end of the inoculation 
procedure. As an inoculation volume of 0.3 ml was used per bird, each broiler received a dose of 104.3 
cfu.  
 
3.3. Adverse vaccinal reactions and serum antibody response 
Serum samples of the surplus broilers were negative for NDV antibodies, confirming the SPF 
status of the animals. 
 Before vaccination no clinical signs of disease were observed in the groups. Six days post-
vaccination some depressed birds were observed in each vaccinated group, increasing in number after 
E. coli inoculation. In the groups exposed to the fine liquid vaccine, the fine powder vaccine and the 
mixed powder vaccine more sick birds were observed than in groups treated with coarse vaccines. 
The adverse vaccinal reactions and serum antibody response of the SPF broiler hens after 
vaccination and E. coli inoculation are outlined in Table 4. 
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Table 4: Adverse vaccinal reactions and serum antibody response of SPF broiler hens exposed to powder and liquid aerosols of live NDV vaccines
1
 at 4 days of 
age and inoculated intratracheally with E.coli strain 506
2
 at 11 days of age. The experiment was ended at 18 days of age. 
1
 Exposure to NDV vaccine strain LZ58 during 30 min. 
2
 E. coli dose = 10
4.3
 cfu/bird. 
3
 Each group consisted of 40 broilers, however only the number of hens is presented here since cockerels (sex faults) were not included in the body weight analysis. 
4
 Mean values. 
5
 All mortality was specific; up to 11 days of age mortality did not occur; groups were not significantly different (P >0.05). 
6
 MLS = mean lesion score. 
7
 90% coarse powder vaccine + 10% fine powder vaccine (wt/wt). 
a-e
 Values within the same column with different superscript are significantly different (P <0.05). 
R
 Reference group for logistic regression analysis; 
*
 Significantly different from reference group (P < 0.05). 
 
 
 
 
 
 
 
   Age (days)
 
 
  4 4 4-11 11-18 11-18 18 18 
Group Treatment E. coli 
inoculation
 
n
3
 Body 
weight ± 
SD (g)
4 
Body weight 
gain ± SD 
(g)
4 
Mortality
5
 Body weight 
gain ± SD (g)
4 
Colibacillosis in surviving birds  
MLS ± SD
6
 Affected 
(%) 
Generalized 
infected (%) 
Mean log2 HI 
NDV titre ± SD         
 
           
1 None no 40 90 ± 7
a
  149 ± 16
a,b,c
  0
 
172 ± 17
a,b,c
  0.0 ± 0.0
a 
0 (0) 0 (0) < 1.0 ± 0.0
a 
2 coarse/fine placebo powder (1:1) PBS 40 86 ± 8
a 
165 ± 17
c
  0
 
196 ± 20
c 
0.0 ± 0.1
a 
1 (3) 0 (0) < 1.0 ± 0.0
a 
3 coarse/fine placebo powder (1:1) yes 37 86 ± 8
a 
161 ± 16
b,c 
2
 
189 ± 54
b,c
  0.2 ± 1.1
a 
1 (3)
R 
1 (3)
R 
< 1.0 ± 0.0
a 
4 coarse powder vaccine yes 38 88 ± 7
a 
152 ± 20
a,b,c 
3
 
160 ± 35
a,b,d 
1.7 ± 1.9
b 
25 (68)
* 
2 (5)
 
3.4 ± 1.3
b,c 
5 coarse liquid vaccine yes 36 89 ± 7
a 
154 ± 18
b,c 
2
 
157 ± 31
a,b,d,e 
2.0 ± 2.3
b 
27 (71)
* 
1 (3)
 
3.2 ± 1.1
b 
6 mixed powder vaccine
7 
yes  38 90 ± 8
a 
145 ± 17
a,b,d 
2
 
139 ± 35
d,e
  3.9 ± 4.0
b,c 
32 (84)
* 
9 (24)
* 
4.3 ± 1.2
b,c 
7 fine powder vaccine yes  39 85 ± 6
a 
136 ± 24
a,d 
4
 
148 ± 46
a,d,e 
3.9 ± 2.8
b,c 
34 (94)
* 
5 (15)
 
4.4 ± 1.0
c,d 
8 fine liquid vaccine yes 38 91 ± 6
a 
131 ± 27
d 
4
 
126 ± 42
e 
4.9 ± 3.3
c 
35 (97)
* 
10 (28)
* 
5.2 ± 0.9
d
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 Before vaccination (day 4) broilers from all groups did not weigh significantly different (P >0.05). 
After E. coli inoculation significant differences (P <0.05) in body weight between vaccinated groups were 
found. The highest average body weight gains ± SD of 172 ± 17 g, 196 ± 20 g and 189 ± 54 g were 
registered for the unvaccinated groups 1, 2 and 3, respectively. The group vaccinated with the fine liquid 
vaccine exhibited the lowest body weight gain ± SD (group 8; 126 ± 42 g), followed by the groups treated 
with the mixed powder vaccine (group 6; 139 ± 35 g) and the fine powder vaccine (group 7; 148 ± 46 g). 
Remarkably, the blanco group 1 showed a lower body weight gain compared to the placebo treated 
groups 2 and 3, albeit not significantly (P >0.05).  
 After E. coli inoculation, moderate mortality rates (0 to 4 dead birds per group) occurred 
without significant differences (P >0.05) between the vaccinated groups and the E. coli positive control 
group (group 3). All mortality proved to be specific. 
 Vaccinated broilers showed a significantly increased sensitivity to colibacillosis (P <0.05) 
compared to the non-vaccinated but E. coli inoculated group 3, as reflected by the percentage of 
affected animals ranging from 68 to 97 for the vaccinated groups while 3% affected animals were 
observed in group 3. The severity of E. coli lesions for each group is expressed by the mean lesion score 
(MLS) and the rate of generalized colibacillosis, which are the highest for the group treated with the fine 
liquid aerosol (MLS of 4.9; generalized infected rate of 28%). Significantly (P <0.05) lower MLS values and 
generalized infection rates were obtained for the groups vaccinated with the coarse vaccine (MLS of 1.7 
and 2.0; and generalized infections rate of 3 and 5% for coarse powder and liquid vaccine, respectively), 
although no significant differences (P >0.05) were observed between the powder and liquid vaccine 
formulation. The generalized colibacillosis infection rate for the groups vaccinated with the mixed 
powder vaccine (24%) and the fine liquid vaccine (28%) was significantly different (P <0.05) from the 
non-vaccinated group inoculated with E. coli (3%). 
 The fine liquid aerosol induced a significantly higher (P <0.05) serum antibody response of 5.2 
log2 compared to the coarse vaccines (3.4 and 3.2 log2 HI titre for coarse powder and liquid vaccine, 
respectively) and the mixed powder vaccine (4.3 log2 HI titre). The mean log2 HI NDV titre of 4.4 in the 
group vaccinated with the fine powder vaccine was however not significantly different (P >0.05) from 
the group treated with the fine liquid aerosol. The lowest serum antibody response was observed in the 
group vaccinated with the coarse liquid spray vaccine. 
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 All reisolates, except one (1/26) originating from an air sac, were clonal and showed 100% 
similarity to the parent strain used to induce colibacillosis in the broilers as shown in Figure 2. The 
control strains isolated from the bone marrow of layers with peritonitis were not clonally related to the 
parent strain and the reisolates (similarity <85%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Restriction endonuclease digestion pattern obtained by PFGE after treatment with Xba I of 26 E. coli 
reisolates from air sac, bone marrow and pericardium of broilers inoculated with E. coli 506 (parent strain). Each 
reisolate was obtained from a different experimental bird. Two control isolates obtained from the bone marrow of 
layer hens that died from peritonitis were included as controls. All reisolates showed 100% similarity to the parent 
strain except one isolate from an air sac (*), which was regarded as a contaminant. 
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4. DISCUSSION 
In this study, coarse and fine powder vaccines were compared in SPF broilers with 
corresponding liquid vaccines regarding the serum antibody response and adverse vaccinal reactions. 
Overall, no significant differences were observed between powder and liquid vaccines.  
The coarse vaccines (powder and liquid) showed comparable serum antibody responses and 
adverse vaccinal reactions, despite an estimated inhaled dose of <1 EID50/bird for the liquid vaccine and 
<10 EID50 for the powder vaccine. This raised the question whether the observed vaccinal reactions are 
basal i.e. belonging to the combination of the vaccination method, the vaccine virus and the 
experimental broilers used. Alternatively, it is possible that the virus uptake was underestimated as 
gelatin filters with a pore size of 3 µm were used for air sampling, while likely airborne virus particles 
smaller than 3 µm were present. Research into the feasibility to further reduce the adverse vaccinal 
reactions induced after coarse spray and powder NDV vaccines is described in Chapter 5. 
 Regarding the fine vaccines, the liquid vaccine yielded a higher serum antibody response, albeit 
not significantly (P >0.05), than the powder vaccine, despite a 63-fold lower inhaled vaccine dose (Table 
3). This is explained by the difference in median volume particle size: dried vaccine particles from the 
liquid vaccine were 1.1 µm, while the vaccine particles of the powder vaccine were 6.5 µm. The smaller 
particles from the liquid vaccine likely penetrated into the deepest tissues of the lower respiratory tract 
(i.e. the atria and air capillaries)[19] where they induced a strong immune response [2]. Therefore, it 
was considered that the highest vaccination efficiency could be obtained with vaccine particles 1 µm, 
which was in line with previous aerosol experiments with inactivated NDV vaccines [20]. 
 There was no substantial difference between the mixed and the fine powder vaccine regarding 
the adverse vaccinal reactions and seroresponse, although the estimated inhalable vaccine dose of the 
mixed powder vaccine was about 20 times lower (Table 3). This stresses the importance of avoiding low 
levels of fine particle contamination in the coarse powder vaccines. However, these results were not 
unexpected as the mixed powder vaccine, consisting of 1/10 of fine powder vaccine, could be 
considered as a fine powder vaccine with one log10-unit less vaccine virus.  
 In agreement with earlier studies, the present results showed again that coarse vaccine 
nebulizations induced less adverse vaccinal reactions in young broilers compared to fine vaccine 
aerosols [21, 22]. However, the significant increase in adverse vaccinal reactions, and thus colibacillosis 
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susceptibility, after using fine vaccine aerosols compared to coarse vaccines was a novel finding, which 
has not been described before. 
  Further, in the present experiments it was confirmed again that an inhaled vaccine dose of 
about 100 to 1000 EID50 NDV per bird administered via fine vaccine particles is able to induce excellent 
serum antibody responses in SPF broilers [4, 23, 24]. However, it should be considered that if the same 
vaccine dose is used in maternally immune broilers a lower antibody response will be obtained [7, 25, 
26].
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5. CONCLUSION 
No significant differences (P >0.05) regarding adverse vaccinal reactions and serum antibody 
response were observed between the powder vaccines and their liquid counterparts, despite the higher 
initial vaccine loss following vaccine dispersion and the wider particle distribution of the liquid vaccines. 
The fine liquid vaccine was found superior in inducing serum antibody response, but also provoked more 
adverse vaccinal reactions. This was likely due to the fine vaccine particles ( 1 µm) penetrating deep 
into the lung, while the median particle sizes of other vaccine formulations were larger. 
Additional experiments need to be performed in order to investigate if a further decrease of 
adverse vaccinal reactions is feasible by exclusively targeting the upper respiratory tract during 
vaccination (eye-nose drop vaccination) compared to spray vaccination without affecting the serological 
response (Chapter 5). If so, the coarse powder vaccine should be optimized further to eliminate all fine 
particles able to reach the lower airways.  
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CHAPTER 5 
FEASIBILITY TO DECREASE ADVERSE VACCINAL 
REACTIONS BY REPLACING COARSE SPRAY BY DRY 
POWDER NEWCASTLE DISEASE VACCINATION  
 
1. INTRODUCTION 
In primary Newcastle disease (ND) vaccination of day-old chicks coarse spray vaccination is a 
practical alternative to the individual eye-nose drop vaccination method. However, due to a small 
fraction of fine vaccine particles generated during spray vaccination adverse vaccinal reactions 
persistently occur in young spray-vaccinated broilers as demonstrated in Chapter 4. Fine vaccine particle 
deposition in the lower respiratory system of the chicks can induce respiratory signs, growth retardation 
and increased susceptibility to secondary diseases such as colibacillosis (Chapter 4), a poultry disease 
with great economic consequences. 
In Chapter 4, coarse powder vaccination of broilers could not decrease the adverse vaccinal 
reactions compared to the commercial coarse liquid spray vaccine, although the calculated inhaled 
vaccine dose for both methods was very low. It was therefore questioned whether the observed adverse 
vaccinal reactions after coarse vaccination were inherent to the vaccination method, vaccine type and 
broilers used or if further decrease of the adverse vaccinal reactions was possible by optimal vaccine 
deposition while retaining the immune response. If so, the particle size distribution of the coarse 
powder vaccine should be optimized further resulting in particles that are, amongst others, deposited in 
the eyes and regarding the respiratory tract only in the nose.  
In the infection model used in the present study [1], post vaccinal reactions as growth 
retardation, increased susceptibility to colibacillosis and serum antibody response were assessed at 
fixed time points after ND vaccination. The magnitude of these reactions depends amongst others on 
the phase of the vaccine virus infection at the day they are measured. Therefore, it is a prerequisite that 
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vaccine virus dynamics in groups of birds, of which vaccinal reactions are compared, are similar. In order 
to fulfil this demand the vaccine virus dose actually involved in the infection of the birds should be 
similar in groups that are compared. 
In the present study, serial 10-fold diluted vaccine virus suspensions were administered to SPF 
broiler hens by eye-nose drops or by conventional liquid coarse spray until endpoint, i.e. until no 
vaccinal response in the birds was obtained anymore. This procedure allows assessment of vaccine virus 
loss following coarse spray in comparison with eye-nose drop and subsequently allows comparison of 
groups of broilers in which similar vaccine doses were involved in the actual vaccine take either after 
application by eye-nose drop or by coarse spray regarding their adverse vaccinal reactions and 
seroresponse. In case this comparison yields favourable results for the eye-nose drop method and 
considering that virus loss of coarse liquid spray and coarse powder vaccine is similar ([2]; Chapter 4 this 
thesis), then manufacturing a coarse dry powder vaccine that perfectly mimics the eye-nose drop 
vaccination regarding deposition in the eyes and respiratory tract (further referred to as perfect coarse 
powder vaccine), would be very valuable for the field.  
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2. MATERIALS AND METHODS 
2.1. Experimental design 
Day-old SPF broilers (day 0 = day of hatch; Animal Health Service, Deventer, the Netherlands) 
were sexed cloacally after which the hens were randomly divided into 14 groups; each consisting of 45 
birds, individually tagged and treated as outlined in Table 1. Groups were exposed to a different vaccine 
doses, aiming at a range from 106.6- 100.6 50% Egg Infectious dose (EID50)/bird for oculonasal vaccination 
and from 106.6 – 102.6 EID50/bird in case of spray vaccination. Exact NDV vaccine titres were determined 
by virus titrations as described in Section 2.7.  
 
Table 1: Experimental design to compare the adverse vaccinal reactions and serum antibody response of 4-day-old 
SPF broilers induced by eye-nose drop (E-N) or coarse liquid spray (S) vaccination with serial 10-fold diluted NDV 
vaccine. 
Group
1
 
 Treatment
2
 
 ND vaccination
3
 
E. coli inoculation
4 
Vaccination method Vaccine dilution  
 
Targeted dose 
(10
x
EID50/bird) 
1 E-N 10
0 
6.6 yes 
2 E-N 10
-1 
5.6 yes 
3 E-N 10
-2 
4.6 yes 
4 E-N 10
-3 
3.6 yes 
5 E-N 10
-4 
2.6 yes 
6 E-N 10
-5 
1.6 yes 
7 E-N 10
-6 
0.6 yes 
8 S 10
0 
6.6 yes 
9 S 10
-1 
5.6 yes 
10 S 10
-2 
4.6 yes 
11 S 10
-3 
3.6 yes 
12 S 10
-4 
2.6 yes 
13 E-N/S water
5
 - yes 
14 - - - no 
1
 Per group: n = 45. 
2
 Day 0: hatch; day 4: ND vaccination; day 11:intratracheal E. coli inoculation; day 18: post-mortem examination, 
serum sampling (end of the experiment).  
3
 NDV vaccine strain LZ58; 0.2 ml vaccine suspension/bird. 
4 
Aimed E. coli dose = 10
4.0-5.0
 cfu/bird. 
5
 Sterile demineralized water. 
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At the age of 11 days, the vaccinated groups were randomly reduced to 40 birds per group and 
inoculated intratracheally (i.t.) with a virulent strain of E. coli (strain 506, serotype O78K80) as described 
in Section 2.5. The i.t. route was chosen as it is most likely that the natural route of infection is airborne 
[3].  
The experiment was ended at day 18. Birds were euthanized for post-mortem examination, 
explained in Section 2.7, and bled for serum sampling.  
 Broilers were weighed at 4, 11 and 18 days of age, while mortality was registered throughout 
the entire experiment. Dead birds were frozen at -20ºC until post-mortem examination at the end of the 
experiment. 
 
2.2. Housing and handling of broilers 
Broiler groups were housed in negative pressure HEPA isolators (Beyer & Eggelaar, Utrecht, the 
Netherlands) with a volume of 1.38 m3 (194 cm width, 95 cm height and 75 cm depth). The birds were 
exposed to 22h of light per day from day 0 to 8, after which it was reduced to 16h per day. The isolator 
temperature was set at 35ºC at the start of the experiment and was gradually decreased to 25ºC by the 
end of the experiment. Unrestricted access to commercial broiler feed and tap water were provided 
during the entire experiment. Surviving animals on day 18 were stunned by exposure to a mixture of CO2 
and O2 and subsequently debleeded by an incision in the vena jugularis. 
 
 
2.3. Vaccination against Newcastle disease 
An LZ58 NDV vaccine vial containing approximately 1010 EID50/ml was used for the preparation 
of the 100 vaccine suspension, aiming at a vaccine concentration of 107.3 EID50/ml. From this 10
0 vaccine 
suspension ten-fold dilutions were made as shown in Table 1. All dilutions were made using sterile 
demineralized water. The vaccine dilutions were stored at 6ºC until use. After vaccination, samples of all 
vaccine suspensions were frozen by submersion into a mixture of dry ice and 70% ethanol (Chemlab, 
Zedelgem, Belgium). Frozen samples were stored at -80ºC until virus titrations were performed (Section 
2.8).  
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Oculonasal vaccination of groups 1 to 7 was performed using a sterile eye dropper (DRU-00304, 
GEMO 10 ml, Blockland, Maarssen, the Netherlands) containing 10 ml of the corresponding vaccine 
dilution. Each bird received a drop of 0.05 ml into each eye and each nostril (i.e. 0.2 ml/bird).   
 Spray vaccination was performed using a hand-held spray bottle (Powerplus Garden POW 
63868, Varo, Lier, Belgium), which delivered 1 ml liquid vaccine per actuation. The droplet size 
distribution and the particle size distribution of the dried particles of the spray have been described in 
Chapter 4. After driving the chicks together in a corner of the isolator and switching off the ventilation, 9 
ml of the vaccine dilution was nebulized per group, dispersing 0.2 ml per bird. The ventilation remained 
switched-off until 30 min after vaccination.  
  Groups were vaccinated starting with the highest dilution and ending with the lowest vaccine 
dilution to minimize the effect of a possible contamination between groups. The placebo group (group 
13) was treated before starting the vaccination for the same reason. 
  
2.4. Airborne vaccine concentration and estimation of inhaled vaccine dose in 
group 8 
In group 8, spray vaccinated with the highest vaccine dose, air samples were collected 
immediately after spraying (t = 0 min) and 10 and 20 min thereafter. To capture the airborne vaccine, 
sterile gelatin filters with a pore size of 3.0 µm (17528-80-ACD, Sartorius, Stedim Biotech, Goettingen, 
Germany) were placed vertically at a height of 15 cm above the wired floor of the isolator and coupled 
to an MD 8 Airscan (Sartorius, Nieuwegein, the Netherlands) which provided air suction through the 
filter at a rate of 2000 l/h during 2 min. Gelatin filters were then dissolved in 10 ml preheated (37ºC) 
Dulbecco’s phosphate buffered saline (DPBS, Gibco, Invitrogen, Paisley, UK) and frozen as described in 
Section 2.3. Samples were stored at -80ºC until virus titrations (Section 2.7). During air sampling, the 
environmental conditions in the isolator were recorded every 2 seconds via a temperature-humidity 
logger (Testostor 171-2; Testo, Ternat, Belgium). 
The amount of vaccine inhaled per broiler over the period from the start of vaccination until 30 
min after the end of it, was estimated based on the ventilation rate of the birds  of 738 ml/min per kg 
body weight [4]. For the calculation of the virus-uptake, following assumptions were made: (1) all 
airborne vaccine particles measured by air sampling are inhalable; (2) there is a linear increase and 
decrease of the vaccine aerosol in the isolator; (3) 30 minutes after vaccine dispersion the airborne 
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vaccine titres are considered to be ‘0’ as well as virus titres from the air samples which were below the 
detection limit; (4) vaccine particle retention in the birds is 100% [5, 6].  
 
2.5. Escherichia coli inoculum and inoculation procedure 
The virulent E. coli strain (strain 506, serotype O78K80) used for inoculation of the 11-day-old 
broilers was a flumequine resistant and doxycycline intermediary sensitive strain isolated from a natural 
case of colibacillosis in a broiler chick. Deep-frozen beads (-70ºC) containing this strain were submersed 
in 0.1% glucose broth (1000 ml purified water, 5 g Lab Lemco (Oxoid LP0029), 10 g bacteriological 
peptone (Oxoid LP0-037), 5 g NaCl (VWR 1.06404.1000) (Merck) and 1 g glucose (VWR 1.08342.1000) 
(Merck)) and incubated at 37ºC for 17 hours.  To obtain a bacterial concentration of 104.5-5.5 cfu/ml, the 
grown culture was diluted 1:5000 using phosphate buffered saline (PBS).  
Broilers were intratracheally inoculated with 0.3 ml of the diluted bacterial suspension, using a 
sterile dropper (DRU-00304, GEMO 10 ml, Blockland, Maarssen, the Netherlands) administering a dose 
of 104.0-5.0 cfu per broiler. During the procedure, the bacterial inoculate was kept on ice. Broiler groups 
were treated in the same order as vaccination was performed. Samples of the E. coli inoculate were 
taken before and after the inoculation procedure and bacterial concentration was determined as 
described in Section 2.10. 
 
2.6. Clinical signs 
Broiler groups were observed daily for clinical signs, including depression and respiratory signs, 
resulting from the ND vaccination and/or E. coli inoculation. 
 
2.7. Post-mortem examination 
At day 18, surviving broilers were visually examined for the presence of macroscopic lesions in 
left and right thoracic air sacs, pericardium and liver. Scoring was performed blindly according to Van 
Eck and Goren [1], implying a maximum score of 12 for each bird. Results were expressed for every 
group as mean lesion score and as number of birds affected by colibacillosis (i.e. lesion score greater 
than ‘0’) and number of birds with generalized colibacillosis (i.e. pericardium and/or liver score higher 
than ‘0’). 
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The gender of every bird was re-determined during post-mortem examination to ensure that 
only hens were included in the body weight data.  
 
2.8. Virus titrations 
The deep-frozen vaccine samples (-80ºC) were thawed at room temperature, and 10-fold 
dilutions were made in DPBS with 1% penicillin-streptomycin solution (Penicillin G (10,000 IU/ml) – 
streptomycin sulphate (10,000 µg/ml)). A volume of 0.3 ml of the undiluted virus suspension and of each 
dilution was inoculated into the allantoic cavity of 10-day-old embryonated SPF eggs, using five eggs per 
dilution. The inoculated eggs were incubated for 72 hours at 37ºC and subsequently tested for 
haemagglutinin activity [7]. Results were calculated as EID50 according to the formula of Reed and 
Muench [8]. The detection limit for vaccine suspensions was 100.7 EID50/ml and 10
2.9 EID50/m
3 for the air 
samples, considering 67 l of sampled air. 
As all vaccine dilutions were prepared from the same 100 dilution, the average vaccine virus titre 
of this dilution was calculated from the titres of the 100 to the 10-6 dilution. This average value 
represents the virus titre most accurately as results of virus titrations may differ up to 1 log10 between 
titrations of the same sample. Consequently, throughout the paper, calculated average titres are given. 
 
2.9. Serology  
At the day of hatch (day 0), sera of 24 surplus birds showed no haemagglutination inhibiting 
antibodies to NDV (log2 heamagglutination inhibition (HI) titres <1.0).  Serum of all surviving broilers was 
sampled and analyzed by HI [9] at the end of the experiment (day 18); the serological analysis was 
performed in one run. 
 
2.10.  Assessment of bacterial concentration of the inoculum and bacteriology 
of birds 
The bacterial concentration of the E. coli inoculum was determined by bacterial counting 
performed according to international standards [10, 11]. Samples were taken both at the start and at 
the end of the inoculation procedure. 
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Bacteriological analysis of all dead birds was performed on tissue samples from the femur bone 
marrow to determine specific mortality. Mortality was considered specific if E. coli was reisolated from 
bone marrow and/or if generalized colibacillosis lesions was observed at post-mortem examination. 
The surface of sagitally cut bone physis was sterilized with a hot scalpel blade after which the 
bone marrow sample was collected with a wire. Then, sheep-blood agar plates (K004P090; Biotrading, 
Mijdrecht, the Netherlands) were inoculated, subsequently incubated overnight at 37°C and thereafter 
visually inspected for purity. Biochemical identification of colonies was performed using the indole and 
β-glucuronidase test, which are both positive for E. coli. 
 
2.11.  Statistical analysis 
The survival rate between groups was compared using the Mantel-Cox log-rank test. 
Body weight and body weight gain were analyzed with a one-way ANOVA followed by the post-
hoc Scheffé’s test after verifying the normality of residuals with a Q-Q plot and homogenicity of 
variances with the Levene’s test. Survival analysis and body weight analysis were performed in SPSS 
version 20 (IBM, New York, USA). 
Serum antibody titres and E. coli scores were compared between the 14 groups using the 
Kruskal-Wallis test. Pairwise comparisons were carried out using Wilcoxon rank sum test, adjusting the 
p-values for the number of performed tests with the Bonferroni correction. 
Number of affected and generalized infected birds were compared in the vaccinated groups by 
fitting a logistic regression with infection as response and vaccination treatment as explanatory variable. 
Only vaccinated groups were compared to the control group 13, treated with the placebo on day of 
vaccination and inoculated with E. coli. 
All analyses were performed in R (version 2.14.1, the R Foundation for Statistical Computing) 
unless specified differently. For all analyses a significance level of P <0.05 was applied. 
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3. RESULTS  
 
3.1. Group 8: airborne vaccine concentration, inhaled vaccine dose, 
temperature and relative humidity 
Air samples taken in group 8 immediately after vaccine dispersion and 10 and 20 minutes after 
dispersion, resulted in a vaccine concentration of 103.2 EID50/m
3 immediately after dispersion, while 
vaccine concentrations 10 and 20 minutes after dispersion were below the detection limit (i.e. 102.9 
EID50/m
3). As the dispersed vaccine dose was 108.0 EID50/m
3, this implied an initial decrease in vaccine 
concentration of 4.8 log units. The inhaled vaccine dose was estimated at 10-0.4 EID50/bird. 
 
Figure 1: Relative humidity (%) in the isolator of group 8 immediately after vaccine nebulization until 30 
min thereafter. 
 
The relative humidity (RH) in the isolator during vaccine exposure of the broilers belonging to 
group 8 is given in Figure 1. The RH increased from 60% to 88% during the vaccination procedure, while 
the isolator temperature remained relatively constant (28.0 ± 0.6 ºC). 
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3.2. Bacterial concentration of the Escherichia coli inoculum 
The E. coli concentration of the administered suspension before and after the inoculation 
procedure was 105.0 and 104.9 cfu/ml, respectively, resulting in a dose of 104.4 cfu/0.3 ml per bird. 
 
3.3. Clinical signs 
The rate of clinical signs after ND vaccination and E. coli inoculation are graphically 
demonstrated in Figure 2. No clinical signs were observed up to 7 days after ND vaccination. The first 
sick bird was observed in group 13, one day after E. coli inoculation (day 12). Five days post-inoculation, 
respiratory signs were observed in 3 and 4 birds in groups 7 and 11, respectively. Other sick birds were 
registered between 4 to 6 days post-inoculation. 
 
 
Figure 2: Number of birds per group, showing clinical signs after ND vaccination and E. coli inoculation. 
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3.4. Vaccine dose, adverse vaccinal reactions and serum antibody response 
Vaccine dose per bird, mortality and body weight gain from day of vaccination until the end of 
the experiment are presented in Table 2. In Table 3, the serum antibody response and colibacillosis 
lesions in the surviving birds are outlined. 
Table 2: Vaccine dose, mortality and body weight gain of SPF broiler hens, vaccinated with live NDV (strain LZ58) at 
4 days of age (day of hatch = day 0) and i.t. inoculated with virulent E.coli (strain 506)
1
 at 11 days of age. The 
experiment was ended at the age of 18 days 
Group Vaccination 
method
2
 
Vaccine 
dilution 
Vaccine dose                
(10
x
 EID50/bird) 
n
3
 Mortality
4
 Body 
weight
5
 
Body weight gain
5
 
  
 Determined Averaged   day 4 days 4 - 11 days 11 - 18 
1 E-N 10
0 
7.0 6.4 37 2
a 
68 ± 6
a 
147 ± 15
ab 
167 ± 21
abcd 
2 E-N 10
-1 
5.3 5.4 38 2
a 
65 ± 6
a 
130 ± 17
cde 
167 ± 37
abcd 
3 E-N 10
-2 
3.7 4.4 39 2
a 
63 ± 6
a 
119 ± 17
c 
170 ± 29
bcde 
4 E-N 10-
3 
2.5 3.4 36 1
a 
64 ± 8
a 
134 ± 16
cde 
167 ± 29
abcd 
5 E-N 10
-4 
2.0 2.4 40 0
a 
64 ± 6
a 
134 ± 14
ade 
181 ± 20
cdef 
6 E-N 10
-5 
1.0 1.4 37 3
a 
63 ± 7
a 
128 ± 12
cde 
147 ± 39
ag 
7 E-N 10
-6 
0.1 0.4 37 1
a 
64 ± 5
a 
138 ± 17
abe 
164 ± 33
abcd 
8 S 10
0 
7.0 6.4 37 2
a 
67 ± 8
a 
127 ± 22
cde 
158 ± 29
ab 
9 S 10
-1 
5.3 5.4 37 1
a 
66 ± 6
a 
121 ± 15
cd 
162 ± 27
abc 
10 S 10
-2 
3.7 4.4 36 1
a 
65 ± 7
a 
134 ± 16
ad 
151 ± 26
abg 
11 S 10
-3
 2.5 3.4 37 4
a 
64 ± 6
a 
123 ± 15
cd 
134 ± 22
g 
12 S 10
-4 
2.0 2.4 39 0
a 
66 ± 7
a 
136 ± 11
abe 
192 ± 16
ef 
13 E-N/ S water
6
 - - 36 0
a 
65 ± 5
a 
151 ± 15
b 
187 ± 42
def 
14 - - - - 36 0
a 
63 ± 7
a 
146 ± 18
ab 
195 ± 21
f 
1
 E. coli dose: 10
4.4
 cfu/bird, except for group 14 (no E. coli). 
2
 E-N = eye-nose drop; S = coarse spray. 
3
 Groups consisted of 45 birds each at time of vaccination and were randomly reduced to 40 on day of E. coli inoculation, except 
for group 1 (n =39); n was corrected for the presence of cockerels (sexing faults). 
4 
Almost all mortality was specific; no mortality occurred up to 11 days of age. 
5 
Mean values (g) ± SD. 
6
 Sterile demineralized water. 
a-g
 Values within the same column with the same superscript were not significantly different (P >0.05). 
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Except for group 12 (spray vaccinated with 102.4 EID50 per chicken), vaccine take was observed in 
all other groups as deduced from their seroresponse and was accompanied by adverse vaccinal 
reactions in mentioned groups. Body weight gain was depressed and following E. coli inoculation, the 
MLS was significantly (P <0.05) increased in most groups, while the number of chickens with 
colibacillosis was significantly (P <0.05) increased in all groups in comparison with the placebo 
vaccinated and E. coli inoculated control group (group 13).  
Mortality was only observed after E. coli inoculation and ranged from 0 to 4 per group; 
differences between groups were not significant (P >0.05). Also the number of surviving broilers at 18 
days of age with generalized colibacillosis varied from 0 to 4 per group; differences between groups 
being not significant (P >0.05). 
Groups with high MLS (group 10: 3.3; group 8: 3.9; group 11: 4.0; group 6: 4.3) showed body 
weight gains following E. coli inoculation varying from 134 ± 22 g (group 11) to 158 ± 29 g (group 8), 
while in the other E. coli inoculated groups with an MLS ranging from 0.1 to 2.2 body growth varied from 
162 ± 27 g (group 9; MLS = 2.1) to 192 ± 16 g (group 12; MLS = 0.1). 
The MLS of groups vaccinated by eye-nose drop gradually increased from 0.7 via 1.3, 1.4 and 1.7 
to 2.0 (groups 1, 2, 3, 4 and 5, respectively) with a decreasing vaccine virus dose per bird (with decimal 
steps decreasing from 106.4 to 102.4 EID50). Applying 10
1.4 EID50 per chicken resulted in a relative strong 
increase of the MLS to 4.3 (group 6), while using a dose of 100.4 EID50 per chicken a decrease of the MLS 
to 2.2 was measured (group 7). In the spray vaccinated groups a MLS of 3.9 was observed in the group 
vaccinated with 106.4 EID50 per bird (group 8); the MLS decreased to 2.1 in birds sprayed with 10
5.4 EID50 
per chicken (group 9) after which the MLS increased again to 3.3 and 4.0 in groups vaccinated with 104.4 
and 103.4 EID50 per broiler, respectively. 
Except for group 8, two weeks after vaccination mean HI NDV log2 titres ± SD in seroresponding 
groups ranging from 1.2 ± 0.5 (group 11) to 1.8 ± 0.9 (group 6). Differences between groups were not 
significant (P >0.05). Group 8, which was spray vaccinated with 106.4 EID50 per bird, had a mean HI NDV 
log2 titres ± SD of 2.2 ± 1.3 at 18 days of age, being significantly higher (P <0.05) than mean titres of 
most other vaccinated groups. 
The percentage of chickens with HI NDV log2 titres ≥ 2 varied from 17 to 58 between the 
seroresponding groups. 
The endpoint of the coarse spray vaccine virus titration in broilers was achieved with 103.4 EID50 
per chicken (group 11); administration of 102.4 EID50 per chicken (group 12) did not result in a 
seroresponse anymore and no vaccinal reactions were observed in this group. Using the eye-nose drop 
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vaccination method, the titration endpoint was not reached as in the group in which the highest vaccine 
dilution (group 7; 10-6 vaccine dilution; 100.4 EID50 per broiler) was applied, still a seroresponse occurred.  
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Table 3: Serum antibody response and colibacillosis lesions in surviving SPF broilers at 18 days of age (day of hatch = day 0) and mortality from 11 days of age 
after vaccination with live NDV (strain LZ58) at 4 days of age and i.t. inoculation with virulent E.coli (strain 506)
1
 at 11 days of age 
Group
2
 
Vaccination 
method
3
 
Vaccine dilution Vaccine dose (10
x
 EID50/bird) Mortality
4 
Colibacillosis in surviving birds 
Mean log2 HI NDV 
titre ± SD 
  
 Determined Averaged 
 
MLS
5
 ± SD 
MLS 
significance 
Affected (%) 
Generalized 
infected (%) 
(% birds ≥2 log2) 
1 E-N 10
0 
7.0 6.4 2 0.7 ± 1.1 abcd 14 (38)* 3 (1) 1.4 ± 0.7
ab
 (30) 
2 E-N 10
-1 
5.3 5.4 2 1.3 ± 2.7 bcde 21 (55)* 2 (5) 1.3 ± 0.6
ab
 (18) 
3 E-N 10
-2 
3.7 4.4 2 1.4 ± 2.4 cdef 25 (66)* 3 (8) 1.5 ± 0.8
ab
 (34) 
4 E-N 10
-3 
2.5 3.4 1 1.7 ± 2.3 def 29 (74)* 4 (10) 1.6 ± 0.9
ab
 (38) 
5 E-N 10
-4 
2.0 2.4 0 2.0 ± 1.2 efg 37 (93)* 0 (0) 1.5 ± 0.9
ab
 (33) 
6 E-N 10
-5 
1.0 1.4 3 4.3 ± 2.2 g 35 (95)* 3 (8) 1.8 ± 0.9
bc
 (50) 
7 E-N 10
-6 
0.1 0.4 1 2.2 ± 2.8 defj 23 (59)* 2 (5) 1.3 ± 0.6
ab
 (23) 
8 S 10
0 
7.0 6.4 2 3.9 ± 2.0 gh 34 (89)* 1 (3) 2.2 ± 1.3
c
 (58) 
9 S 10
-1 
5.3 5.4 1 2.1 ± 2.2 defh 33 (85)* 2 (5) 1.7 ± 1.1
bc
 (44) 
10 S 10
-2 
3.7 4.4 1 3.3 ± 1.5 ghij 37 (95)* 1 (3) 1.5 ± 0.8
ab
 (33) 
11 S 10
-3
 2.5 3.4 4 4.0 ± 1.0 ghi 36 (100)* 0 (0) 1.3 ± 0.6
ab
 (17) 
12 S 10
-4 
2.0 2.4 0 0.1 ± 0.2 ab 4 (10) 0 (0) < 1.0 ± 0.0
ad
 (0) 
13 E-N/S water
6
 - - 0 0.3 ± 1.3 abc 5 (13)R 1 (3)R < 1.0 ± 0.0
ad
 (0) 
14 - - - - 0 0.0 ± 0.0 a 0 (0) 0 (0) < 1.0 ± 0.0
ad
 (0) 
1
 E. coli dose: 10
4.4
 cfu/bird; except for group 14 (no E.coli). 
2 
Each group consisted of 45 broilers at day of vaccination and was randomly reduced to 40 broilers at day of E. coli inoculation, except for group 1 (n = 39). 
3 
E-N = eye-nose drop; S = coarse spray. 
4 
Almost all mortality was specific; no significant differences were observed between groups (P >0.05); no mortality occurred up to 11 days of age. 
5 
Mean lesion score. 
6
 Sterile demineralized water.  
R
 Reference group for logistic regression analysis; * significantly different from reference group (P <0.05). 
a-j
 Values within the same column with the same superscript (HI NDV titre) or letters (MLS) are not significantly different (P >0.05).  
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4. DISCUSSION 
 
In the present study, vaccinal reactions in SPF broilers after ND vaccination with strain LZ58 by 
eye-nose drop or coarse liquid spray were compared in order to assess if oculonasal vaccination induces 
less adverse vaccinal reactions in comparison with coarse spray, while retaining a similar seroresponse. 
If so, manufacturing the perfect coarse powder vaccine would be very valuable in the field. 
Vaccine titrations in broilers intended to assess endpoints were performed, but in oculonasal 
vaccinated birds this point was not reached as the lowest vaccine virus dose used i.e. 100.4 EID50 per 
broiler (group 7) still provoked a seroresponse. However, it is reasonable to assume that administration 
of one tenth of this dose i.e. 10-0.6 EID50 = 0.3 EID50 per broiler, would not have resulted in take of the 
vaccine. Therefore, the dose of 100.4 EID50 per broiler was considered the endpoint. As the lower dose 
applied by spray, which still produced a seroresponse was 103.4 EID50 per broiler (group 11), it can be 
concluded that with spray vaccination approximately 1000 times less vaccine virus is actually involved in 
the infection process compared to the eye-nose drop method at equal vaccine virus concentrations. 
Considering that virus losses after application of coarse liquid spray and coarse powder vaccine are 
similar ([2]; Chapter 4), the perfect coarse powder vaccine containing 106.4 EID50 per broiler would 
induce vaccinal reactions similar to those induced by the 10-3 diluted vaccine (103.4 EID50 per broiler) 
given by eye-nose drop. Thus, in comparison with the undiluted vaccine applied by spray, the perfect 
coarse powder vaccine will significantly (P <0.05) lower adverse vaccinal reactions, especially the 
increase of susceptibility to colibacillosis reflected by a decrease of the MLS value from 3.9 (group 8; 100 
diluted vaccine; 106.4 EID50 per broiler vaccinated via spray) to 1.7 (group 4; 10
-3 diluted vaccine; 103.4 
EID50 per broiler vaccinated via eye-nose drop). However, this will also result in a slight although 
significant (P <0.05) decrease in mean log2 HI NDV serum titre from 2.2 to 1.6. These effects were not 
observed with the 10-1 and 10-4 vaccine dilutions after administration of the vaccine per spray and eye-
nose drop, respectively. 
The relatively strong vaccinal reactions in broilers vaccinated with the undiluted vaccine spray 
are likely due to the presence of fine inhalable vaccine particles (D (v, 0.1) after evaporation of the 
droplets is 3.9 µm (Chapter 4); calculated inhaled vaccine dose is 10-0.4 = 3 EID50 per broiler), which will 
be deposited in the deep parts of the respiratory tract [6, 12]. Obviously, the vaccine dose in the fine 
dispersed particles is too low to produce strong reactions after diluting the vaccine 1:10. It may 
therefore seem reasonable to argue that spray vaccination with 10-1 diluted vaccine (105.4 EID50 per 
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broiler) could solve the problem of adverse vaccinal reactions. However, coarse spray vaccination as 
carried out in practice lacks standardization. In case a spray device, which generates greater numbers of 
small droplets than the one used in the present study is used, strong vaccinal reactions could still be 
induced during the application of diluted vaccine suspensions. Moreover, good quality live NDV vaccines 
contain at least 106.0 EID50 per dose [13] as this dose is required to induce protective immunity under 
field conditions [14]. Thus, although some dilution of NDV vaccines could reduce adverse vaccinal 
reactions, it may comprise the development of protective immunity. 
Both gradual and rapid increases of the MLS were observed in the present experiment. The 
gradual rise from 0.7 to 2.0 in groups vaccinated by eye-nose drop with vaccine doses decreasing from 
106.4 to 102.4 EID50 per chicken (groups 1 - 5) might be due to difference in phase of the vaccine virus 
infection at the day they were E. coli inoculated. The rapid rise from 2.0 to 4.3 in birds vaccinated by 
eye-nose drop with 102.4 and 101.4 EID50 per chicken (groups 5 and 6), respectively, and the similar rise 
from 2.1 to 3.3 and 4.0 in broilers spray vaccinated with 105.4, 104.4 and 103.4 EID50 per bird, respectively, 
is most probably caused by the heterogeneous distribution of the vaccine virus within the groups 
resulting in the so-called ‘rolling’ vaccinal reaction [15]. 
In case of heterogeneous distribution of the vaccine virus, it will replicate in the infected birds, 
will be shed and subsequently spread to the non-vaccinated flock mates. In the latter animals the time 
frame between viral infection and E. coli inoculation is then reduced, which may result in higher 
susceptibility to colibacillosis [3]. Moreover, virus transmission after shedding may occur by fine aerosol 
particles [16], enabling vaccine virus deposition in the deeper airways. Heterogeneous take of the 
vaccine was observed in eye-nose drop and spray vaccinated birds using doses of 101.4 and 104.4 EID50 
per bird, respectively, again indicating that after spray vaccination approximately 1000 times less 
vaccine virus is actually involved in the vaccine take compared to eye-nose drop. 
The percentages of broilers that did not show seroresponse (HI NDV titre <2 log2) after 
vaccination ranged from 42 to 82. This percentage of non-responders is not unusual as broilers are 
known to yield poor serum antibody titres [17]. Additionally, vaccinated birds were young broilers with 
an immature immune system, adding to the low production of serum antibodies. However, the serum 
antibody response is not fully representative for the entire immune response as locally produced 
immunoglobulin A in the respiratory mucosa might occur in the absence of serum antibodies [14].  
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5. CONCLUSIONS 
In case monodisperse coarse NDV powder vaccines can be produced, perfectly mimicking eye-
nose drop vaccination regarding deposition in the eyes and respiratory tract, they will induce lower 
adverse vaccinal reactions in comparison with liquid spray. 
In 4-day-old SPF broilers: 
 After liquid spray vaccination approximately 1000 times less NDV vaccine is actually 
involved in the vaccine take compared to eye-nose drop vaccination. 
 Vaccine virus titres of ≥102.4 and ≥105.4 EID50 per broiler resulted in a homogeneous take 
of the vaccine following eye-nose drop and liquid spray application, respectively. 
Administration of smaller amounts of vaccine virus led to heterogeneous distribution of 
the vaccine virus resulting in ‘rolling’ adverse vaccinal reaction. 
 A vaccine virus dose of 102.4 EID50 per broiler applied by liquid coarse spray did not 
provoke a serum HI antibody response anymore. The corresponding dose for the eye-
nose drop method likely was 10-0.6 = 0.3 EID50 per bird.  
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The effectiveness of mass vaccination of poultry using commercial liquid vaccines applied by 
spray or aerosol is mainly limited by its water component, in which the freeze-dried vaccines need to be 
reconstituted immediately before administration. Poor water quality and evaporation of airborne 
droplets may lead to substantial or complete vaccine virus loss before it reaches the birds. Moreover, 
the wide spray and aerosol droplet size distributions complicate targeted vaccine deposition, which 
reduces their efficiency and increases the risk for adverse vaccinal reactions. Therefore, monodisperse 
dry powder vaccines were considered as a potential alternative for improving vaccine delivery currently 
performed by spray or aerosol. After previous related research performed by Corbanie [1], this work 
was aiming to further improve the usability of dry powder vaccines for mass vaccination of poultry. 
 In Chapter 2, a low hygroscopic mannitol/myo-inositol/BSA powder combination in a mass ratio 
of 73.3:13.3:13.3 showed improved stability of the live vaccine virus during spray drying (max. vaccine 
loss of 2 log10 EID50) and similar storage stability afterwards (max. vaccine loss of 0.8 log10 EID50 after 6 
months at 6ºC) compared to the low hygroscopic mannitol powder vaccine developed by Corbanie 
(vaccine loss of 4.1 log10 EID50 during spray drying and 0.7 log10 EID50 after 5 months storage at 6ºC; [1]). 
This stabilizer combination was then used in Chapter 3 to spray dry powder vaccines with specific and 
narrow particle size distributions (<5 µm, <10 µm and >20 µm). Powders with primary particles smaller 
than 10 µm were produced, achieving full particle deagglomeration after dry dispersion, while in 
contrast the fine powders (<10 µm) produced by Corbanie were difficult to deagglomerate [1]. In 
addition, powders with smaller primary particles (<5 µm, suitable for the vaccination of 2-week-old 
broilers) were spray dried while they could not be produced in the previous research. However, these 
powders were not fully deagglomerable upon dry dispersion, even after increasing air flow rates. In 
order to maximally reduce the amount of particles smaller than 20 µm in the coarse powder vaccine, the 
stabilizer combination mannitol/BSA (mass ratio of 60:40) was used instead of the mannitol/myo-
inositol/BSA formulation. This lead to a comparable particle size distribution for the coarse powder 
vaccine as the one obtained by Corbanie [1]. However, in vivo data were lacking regarding the 
importance and influence of a small percentage of powder particles smaller than 20 µm on the 
occurrence of adverse vaccinal reactions after primary vaccination of broiler chicks. Therefore, the 
adverse vaccinal reactions as well as the serum antibody response were compared between powder and 
liquid vaccines (Chapter 4). As the coarse powder vaccine, despite its narrower particle size distribution 
and low inhaled vaccine dose, showed no significant decrease (P >0.05) regarding the adverse vaccinal 
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reactions, it was further investigated in Chapter 5 if the adverse vaccinal reactions could be prevented 
by manufacturing a monodisperse coarse dry powder vaccine devoid of small particles (<20 µm). Using 
eye-nose drop vaccination, which ensures deposition of vaccine virus in the upper airways, the adverse 
vaccinal reactions were significantly reduced (P <0.05) compared to the conventional liquid spray 
method in those groups, which were similar regarding the actual virus dose involved in the vaccine take. 
Thus, a perfectly monodisperse coarse powder vaccine mimicking an eye-nose drop vaccination 
regarding deposition in the eyes and upper respiratory tract will be of great value for the field. 
Dry powder vaccines seem therefore promising alternatives for the conventional liquid spray 
and aerosol vaccines. However, before dry powder vaccination can be applied in practice, a number of 
shortcomings must be solved. First, vaccine virus loss during manufacturing and storage of powder 
vaccine should be further reduced to the level of the conventional freeze-dried vaccines used for liquid 
vaccination. Vaccine losses during the production of the dry powder vaccines are considerably higher 
than those during freeze-drying of conventional vaccines (max. vaccine loss of 0.5 log10 EID50 after 
productions; max vaccine loss of 1 log10 EID50 after 1 year storage). This problem can be addressed by 
screening more potential stabilizers (e.g. sugars, proteins). However, during the search for new 
stabilizers, physicochemical characteristics such as low hygroscopicity should be kept in mind. Also 
changes to the spray drying process may improve the vaccine stability during production, however, this 
must be performed with care as changing the parameters of the spray drying process may influence 
powder vaccine characteristics such as moisture content and particle size. Alternatively to spray drying, 
spray freeze drying might offer possibilities to improve vaccine stability. In this case the vaccine liquid is 
sprayed into a cryogenic liquid or vapor, controlling the final particle size of the powder, after which 
water is separated from the solid fraction by ice sublimation at decreased temperature and/or pressure, 
as is done during conventional freeze drying. Second, all small particles (<20 µm) must be eliminated 
from the coarse dry powder vaccine used for the primary vaccination thereby avoiding vaccine virus 
deposition into the lower respiratory tract and adverse vaccinal reactions, while retaining the same 
immunogenicity. To produce this coarse powder vaccine by spray drying, the selection of an atomization 
system which can produce droplet size distributions with a lower span than the conventional ultrasonic 
nozzle (span ≈ 0.8), utilized here, such as the ultrasonic Micro-sieve™ nozzle (span <0.6; Nanomi 
technology, the Netherlands; [2]) could be used. A disadvantage of currently available ultrasonic 
atomization systems is that it is not economically feasible to upscale them, due to limited throughput. A 
possible alternative is therefore the pressure nozzle [6]. However, this is an atomization system reserved 
for large spray dryers, impeding experiments on a laboratory scale. Third, fine powder vaccines with 
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smaller particles should be manufactured ( 2 µm), which should be as effective as the liquid aerosol 
vaccination. In Chapter 4 it was shown that the latter vaccine induced the highest humoral response and 
adverse vaccinal reactions despite large losses of vaccine virus, which was attributed to the generation 
of very small vaccine virus particles (D (v, 0.5) 1.1 µm) after evaporation of larger droplets that likely 
penetrated into the deeper airways. It should be taken into account, when producing powders of a very 
small particle size, that full particle deagglomeration after dry dispersion may be compromised due to 
interparticulate adhesive forces. A possibility to overcome this adhesive behavior is to develop particles 
with corrugated surfaces [3] or to produce low density particles [4]. Although both approaches can 
decrease the adhesive forces between small particles, this will require changes of the production 
process, possibly affecting the vaccine stability during production. Another approach to avoid particle 
agglomeration upon dry dispersion is to adapt the dry powder dispersion system e.g. by introducing 
baffles in the device, so that particle/particle or particle/wall collision within the disperser is improved 
[5].  
Dry powder vaccination is a much more robust vaccination method than the current liquid 
based systems as physical state transitions are avoided since the vaccine virus does not need to be 
suspended in liquid and is not affected by inactivation due to droplet evaporation, leading to inevitable 
vaccine losses of up to 3 log10 EID50. Furthermore, as the liquid vaccines, despite these large losses 
during administration, induce good immune responses the vaccine dose might be reduced in the fine dry 
powder vaccines consisting of very small particles ( 2 µm), which offers opportunities for a more 
efficient administration of vaccines with low doses due to poor production yields, such as infectious 
bronchitis vaccines.  
In addition to a possible reduction of the vaccine dose required during dry powder vaccination, 
the manufacturer would also benefit from the more economical spray drying process compared to the 
expensive freeze drying, which is currently used for the production of vaccines for liquid vaccination. 
This would enable a competitive market price for the dry powder vaccines compared to their freeze 
dried counterparts, with possibly higher profit margins in the long term.  
A drawback of the dry powder vaccines compared to the currently used freeze dried liquid 
vaccines might be the volume of powder needed for vaccination of large numbers of birds. In liquid 
vaccination a small vial containing a freeze dried vaccine tablet is reconstituted into a larger volume of 
water (e.g. 500 ml for 1000 4-week-old chickens) which is available at the premises. In the case of dry 
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powder vaccines the entire powder volume needs to be transported to the poultry farm, as no further 
dilution into water is required before application. Although additional experiments will have to clarify 
the ideal amount of vaccine per gram for the mass application of dry powder vaccines, it is certain that a 
larger volume of powder vaccine will be required compared to the currently used freeze dried vaccine. 
Nevertheless, the hindrance caused by the larger volume of powder vaccines may be counterbalanced 
by the benefits they may offer, such as the reduced adverse vaccinal reactions after primary vaccination 
and overall increased vaccination efficiency compared to liquid vaccination.  
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In Chapter 1, an introduction on the prevention and control of infectious diseases in commercial 
poultry is given. Herein, vaccinology plays a crucial role. The vaccination of chicken flocks is preferably 
done using mass application techniques due to their low cost and high efficiency compared to the 
individual inoculation of birds. Liquid spray and aerosol vaccinations are popular mass vaccination 
techniques against respiratory infectious diseases, such as Newcastle disease (ND), in extensive poultry 
farming and induce good immune responses. However, as the vaccination efficiency is reduced by a 
number of factors, such as wide droplet size distribution and droplet evaporation, dry powder vaccines 
produced by spray drying were previously investigated as a potential alternative. The particle sizes 
necessary to target efficiently the upper and lower airways of broilers of different ages during 
vaccination were determined and subsequently, a first series of Newcastle disease virus (NDV) powder 
vaccines using mannitol, trehalose, polyvinylpyrrolidon (PVP) and/or bovine serum albumin (BSA) were 
spray dried and evaluated in vitro, regarding aerosol and vaccine stabilizing powder properties, and in 
vivo, regarding the induction of the serum antibody response. As the powder vaccines induced similar 
immune responses as the liquid vaccines, further investigations aiming at developing new dry powder 
formulations, which were compared with liquid vaccines, were developed. Finally, the feasibility to 
decrease adverse vaccinal reactions of powder vaccines was assessed. 
 
Previous experiments showed that combinations of trehalose with PVP and/or BSA resulted in 
spray drying but poor storage vaccine stability, while the opposite was observed for a 100% mannitol 
powder vaccine. Therefore, in Chapter 2, new combinations with the above mentioned stabilizers were 
evaluated in order to improve the vaccine stability during both spray drying and storage. The low 
hygroscopic myo-inositol was introduced as a new stabilizer to substitute the hygroscopic trehalose. In 
addition, the powder combinations were characterized regarding hygroscopicity, moisture content and 
dry-dispersibility, measured by dynamic vapor sorption, Karl Fischer titrations and laser diffraction, 
respectively. After these preliminary experiments, a mainly crystalline powder combination of mannitol, 
myo-inositol and BSA, with a maximal vaccine loss of 102.1 50% Egg Infectious Dose (EID50) during spray 
drying and 101.2 EID50 after 12 months storage at 6ºC, was selected for further optimization of the 
formulation in a design of experiments, aiming for a high vaccine stability as well as a low 
hygroscopicity, low moisture content and good dry-dispersibility. Increasing the BSA content yielded 
more hygroscopic powders with higher moisture contents. Finally, the combination of mannitol/myo-
inositol/BSA in a mass ratio of 73.3/13.3/13.3 rendered a good process (max. vaccine loss of 102.0 EID50) 
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and storage (max. vaccine loss of 100.8 EID50 after 6 months at 6ºC) stability of the vaccine with 
additionally a limited moisture content (max. 1.4%), low hygroscopicity (max. 2.1% at 60%RH, 25ºC) and 
good dry powder dispersibility.  
 
The identified mannitol/myo-inositol/BSA combination was used in Chapter 3 for the production 
of powder vaccines with particle size distributions in agreement with the particle size criteria required to 
efficiently target the different parts of the respiratory tract according to the vaccine type and age of 
broilers (i.e. >20 µm for the primary vaccination of day-old chicks; <5 µm and <10 µm for the secondary 
vaccination of 2- and 4-week-old broilers). Particle sizes were measured by laser diffraction after dry 
powder dispersion. First, particle-defining spray drying process parameters were specified on a 
laboratory spray dryer by means of a design of experiments, varying the solids content of the liquid 
feed, atomization air flow, feed rate and inlet air temperature. Next, the most significant factors, 
atomization air flow and feed solids content, were varied in a pilot plant spray dryer in combination with 
three different atomizer systems (i.e. rotary atomizer, two fluid nozzle and fountain nozzle) to detect 
the most appropriate atomizer system for each required particle size distribution. Finally, powders with 
required particles size distributions were spray dried. For the production of particles smaller than 5 µm, 
a laboratory spray dryer with a two fluid nozzle equipped with a small nozzle diameter opening (0.15 
mm) was used at various atomization air flows. Although the scanning electron microscope images 
showed individual particles in the micron range when the liquid feed (1% solids content) was spray dried 
at high atomization air flow (38.5 l/min), the fine powder was difficult to deagglomerate upon dry 
dispersion (maximal 37% below 5 µm), even with increasing air flow rates. The pilot plant spray dryer, 
combined with the two fluid nozzle (diameter 1 mm) operating at a high atomizing air flow (113.9 l/min) 
was suitable for producing a well dry-dispersible powder with particles smaller than 10 µm (80-90% 
dispersible particles below 10 µm) from a feed with 1% solids content. For spray drying particles bigger 
than 20 µm the mannitol/myo-inositol/BSA combination was replaced by a mannitol/BSA combination 
(mass ratio of 60/40) as the higher BSA content enhanced the formation of larger particles. The high 
solids-containing feed (15%) was spray dried using a laboratory spray dryer with an ultrasonic nozzle at 
low frequency (25 kHz). Further reduction of particles below 20 µm (from 4.8% to 2.6%) was obtained by 
air-jet sieving the powder through a micro-sieve of 20 µm. The coarse powder showed good dry 
dispersibility characteristics.  
 
SUMMARY 
 
 
139 
 
Next, in Chapter 4, a coarse (>20 µm; D (v, 0.5) = 37 µm) and fine (<10 µm; D (v, 0.5) = 6.5 µm) 
powder NDV (LZ58 strain) vaccine were compared with the conventional coarse liquid spray (D (v, 0.5) of 
the droplets = 106 µm) and fine liquid aerosol (D (v, 0.5) of the droplets = 10 µm) in 4-day-old SPF 
broilers. Vaccines were compared in efficacy, assessed by the serum antibody response, and in the 
occurrence of adverse vaccinal reactions, estimated by body weight gain, mortality and susceptibility to 
colibacillosis. To evaluate the influence of fine particle contamination (<20 µm) in the coarse powder 
vaccine, an additional group was vaccinated by a mixed powder vaccine, consisting of 90% of coarse 
powder vaccine and 10% of fine powder vaccine. During vaccination a total vaccine dose of 108.1-8.5 EID50 
was dispersed in each isolator and air samples were taken at several points in time (immediately after, 
10 and 20 minutes after dispersion) to assess the amount of inhaled NDV vaccine per broiler. At the age 
of 11 days broilers were inoculated intratracheally (i.t.) with a virulent E. coli strain. A blanco (no 
treatment), positive (placebo powder, E. coli i.t.) and negative control group (placebo powder, PBS i.t.) 
were included in the experimental design. The experiment was ended at the age of 18 days, when 
broilers were debleeded for serum sampling and scored for E. coli lesions in thoracic air sacs, liver and 
pericardium to determine the severity of colibacillosis. In general, no significant differences (P >0.05) 
regarding adverse vaccinal reactions and serum antibody response were observed between the powder 
vaccines and their liquid counterparts. There was no significant difference (P >0.05) between the coarse 
powder vaccine and the coarse liquid vaccine regarding adverse vaccinal reactions and serum antibody 
response. However, there was a significant increase (P <0.05) in serum antibody response and adverse 
vaccinal reactions after vaccination with fine vaccines compared to the coarse vaccines. Despite the 
lower calculated vaccine take, the highest serum antibody response was obtained by the fine liquid 
vaccine, which also provoked the most severe adverse vaccinal reaction. This was explained by the 
evaporation of small droplets yielding very fine dry vaccine particles (D(v, 0.5) of 1.1 µm), which most 
likely penetrated into the deepest tissues of the lower respiratory tract and induced a strong immune 
response, while in comparison the median particle size of the fine powder vaccine was 6.5 µm. There 
was no significant difference (P >0.05) between the mixed and fine powder vaccine, which was not 
unexpected as the mixed powder vaccine, consisting of 1/10 of fine powder vaccine, could be 
considered as a fine powder vaccine with 1 log10 EID50 less. This stresses the importance of avoiding fine 
particle contamination in the coarse powder vaccine. The significant increase of adverse vaccinal 
reactions including the susceptibility of colibacillosis after vaccination with fine vaccines compared to 
the coarse vaccines was a novel finding, which was not described before. Excellent serum antibody 
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responses were obtained in SPF broilers after the inhalation of 100-1000 EID50 per bird delivered via fine 
vaccine particles 1 µm. 
 
As the coarse powder vaccine, despite the low inhalable vaccine dose, could not significantly 
reduce adverse vaccinal reactions compared to the liquid coarse spray, it was investigated in Chapter 5 
if adverse vaccinal reactions could be significantly reduced if a coarse powder vaccine, devoid of fine 
vaccine particles ( 20 µm) and monodisperse, could be developed. Seven experimental groups of 4-day-
old SPF broilers were vaccinated with ten-fold diluted vaccine virus suspensions (vaccine dose of 106.4 to 
100.4 EID50 LZ58 NDV per bird) by the eye-nose drop method while five groups were vaccinated by the 
coarse liquid spray method (vaccine dose from 106.4 to 102.4 EID50 LZ58 NDV per bird). This allowed the 
assessment of vaccine loss following coarse spray vaccination compared to eye-nose drop vaccination 
and subsequently allows comparison of groups of birds in which similar vaccine doses were involved in 
the actual vaccine take either by eye-nose drop of coarse spray method regarding their adverse vaccinal 
reactions and serum antibody response. Seven days after vaccination (day 11), the broilers were 
inoculated i.t. with virulent E. coli. The last day of the experiment (day 18), serum samples were taken 
and broilers were evaluated for macroscopical colibacillosis lesions in thoracic air sacs, liver and 
pericardium. Other parameters to assess the adverse vaccinal reaction were weight gain and mortality. 
A blanco (no treatment) and positive control group (PBS vaccination, E. coli inoculation) were included in 
the experimental design. It was found that adverse vaccinal reactions increased after the administration 
of a suboptimal vaccine dose, being 101.4 EID50 per bird for the eye-nose drop groups and 10
4.4 EID50 
per bird for the spray vaccinated groups. This suggested that if the same vaccine dilution is administered 
by spray vaccination about 1000 times less vaccine virus is actually involved in the vaccine take in 
comparison to when delivered by the eye-nose drop method. Therefore, the spray vaccinated group 
with a vaccine dose of 106.4 EID50/bird was compared with the eye-nose drop group, which received 10
3.4 
EID50/bird regarding adverse vaccinal reactions and serum antibody response. Significantly (P <0.05) 
lower adverse vaccinal reactions, especially increases in the susceptibility to colibacillosis, were induced 
by the eye-nose drop method (MLS of 1.7) compared to the spray vaccination (MLS of 3.9), accompanied 
with a slight, albeit significant (P <0.05) decrease in the serum antibody response in case of eye-nose 
drop vaccination (HI titre of 2.2 vs. 1.6 log2 for the spray and eye-nose drop group, respectively). The 
latter was not considered important as a local immune response that will also participate in the defense 
mechanism against challenge with a virulent field strain is likely to have occurred. The higher serum 
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antibody response and the increased susceptibility to colibacillosis in the spray vaccinated birds were 
explained by the occurrence of fine inhalable particles. It was concluded that adverse vaccinal reactions 
can be decreased significantly if the coarse liquid spray vaccination is replaced by a monodisperse 
coarse powder vaccine mimicking the eye-nose drop vaccination method regarding the vaccine 
deposition pattern in the eyes and respiratory tract. 
 Future research should be conducted to further optimize the coarse powder vaccine regarding 
particle size distribution to avoid vaccine particle respiration and thus adverse vaccinal reactions in 
young broilers. Taken into account the results of Chapter 4, a fine powder vaccine should be produced 
with particles 2 µm, in which particle agglomeration does not occur.  
In conclusion, the performed research has gained new insights regarding the usability of powder 
vaccines for mass vaccination of poultry. Although dry powder vaccination shows great potential in 
improving the currently used spray and aerosol methods, additional research is needed for the further 
optimization of the dry powder vaccination system. 
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In Hoofdstuk 1 werden preventieve en controlerende maatregelen tegen infectieuze ziektes in 
de pluimveesector toegelicht, waarin vaccinatie een belangrijke rol speelt. Vooral 
massavaccinatietechnieken genieten de voorkeur boven de individuele methoden aangezien dit een 
relatief goedkope en snelle vaccinatiemethode is. Vloeibare spray en aerosol vaccinatie zijn populaire 
massatechnieken bij de vaccinatie tegen respiratoire infectieuze ziektes, zoals de Newcastle disease of 
pseudovogelpest, aangezien ze goede immuunresponsen opwekken. Toch wordt een verminderde 
vaccinatie-efficiëntie vastgesteld door de brede druppelgroottedistributie en druppel-verdamping, 
waardoor de toepassing van gesproeidroogde poedervaccins als mogelijk alternatief werd onderzocht. 
De partikelgroottes nodig om efficiënt in de hoge en lage luchtwegen van vleeskuikens van verschillende 
leeftijden terecht te komen waren bepaald en vervolgens een eerste reeks Newcastle disease virus 
(NDV) poedervaccins ontwikkeld. Poedervaccins op basis van mannitol, trehalose, polyvinylpyrrolidone 
(PVP) en/of bovine serum albumine (BSA) werden gesproeidroogd en zowel in vitro, op het gebied van 
aerosol- en vaccinstabilisatie eigenschappen, als in vivo, op het gebied van het induceren van de serum 
antilichaamrespons, geëvalueerd. Aangezien in vivo goede immuunresponsen verkregen werden in 
vergelijking met de conventionele vloeibare vaccins, werd dit project verdergezet met het oog op het 
ontwikkelen van nieuwe poederformulaties, die vergeleken werden met de vloeibare vaccins. 
Uiteindelijk werd verder onderzocht of het mogelijk was de ongewenste vaccinale reacties te 
verminderen met behulp van poedervaccins. 
 
Voorafgaande experimenten toonden aan dat combinaties van trehalose met PVP en/of BSA het 
vaccin goed stabilizeerden tijdens het sproeidroogproces maar dat een groot vaccinverlies optrad tijdens 
bewaring, terwijl het tegenovergestelde werd vastgesteld indien het vaccin in een mannitol-matrix 
gesproeidroogd en bewaard werd. Daarom werden in Hoofdstuk 2 nieuwe combinaties met de 
bovenvermelde stabilisatoren gesproeidroogd om de vaccinstabilisatie te verbeteren zowel tijdens 
productie als tijdens bewaring. Het weinig hygroscopische myo-inositol werd geïntroduceerd als nieuwe 
stabilisator als mogelijk alternatief voor het sterk hygroscopische trehalose. De poederformulaties 
werden verder gekarakteriseerd op het gebied van hygroscopiciteit, vochtgehalte en dispergeerbaarheid 
als droog poeder met behulp van respectievelijk dynamic vapor sorption, Karl Fischertitraties en 
laserdiffractie. Na deze preliminaire experimenten werd een overwegend kristallijne poedercombinatie 
op basis van mannitol, myo-inositol en BSA geselecteerd (maximaal vaccinverlies van 102.1 50% Ei-
infecterende dosis (EID50) tijdens sproeidrogen; en 10
1.2 EID50 na 12 maand bewaring bij 6ºC) voor 
 
SAMENVATTING 
 
146 
 
verdere optimalisatie van de formulatie via een experimenteel design. Hierbij werden, naast een goede 
vaccinstabilisatie, ook een lage hygroscopiciteit, laag vochtgehalte en goede deagglomeratie van de 
droge poeders bij verneveling nagestreefd. Indien meer BSA geïncorporeerd werd in de poedermatrix, 
werden hygroscopischere poeders met hogere vochtgehaltes bekomen. Uiteindelijk werd met de 
combinatie mannitol/myo-inositol/BSA in een massaverhouding van 73.3/13.3/13.3 een goede 
vaccinstabiliteit tijdens sproeidrogen (max. 102.0 EID50 vaccinverlies) en bewaring (max. 10
0.8 EID50 
vaccinverlies na 6 maand bij 6ºC) bekomen, alsook een laag vochtgehalte (max. 1.4%), lage 
hygroscopiciteit (max. 2.1% bij 60% RH en 25ºC) en goede dispergeerbaarheid na poederverneveling. 
 
Deze mannitol/myo-inositol/BSA combinatie werd in Hoofdstuk 3 aangewend voor de productie 
van de geschikte partikelgroottedistributies overeenkomstig de criteria vastgelegd voor de specifieke 
vaccinatieleeftijden van vleeskuikens (i.e. >20 µm voor de primaire vaccinatie van ééndagskuikens; <5 
µm en <10 µm voor de secundaire vaccinatie van 2- en 4-weken-oude vleeskuikens). De partikelgroottes 
van de poeders werden gemeten via laserdiffractie tijdens droge poederdispersie. Eerst werden de 
sproeidroogparameters die de resulterende partikelgrootte van het poeder bepalen via een 
experimenteel design geïdentificeerd met behulp van een laboratoriumsproeidroger. Hierbij waren het 
vaste stofgehalte van de vloeibare feed, de atomizatieluchtstroom, de sproeisnelheid en de 
inlaattemperatuur de variabele factoren. Vervolgens werden de meest significante factoren, de 
atomizatieluchtstroom en het vaste stofgehalte in de feed, gevarieerd in een pilot sproeidroger in 
combinatie met drie verschillende atomizatiesystemen (roterende atomizer, two-fluid sproeikop en een 
fontein sproeikop) om het optimale atomizatiesysteem voor de productie van de specifieke 
partikelgroottedistributies te achterhalen. Deze poeders werden in een laatste fase gesproeidroogd en 
gekarakteriseerd. Voor de productie van poederpartikels kleiner dan 5 µm werd een 
laboratoriumsproeidroger met een two-fluid sproeikop uitgerust met een kleine openingsdiameter (0.15 
mm) aangewend bij verschillende atomizatieluchtstromen. Hoewel via elektronenmicroscopie 
individuele partikels in de micronrange werden geïdentificeerd indien de vloeibare feed (1% vaste 
stofgehalte) gesproeidroogd werd bij een hoge atomizatieluchtstroom (38.5 l/min), was deagglomeratie 
van het fijne poeder tijdens verneveling beperkt (max. 37% was kleiner dan 5 µm), zelfs indien hogere 
dispergerende luchtstromen werden aangewend. In combinatie met de two-fluid sproeikop 
(openingsdiameter 1 mm) en een hoge atomizatieluchtstroom (113.9 l/min) was de pilot sproeidroger 
geschikt voor de productie van een goed deagglomereerbaar poeder met partikels kleiner dan 10 µm 
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(80-90% dispergeerbare partikels kleiner dan 10 µm) vanuit een vloeibare feed met 1% vaste 
stofgehalte. Om partikels groter dan 20 µm te bekomen werd de mannitol/myo-inositol/BSA combinatie 
vervangen door een mannitol/BSA combinatie (verhouding 60:40) aangezien het hogere BSA-gehalte de 
vorming van grotere partikels bevorderde. De vloeibare feed met hoge vaste stofgehalte (15%) werd 
gesproeidroogd met een laboratoriumsproeidroger uitgerust met een lage frequentie-ultrasone nozzle 
(25 kHz). De hoeveelheid partikels kleiner dan 20 µm werd verminderd (van 4.8% naar 2.6%) door het 
poeder te zeven door een luchtstroom zeef met een poriëngrootte van 20 µm. Het grove poeder 
vertoonde goede dispergeereigenschappen bij verneveling.  
 
In Hoofdstuk 4 werden een grof (>20 µm; D(v, 0.5) = 37 µm) en fijn (<10 µm; D(v,0.5) = 6.5 µm) 
poedervaccin (LZ58 NDV), vergeleken in 4-dag-oude SPF vleeskuikens met de conventionele grove 
vloeibare spray (D(v,0.5) van de druppels = 106 µm) en de fijne vloeibare aerosol (D(v,0.5) van de 
druppels = 10 µm). Vaccins werden vergeleken op gebied van doeltreffendheid, beoordeeld via de 
serum antilichaamrespons, en op voorkomen van de ongewenste entreacties, beoordeeld aan de hand 
van toename in lichaamsgewicht, sterfte en vatbaarheid voor colibacillose. Om de invloed van de 
hoeveelheid kleine vaccinpartikels (<20 µm) tijdens primaire vaccinatie met een grof-geformuleerd 
vaccin in te schatten, werd een extra experimentele groep behandeld met een gemengd poedervaccin, 
bestaande uit 90% grof poedervaccin en 10% fijn poedervaccin. Bij vaccinatie werd een totale 
vaccindosis van 108.1-8.5 EID50 gedispergeerd in elke isolator en werden luchtmonsters genomen op 
verschillende tijdstippen (onmiddellijk na verneveling en 10 en 20 minuten na verneveling) om de 
geïnhaleerde NDV vaccindosis per vleeskuiken te bepalen. Zeven dagen post-vaccinatie (dag 11) werden 
de kippen intratracheaal (i.t.) geïnoculeerd met virulent E. coli. Een blanco (geen behandeling), een 
positieve (placebo poeder, E. coli i.t.) en negatieve (placebo poeder, PBS i.t.) controlegroep werden 
opgenomen in de proefopzet. Het experiment werd beëindigd op dag 18: bloedstalen van de kuikens 
werden genomen en de ernst van de colibacilloseletsels in de luchtzakken, lever en pericardium werd 
beoordeeld door middel van een score-methode. Over het algemeen werden geen significante (P >0.05) 
verschillen teruggevonden tussen de poeder- en overeenkomstige vloeibare vaccins op het gebied van 
ongewenste entreactie en de inductie van een serum antilichaamrespons. Tussen het grove 
poedervaccin en het grove vloeibare vaccin was geen significant verschil (P >0.05) inzake de entreactie 
en serum antilichaamrespons. Na vaccinatie met de fijne vaccins werd wel een significante (P <0.05) 
toename in ongewenste entreacties en serum antilichaamrespons waargenomen vergeleken na 
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vaccinatie met de grove vaccins. Verder induceerde het fijne vloeibare vaccin ondanks de lagere 
geschatte dosisopname de hoogste serum antilichaamrespons, weliswaar gepaard met de meest hevige 
ongewenste entreacties. Dit was te wijten aan het indrogen van kleine druppels tot zeer kleine droge 
stof partikels (D(v,0.5) van 1.1 µm) die wellicht konden doordringen tot in de diepst gelegen weefsels 
van de lage luchtwegen, waar ze een sterke respons uitlokten. In vergelijking was de mediane 
partikelgrootte van het fijne poedervaccin groter (6.5 µm). Er was geen significant verschil (P >0.05) 
tussen het gemengde en fijne poedervaccin, wat verwacht kon worden aangezien het gemengde 
poedervaccin bestaat uit 1/10 fijne poedervaccin en daardoor kon beschouwd worden als een fijn 
poedervaccin met 1 log10 EID50 minder. Dit benadrukte het belang om fijne partikelcontaminatie in het 
grove poedervaccin te voorkomen. De significante toename van de ongewenste entreacties met 
inbegrip van de verhoging van de colibacillose-gevoeligheid na vaccinatie met fijne vaccins vergeleken 
met grove vaccins was een nieuwe bevinding die nooit eerder werd beschreven. Verder konden 
uitstekende serum antilichaamresponsen bekomen worden in SPF vleeskuikens na een geïnhaleerde 
vaccindosis van 100-1000 EID50 per kuiken indien dit toegediend werd met fijne vaccinpartikels 1 µm. 
 
Aangezien het grove poedervaccin, ondanks de lage inhaleerbare vaccindosis, de ongewenste 
entreactie niet significant kon verminderen vergeleken met de grove vloeibare spray, werd in Hoofdstuk 
5 onderzocht of een vermindering van de ongewenste entreacties mogelijk was indien een grof 
poedervaccin kan worden ontwikkeld dat geen kleine partikels bevat ( 20 µm) en redelijk monodispers 
is. Hiervoor werden zeven experimentele groepen met 4-dag-oude vleeskuikens gevaccineerd met 10-
voudig verdunde vaccinsuspensies via de oog-neusdruppelmethode (vaccindosis van 106.4 tot 100.4 
EID50/kuiken) en vijf groepen vleeskuikens gevaccineerd via de vloeibare spray methode (vaccindosis van 
106.4 tot 102.4 EID50/kuiken). Via deze proefopzet kon het vaccinverlies bij spray vaccinatie nagegaan 
worden in vergelijking met de oog-neusdruppelmethode, wat het mogelijk maakte om die 
experimentele groepen te vergelijken op vlak van ongewenste entreacties en serum antilichaamrespons 
die effectief dezelfde vaccindosis toegediend kregen ofwel via spray ofwel via oog-neusdruppel. Zeven 
dagen na de vaccinatie (dag 11) werden de vleeskuikens intratracheaal geïnoculeerd met virulente E. 
coli. De laatse dag van het experiment (dag 18) werden serumstalen genomen en werden de 
macroscopische colibacillose lesies op de luchtzakken, lever en pericardium van de vleeskuikens 
geëvalueerd. Andere parameters om de ongewenste entreacties in te schatten waren gewichtstoename 
en sterfte. Een blanco (geen behandeling) en een positieve controlegroep (PBS vaccinatie, E. coli 
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inoculatie) werden opgenomen in de proefopzet. Uit dit experiment bleek dat de ongewenste 
entreacties toenamen vanaf een bepaalde suboptimale vaccin dosis, zijnde 101.4 EID50/kuiken voor de 
oog-neusdruppelgroepen en 104.4 EID50/kuiken voor de spray gevaccineerde groepen. Dit gaf aan dat 
indien een vaccinsuspensie wordt toegediend via vloeibare spray er 1000 keer minder virusvaccin 
deelneemt aan de virale infectie dan indien diezelfde vaccinsuspensie zou worden toegediend via de 
oog-neusdruppelmethode. Daarom werd de spray groep gevaccineerd met 106.4 EID50/kuiken vergeleken 
met de oog-neusdruppelgroep gevaccineerd met 103.4 EID50/kuiken op vlak van de graad van 
ongewenste entreactie en serum antilichaamrespons. De ongewenste entreacties uitgelokt door de oog-
neusdruppelmethode (MLS van 1.7) waren significant minder hevig (P <0.05) dan deze door de spray 
(MLS van 3.9). Dit ging echter wel gepaard met een licht verminderde serum antilichaamrespons voor de 
oog-neusdruppelmethode (HI titer van 2.2 vs 1.6 log2 voor de spray- en oog-neusdruppelgroep, 
respectievelijk). Maar aangezien de lokale immuunreactie, die bijkomende bescherming biedt tegen het 
virulente pathogeen, niet in rekening werd gebracht en de fijne inhaleerbare vaccinpartikels van de 
spray gekend zijn om een sterke serum immuunrespons op te wekken, werd dit niet als problematisch 
aanzien. Uit deze studie kon besloten worden dat de ongewenste entreacties significant konden 
verminderd worden indien de vloeibare sprayvaccinatiemethode vervangen zou worden door een 
monodispers grof poedervaccin dat qua depositie in de ogen en het respiratieapparaat de 
oogneusdruppelmethode perfect nabootst. 
Tenslotte kan besloten worden dat verder onderzoek nodig is om de partikelgroottedistributie 
van het grove poedervaccin te optimaliseren zodat vaccinrespiratie door de kuikens tijdens de primaire 
vaccinatie wordt voorkomen en aldus de ongewenste entreacties teruggebracht worden tot een 
minimum. Gelet op de resultaten van Hoofdstuk 4 zou een fijn poedervaccin geproduceerd kunnen 
worden dat nog fijner is, namelijk 2 µm, waarbij agglomeratie moet worden voorkomen. 
 De uitgevoerde experimenten hebben nieuwe informatie vergaard omtrent de toepasbaarheid 
van poedervaccins voor de massavaccinatie van pluimvee.  Hoewel droge poedervaccinatie de huidige 
spray en aerosolvaccinatie substantieel zou kunnen verbeteren, is bijkomend onderzoek nodig voor de 
verdere optimalisatie van het droge poedervaccinatiesysteem. 
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dit project, alsook Matthias Ide voor de praktische hulp en raadgevingen. Olivier Janssens had ik graag 
bedankt voor de beeldopnames van de eindeloze aantallen poedertjes met de SEM. Voor de hulp bij de 
DVS-metingen had ik graag Dr. Sandra Van Vlierberghe en Veerle Boterberg bedankt. Ook Prof. Thomas 
De Beer bedank ik voor zijn hulp bij het opstellen van de design of experiments en de analyses en uitleg 
hierbij. Dr. Bart Lucas, bedankt om me de reservesleutel van jullie celkelder te lenen zodat ik mijn 
diepgevroren vaccinstalen, meegebracht uit Deventer, ‘s avonds laat toch nog kon komen opbergen in 
jullie -80ºC diepvriezer.  
Verder had ik enkele mensen willen bedanken die me heel wat bijgebracht hebben op het gebied van 
sproeidrogen: Dr. Yves Gonissen (SEPS-pharma), bedankt voor je allereerste inleiding in het onderwerp 
en me je praktische kennis over de Mobile Minor bij te brengen. Filip Van der Gucht (Procept), bedankt 
om me te helpen de grove en ultrafijne vaccinpoeders te maken met jullie sproeidroger en je uitvoerige 
uitleg, die je telkens geïnteresseerd wist over te brengen. 
Dr. Bruno De Geest, bedankt voor je interesse in mijn project en je bereidheid om mee oplossingen te 
bedenken voor de problemen die mijn pad gekruist hebben.  
Ook dank aan mijn thesisstudenten Mieke Morlion en Kaat Strybol voor hun praktische bijdrages aan dit 
werk.  
Natuurlijk wil ik ook al mijn collega’s bedanken en mijn bureaugenootjes Liesbeth DC, Els, André, Wesley 
en Marijke voor de dagelijkse babbels. Katharine, Ilse en Bruno wil ik graag bedanken voor de 
administratieve taken die er vaak bijkwamen. Christine, bedankt voor je continue bereidheid mee te 
helpen met om het even wat. 
Een speciaal plaatsje is voorbehouden aan m’n peter Prof. Claude Cuvelier. Bedankt voor je enthousiaste 
en first class samenwerking om samen op zoek te gaan met de TEM naar waar het virusvaccin zich 
verschanste in mijn poederpartikeltjes. Ondanks de kunde van Dorothy is het dan toch niet gelukt het 
met zekerheid te vinden.  
DANKWOORD 
 
155 
 
Bijzondere dank gaat uit naar mijn vriendinnen Stefanie, Vanessa, Helena, Sarah en Evelien voor hun 
steun en interesse in mijn onderzoek, ookal vonden ze het soms wel wat cru wat er met de kuikentjes 
gebeurde.  
Mama, papa en mijn broer Kevin en Kim, had ik graag bedankt voor hun interesse en steun. Kim, als 
doctor in de Romaanse talen weet je als geen ander hoe het is om een doctoraat af te leggen en 
verstond je me in moeilijke periodes volledig, ookal is het een andere branche. Kevin, bedankt om me je 
hondje toe te vertrouwen die me tijdens de laatste lange dagen gezelschap heeft gehouden en me 
verplichtte de nodige pauzes in te lassen. Papa, bedankt voor je steun en het telkens weer klaarstaan als 
ik iets nodig had. Mama, ook jij stond me telkens weer die mooie auto van je af om veilig naar 
Nederland te rijden en steunde me als wetenschapper als geen ander. And last but not least, Javi, 
gracias por tus consejos técnicos los que, de verdad, me han ayudado mucho. Tu interés en el proyecto 
me sirvió de gran apoyo. Gracias por tu paciencia, tus cuidados y tu amor de cada día. ¡Eres el mejor! 
 
 
 
 
156 
 
 
 
CURRICULUM VITAE 
 
 
157 
 
CURRICULUM VITAE - KATRIEN HUYGE 
PERSONAL DATA 
Name: Huyge  
Surname: Katrien 
Professional address: Harelbekestraat 72, 9000 Gent 
Date of birth: September 14th, 1984 
Nationality: Belgian 
 
 
 
LANGUAGE SKILLS 
Mother tongue: Dutch 
Other languages: English, Spanish, French, (German) 
 
 
 
 
 
EDUCATION 
 
Ghent University PhD research at the Laboratory of Pharmaceutical 
Technology, University of Ghent in collaboration with 
Animal Health Service, Deventer, the Netherlands  
(2007 – Present) 
 
Ghent University      Pharmacist (2002 – 2007) 
 
Graduated with distinction 
 
Sint-Bernarduscollege Oudenaarde  Latin – Science (1996 – 2002) 
 
 
 
 
 
 
CURRICULUM VITAE 
 
 
158 
 
RESEARCH EXPERIENCE 
 
PhD research  Dry powder vaccines for mass vaccination of poultry: new formulations, 
comparison with liquid vaccines and feasibility to decrease adverse 
vaccinal reactions.  
  Department of Pharmaceutics, Ghent University 
  Promoters: Prof. Chris Vervaet and Dr. Wil J.M. Landman 
  Co-promoter: Prof. Jean Paul Remon 
 
Master thesis Stability of a surfactant-free Paclitaxel formulation for hyperthermic 
peritoneal perfusion (HIPEC).  
Department of Pharmaceutics, Ghent University 
Promoter: Prof. Dr. Jean Paul Remon 
 
 
PUBLICATIONS 
 
Huyge, K.; Van Reeth, K.; De Beer, T.; Landman, W.J.M.; Van Eck, J.H.H.; Remon, J.P.; Vervaet, C. 
Suitability of differently formulated dry powder Newcastle disease vaccines for mass vaccination of 
poultry. European Journal of Pharmaceutics and Biopharmaceutics. 2012; 80(3): 649-56. 
 
Huyge, K.; Van Eck, J.H.H.; Vervaet, C.; Remon, J.P.; Landman, W.J.M. Comparison of Newcastle disease 
powder vaccines with liquid vaccines in broilers considering the serum antibody response and vaccinal 
reaction. (in preparation) 
 
Huyge, K.; Van Eck, J.H.H.; Vervaet, C.; Remon, J.P.; Landman, W.J.M. Feasibility to reduce adverse 
vaccinal reactions by replacing coarse spray mass vaccination in poultry by powder vaccines. (in 
preparation) 
 
 
PRESENTATIONS ON CONFERENCES 
 
Oral presentations 
 
Huyge, K.; Van Reeth, K.; Remon, J.P.; Vervaet C. Development of dry powder aerosols for mass 
vaccination of poultry against Newcastle disease. 3rd PSSRC Symposium, August 23-25, 2009. 
Copenhagen, Denmark.  
 
 
 
 
CURRICULUM VITAE 
 
 
159 
 
 
Poster presentations 
 
Huyge, K.; Van Reeth, K.; Remon, J.P.; Vervaet C. Development of dry powder aerosols for mass 
vaccination of poultry against Newcastle disease. 7th World Meeting on Pharmaceutics, 
Biopharmaceutics and Pharmaceutical Technology, March 8-11, 2010. Valetta, Malta.  
 
Huyge, K.; Van Reeth, K.; De Beer, T.; Remon, J.P.; Vervaet, C. Stability of a Newcastle disease 
vaccine in spray dried powder formulations for mass vaccination of poultry. FIP Pharmaceutical 
Sciences World Congress and the AAPS Annual Meeting & Exposition, November 13-18, 2010. New 
Orleans, USA.  
 
 
 
